Lamivudine, a nucleoside analog, is a potent antiviral drug used primarily to treat chronic hepatitis B infection and HIV infection. It is a synthetic analog of cytidine and acts by inhibiting the reverse transcriptase enzyme of HIV and the DNA polymerase of hepatitis B virus, preventing viral replication. It is well-tolerated with a favorable safety profile. It is studied for its antiviral properties and its potential to improve patient outcomes in treating HIV and hepatitis B.'
| ID Source | ID |
|---|---|
| PubMed CID | 60825 |
| CHEMBL ID | 141 |
| CHEBI ID | 63577 |
| SCHEMBL ID | 109675 |
| MeSH ID | M0028682 |
| PubMed CID | 73339 |
| CHEMBL ID | 18314 |
| SCHEMBL ID | 33979 |
| MeSH ID | M0028682 |
| Synonym |
|---|
| BIDD:GT0033 |
| AC-1416 |
| bch189 |
| bch 189 |
| 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one |
| AB00639995-08 |
| 3tc & sst |
| .beta.-l-(-)-2',3'-dideoxy-3'-thiacytidine & sho-saiko-to |
| 3tc and nv-01 |
| lamivir |
| (-)-sddc |
| zefix |
| bch-790 |
| gg-714 |
| 3tc & gna |
| hha & lamivudine |
| 2(1h)-pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2r,5s) & galanthus nivalis agglutinin (gna) |
| hha & 3tc |
| 2(1h)-pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2r,5s) & hippeastrum hybrid agglutinin( hha) |
| lamivudine & gna |
| 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1h)-one |
| hsdb 7155 |
| gr109714x |
| heptovir |
| gr 109714x |
| bch 189, (-)- |
| hepitec |
| epivir |
| (-)-bch 189 |
| 2(1h)-pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2r-cis)- |
| 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone |
| beta-l-3'-thia-2',3'-dideoxycytidine |
| 2(1h)-pyrimidinone, 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)- |
| (-)-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine |
| 3'-thia-2',3'-dideoxycytidine |
| beta-l-2',3'-dideoxy-3'-thiacytidine |
| (+/-)-3tc |
| 136891-12-8 |
| nsc620753 |
| (+/-)-sddc |
| 2(1h)-pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (cis) |
| (+/-)-bch-189 |
| (+/-) (cis)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine |
| bch-189 |
| zeffix |
| (-)ngpb-21 |
| epivir(tm) |
| drg-0126 |
| (-)-(2'r,5's)-1-[2'-hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine |
| gr-109714x |
| (-)-2'-deoxy-3'-thiacytidine |
| (-)-bch-189 |
| heptodin |
| epivir-hbv |
| 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one |
| heptivir |
| dthc |
| MLS001424097 |
| 134678-17-4 |
| lamivudine , |
| 2',3'-dideoxy-3'-thiacytidine |
| C07065 |
| 3tc , |
| MLS000759424 |
| smr000466319 |
| cpd000466319 |
| NCGC00159341-04 |
| DB00709 |
| epivir (tn) |
| D00353 |
| lamivudine (jan/usp/inn) |
| HMS2051D21 |
| (-)-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine |
| L0217 |
| nsc-760061 |
| lamivudine teva |
| virolam |
| chebi:63577 , |
| CHEMBL141 , |
| lamivudinum |
| STK801940 |
| AKOS005622556 |
| NCGC00159341-05 |
| HMS3259F08 |
| 2(1h)-pyrimidinone, 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- |
| 2t8q726o95 , |
| lamivudine [usan:usp:inn:ban] |
| nsc 760061 |
| ccris 9274 |
| unii-2t8q726o95 |
| dtxsid7023194 , |
| CCG-100984 |
| bdbm50366817 |
| lamivudine [usan:ban:inn] |
| kivexa component lamivudine |
| lamivudine [usp-rs] |
| temixys component lamivudine |
| lamivudine [ep impurity] |
| lamivudine component of triumeq |
| lamivudine [mi] |
| triumeq component lamivudine |
| lamivudine [mart.] |
| 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one [who-ip] |
| lamivudine [usp monograph] |
| telura component of lamivudine |
| lamivudine [usan] |
| lamivudine [vandf] |
| lamivudine component of epzicom |
| lamivudine [hsdb] |
| emtricitabine impurity c [who-ip] |
| trizivir component lamivudine |
| lamivudine teva pharma b.v. |
| combivir component lamivudine |
| lamivudine component of dutrebis |
| delstrigo component lamivudine |
| lamivudine [ema epar] |
| lamivudine [who-ip] |
| lamivudine [orange book] |
| lamivudine [inn] |
| epzicom component lamivudine |
| lamivudinum [who-ip latin] |
| lamivudine [jan] |
| lamivudine component of trizivir |
| lamivudine [ep monograph] |
| lamivudine component of delstrigo |
| lamivudine component of lamivudine/zidovudine teva |
| lamivudine component of temixys |
| lamivudine component of combivir |
| lamivudine [who-dd] |
| lamivudine/zidovudine teva component lamivudine |
| S1706 |
| AKOS015854841 |
| cis-lamivudine |
| BBL033871 |
| HY-B0250 |
| AB00639995-06 |
| cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone |
| (+/-)-(cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidin-2-one |
| 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-(1h)-pyrimidin-2-one |
| JTEGQNOMFQHVDC-NKWVEPMBSA-N |
| (2r,5s)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine |
| 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1h)-pyrimidin-2-one |
| lamivudine & tnf-alpha & ifn-gamma |
| SCHEMBL109675 |
| NC00705 |
| NC00234 |
| KS-1073 |
| J-700183 |
| MLS006011910 |
| Q-201275 |
| AB00639995_09 |
| mfcd00869739 |
| 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one |
| 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone |
| SR-01000759420-5 |
| sr-01000759420 |
| 4-amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one |
| P17147 |
| lamivudine, united states pharmacopeia (usp) reference standard |
| lamivudine, 1.0 mg/ml in methanol, certified reference material |
| lamivudine, >=98% (hplc), powder |
| lamivudine for system suitability 1, european pharmacopoeia (ep) reference standard |
| lamivudine for system suitability 2, european pharmacopoeia (ep) reference standard |
| lamivudine, european pharmacopoeia (ep) reference standard |
| lamivudine, pharmaceutical secondary standard; certified reference material |
| HMS3713C16 |
| lamivudine, british pharmacopoeia (bp) reference standard |
| SW197614-3 |
| (-)-l-2',3'-dideoxy-3'-thiacytidine; lamivudine; epivir |
| Q422631 |
| gtpl12673 |
| lamivudine (epivir) |
| mfcd00870542 |
| 1117764-41-6 |
| (-)-bch189 |
| AMY384 |
| NCGC00159341-18 |
| lamivudine 100 microg/ml in acetonitrile:water |
| NCGC00159341-20 |
| rac-cis-lamivudine ((2rs,5sr)-lamivudine) |
| lamivudine- bio-x |
| BL164607 |
| EN300-123034 |
| Z1509637175 |
| lamivudine, (+)-cis- |
| 4-amino-1-((2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one |
| nsc-620753 |
| 2'-deoxy-3'-thiacytidine |
| 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1h)-one |
| 134680-32-3 |
| (+)-bch-189 |
| (+)-sddc |
| (+)-3tc |
| 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one |
| (+)-2',3'-dideoxy-3'-thiacytidine |
| 2(1h)-pyrimidinone, 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- |
| (+)-(2s,5r)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine |
| NCGC00090679-01 |
| smr000673568 |
| MLS001055352 |
| lamavudine |
| azt + 3tc combination |
| 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone |
| ent-lamivudine |
| cis(+)-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane |
| (2s-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone |
| HMS3039G03 |
| dtxcid803194 |
| tox21_303147 |
| cas-134678-17-4 |
| NCGC00257009-01 |
| tox21_111585 |
| tox21_111586 |
| CHEMBL18314 |
| 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one |
| h6s9d88t3d , |
| 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone |
| unii-h6s9d88t3d |
| (+)-bch 189 |
| 2(1h)-pyrimidinone, 4-amino-1-((2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)- |
| (2s-cis)-4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone |
| 2(1h)-pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2s-cis)- |
| JTEGQNOMFQHVDC-RQJHMYQMSA-N |
| (2s*,5r*)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine |
| SCHEMBL33979 |
| bch-189, (+)- |
| lamivudine impurity d [usp impurity] |
| lamivudine impurity d [ep impurity] |
| F8881-8887 |
| AKOS026729682 |
| Q27279715 |
| (+)-cis-lamivudine |
| AT23240 |
| DTXSID301307509 |
| 4-amino-1-[(2s,5r)-2-(hydroxy-methyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1h)-one |
| Z754931268 |
Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is a substrate of renal drug transporters OCT2, MATE1, and MATE2-K.
Lamivudine has an important role in patients with end-stage liver disease caused by HBV precore mutant strain. It has a high rate of antiviral resistance.
Lamivudine (LAM) has been shown to prevent de novo hepatitis B virus (HBV) infection in recipients of hepatitis B core antibody (HBcAb)-positive liver transplants (LT) but primarily in small studies with limited follow-up. Lamivudin resistance has been attributed mainly to a substitution of isoleucine or valine for methionine at residue 550 (M550I or M550V)
Lamivudine therapy would increase the risk of mutations 5.23 times higher than the untreated patients. Lamivudin can inhibit HBV replication rapidly and normalize ALT in majority adolescent CHB patients.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Lamivudine therapy would increase the risk of mutations 5.23 times higher than the untreated patients." | ( The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis. Chen, L; Chen, X; Cui, Q; Ding, K; Gong, Y; Lei, N; Peng, Z; Su, J; Tan, Y; Trinh, X; Yu, R, 2012) | 1.32 |
| "Lamivudine can inhibit HBV replication rapidly and normalize ALT in majority adolescent CHB patients. " | ( [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy]. Cui, ZY; Lu, WL; Wu, L; Xie, DY; Yao, GB; Yao, JL; Zhang, DF, 2004) | 2 |
| "Lamivudine was added because of de nova hepatitis B infection during her follow-up." | ( Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy? Baskin, E; Bayrakci, US; Haberal, M; Karakayali, H; Ozcay, F; Ozdemir, BH, 2008) | 1.07 |
Treatment with lamivudine of patients infected with hepatitis B virus (HBV) results in a high rate of drug resistance, which is primarily associated with the rtM204I/V substitution in the HBV reverse transcriptase domain. Re-treatment with lamvudine can control viral replication.
The use of anti-TNF-alpha therapy (plus lamivudine in the presence of concurrent underlying hepatitis B viral infection) appeared to be safe. Incidence of drug-related adverse events was similar in the two groups, except for nausea and diarrhoea.
Lamivudine pharmacokinetic parameters (mean +/- SD) after administration of 150mg twice daily were: peak plasma concentration (Cmax) 2077+/-816 microg/L; trough plasma concentration. (Cmin) 332+/-219 microg-L; elimination half-life (t 1/2beta) 6.
In therapy-naive patients, DTG combined with abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) resulted in a significantly better virological outcome.
In children aged ≤4 years, the relative bioavailability of lamivudine oral solution was 37% lower than that of a tablet formulation. In several Phase I pharmacokinetic studies, one Dutrebis fixed-dose combination tablet showed a higher bioavailability but comparable lamvudine and 400 mg raltegravir exposures.
The entecavir dose-response curve of lamivudine-resistant HBV RT mutants rtM204 for the replication of HBV decreased less than expected with increasing drug dose. Stavudine and lamivUDine are administered as fixed combination while nevirapine as separate dosage form which often results in poor compliance and adherence to therapy.
| Role | Description |
|---|---|
| HIV-1 reverse transcriptase inhibitor | An entity which inhibits the activity of HIV-1 reverse transcriptase. |
| antiviral drug | A substance used in the prophylaxis or therapy of virus diseases. |
| anti-HBV agent | An antiviral agent that destroys or inhibits the replication of the hepatitis B virus. |
| allergen | A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy. |
| prodrug | A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. |
| EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | A DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| monothioacetal | A thioacetal having the structure R2C(OR')(SR'). The term includes monothioketals, R =/= H, as a subclass. |
| primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
| oxacycle | Any organic heterocyclic compound containing at least one ring oxygen atom. |
| nucleoside analogue | An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Lamivudine Metabolism Pathway | 18 | 16 |
| Lamivudine Action Pathway | 0 | 5 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 3.5481 | 0.1800 | 13.5574 | 39.8107 | AID1468 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.7943 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| TDP1 protein | Homo sapiens (human) | Potency | 17.0980 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 10.0000 | 0.0002 | 21.2231 | 8,912.5098 | AID588516 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 2.5373 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 10.6822 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 14.1254 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 27.3060 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 (µMol) | 54.2000 | 0.0003 | 2.6311 | 9.0000 | AID1207746 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.1100 | 7.1903 | 10.0000 | AID1473738 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 (µMol) | 54.2000 | 0.0003 | 2.5955 | 9.0000 | AID1207746 |
| Capsid protein | Hepatitis B virus | IC50 (µMol) | 50.0500 | 0.1000 | 0.2650 | 0.4300 | AID1555312; AID1555320 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 (µMol) | 54.2000 | 0.0003 | 2.6311 | 9.0000 | AID1207746 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 (µMol) | 54.2000 | 0.0003 | 2.2545 | 9.6000 | AID1207746 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Hsf1 protein | Mus musculus (house mouse) | EC50 (µMol) | 0.2870 | 0.1600 | 24.4900 | 236.5000 | AID2382 |
| Albumin | Homo sapiens (human) | Kd | 44.0000 | 0.0893 | 3.3135 | 8.0000 | AID1238542 |
| Capsid protein | Hepatitis B virus | EC50 (µMol) | 5.1850 | 0.0002 | 0.2603 | 0.8194 | AID1377846; AID1771356 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | EC50 (µMol) | 25.0210 | 0.0004 | 0.6153 | 9.7000 | AID200001; AID200002 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID358077 | Cytotoxicity against HBV transfected human adriamycin-resistant wild type HepW10 cells by MTT assay | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID266288 | Antiviral activity against HBV M204I mutant transfected in B1 cell line at 10 ug/mL | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication. |
| AID519860 | Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1351358 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication at 100 uM after 72 hrs by RT-PCR method relative to control | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID353553 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV early antigen secretion | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Anti-HBV agents. Part 2: synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives. |
| AID246422 | In vitro effective concentration against Lamivudine resistant HIV-1 mutant M184V in human peripheral blood mononuclear cells | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides. |
| AID1320784 | Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring intracellular viral DNA copy number after 6 days by real-time qPCR method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID404999 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase M204I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1555319 | Inhibition of capsid protein in wild type Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in viral DNA level at 100 uM measured after 72 hrs by PCR analysis relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID235481 | Selectivity index is the ratio of CC50 to EC50 values | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept. |
| AID558373 | Drug level in HIV-infected pregnant woman cord blood plasma at 150 mg, po BID by LC/MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. |
| AID1636357 | Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. |
| AID574198 | Cytotoxicity against human skeletal muscle Myotube assessed as change in POLG mitochondrial RNA level on day 5 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID450971 | Cytotoxicity against human PBMC after 7 days by sulforhodamine B assay | 2009 | Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17 | Synthesis and anti-HIV activity of novel 2',3'-dideoxy-3'-thiacytidine prodrugs. |
| AID682494 | Antiviral activity against multidrug-resistant HIV1 4755-5 clade B clinical isolate infected in PHA-stimulated human PBMC assessed as inhibition of viral replication incubated for 6 hrs followed by compound-wash out measured after 6 days by liquid scintil | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID1228533 | Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in liver at 20 mg/kg/day, po measured after 3 days of treatment withdrawal | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID1869632 | Antiviral activity against wild type HBV infected in human HepG2 2.2.15 cells assessed as reduction in viral replication by DNA HYB (RI)/neutral red (Tox) assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID404991 | Antiviral activity against HBV genotype D in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID519963 | Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID685498 | Antiviral activity against HIV1 3B assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID1693334 | Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as decrease in extracellular viral DNA level at 0.8 uM measured after incubation of 6 days by RT-PCR analysis | 2021 | Bioorganic & medicinal chemistry, 01-01, Volume: 29 | Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. |
| AID423215 | Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as inhibition of HBeAg secretion at 200 ug/mL after 9 days by ELISA | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Schisanwilsonenes A-C, anti-HBV Carotane sesquiterpenoids from the fruits of Schisandra wilsoniana. |
| AID454485 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication | 2010 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1 | 2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly. |
| AID1599855 | Cytotoxicity against human HepG2.2.15 cells infected with HBV | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs. |
| AID1055510 | Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID527282 | Antiviral activity against HBV infected in duck primary hepatocytes | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus. |
| AID1197452 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4 | Synthesis and anti-hepatitis B virus activity of C4 amide-substituted isosteviol derivatives. |
| AID576240 | Cmin in HIV-1 infected children aged 8.5 to 12.3 years at 4 mg/kg, po every 12 hrs by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID563941 | Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S/M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. |
| AID311524 | Oral bioavailability in human | 2007 | Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24 | Hologram QSAR model for the prediction of human oral bioavailability. |
| AID1565093 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV IIIB | |||
| AID1862269 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors. |
| AID1226104 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 37.5 uM after 9 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1449529 | Mitochondrial toxicity in human HepG2 cells assessed as cytochrome c oxidase subunit 2 DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | 2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. |
| AID563936 | Antiviral activity against wild-type HIV1 pNL4-3 infected in TZM-bl cells by luciferase assay | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. |
| AID738969 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-hepatitis B virus lignans from the root of Streblus asper. |
| AID1055514 | Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID404909 | Cytotoxicity against human HepG2 cells after 3 days by MTT assay | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues. |
| AID557045 | Antiviral activity against HIV1 CRF17_BF harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID517944 | Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C/G190A mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID586263 | Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. |
| AID541157 | Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 6 low passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID626003 | Fold resistance, ratio of EC90 for adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant to EC90 for wild type Hepatitis B virus | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID245894 | Cytotoxic concentration to inhibit replication in 2.2.15 cells | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID252413 | Fold increase in ratio of EC50 against HIV-1 M184V to that of EC50 against HIV-1wild type | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides. |
| AID322851 | Fold resistance, ratio of entecavir-resistant HBV with reverse transcriptase L180M/S202G/M204V mutant to wild-type HBV genotype H | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID444058 | Volume of distribution at steady state in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1693335 | Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as decrease in extracellular viral DNA level measured after incubation of 6 days by RT-PCR analysis | 2021 | Bioorganic & medicinal chemistry, 01-01, Volume: 29 | Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. |
| AID410758 | Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID467613 | Volume of distribution at steady state in human | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID226233 | Fold increase ratio of HIV-1M184V to HIV-1XXBRU | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance. |
| AID410760 | Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID1226112 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 37.5 uM after 3 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID358085 | Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID626001 | Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID517842 | Cytotoxicity against HuH7 cells | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and |
| AID105891 | Cytotoxicity against uninfected MT-4 cells | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10 | Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. |
| AID354454 | Cytotoxicity against human HOG.R5 cells at 40 ug/ml after 4 days | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | New 3-O-acyl betulinic acids from Strychnos vanprukii Craib. |
| AID152656 | Inhibition of cell growth against HIV-1 infected PBM (Human peripheral blood mononuclear) cells | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Structure-activity relationships of beta-D-(2S,5R)- and alpha-D-(2S,5S)-1,3-oxathiolanyl nucleosides as potential anti-HIV agents. |
| AID1200846 | Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. |
| AID154956 | Anti-HIV-1 activity against human peripheral blood mononuclear (PBM) cells infected with HIV-1 strain LAV | 1993 | Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2 | Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents. |
| AID1507022 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication at 0.8 uM after 8 days by real time fluorescent PCR method relative to control | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. |
| AID266280 | Antiviral activity against HBV M204I mutant transfected in B1 cell line | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication. |
| AID105715 | Antiviral activity against HIV-1 resistant to 2-(2-Benzoyl-4-chloro-phenyl)-N-[4-(3-dimethylamino-propoxy)-2-methyl-phenyl]-acetamide in MT-4 cells | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10 | Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. |
| AID414790 | Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral genome replication after 9 days by Southern blot hybridization | 2009 | Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8 | Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives. |
| AID322825 | Inhibition of wild type HBV replication in Huh7 cells | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID732668 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD4+/CD8+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 0.9 +/-0.2%) | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID1687681 | Antiviral activity against HIV-1 K103N mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. |
| AID444053 | Renal clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1401779 | Antiviral activity against Hepatitis B virus harboring rtV173L/L180M/M204V mutant infected in HepGRL1 cells assessed as inhibition of intracellular HBV DNA level at 20 uM measured on day 9 by FQ-PCR analysis relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID1555321 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for capsid protein in lamivudine/entecavir-resistant Hepatitis B virus harboring rtL180M/rtM204V/rt184L mutant infected in human HepG2.2.15 cells assessed as reduction in viral DNA level | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. |
| AID458526 | Antiviral activity against Hepatitis B virus ayw in human 1.3ES2 cells stably transfected with 1.3 fold wild type HBV ayw strain genome cells assessed as reduction of viral DNA level after 6 days by RT-PCR | 2010 | Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3 | Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents. |
| AID427239 | Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye staining | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Synthesis and in vitro anti-hepatitis B virus activity of 6H-[1]benzothiopyrano[4,3-b]quinolin-9-ols. |
| AID1226126 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 150 uM after 6 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID540097 | Cytotoxicity against human HepG2(2.2.15) after 9 days by neutral dye uptake method | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24 | Synthesis and biological evaluation of 1H-benzimidazol-5-ols as potent HBV inhibitors. |
| AID519866 | Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID341746 | Drug level in human resting PBMC at 2.6 uM after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID1815394 | Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase F227L/V106A double mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID257335 | Inhibition of synthesis of extracellular virion DNA release in cultured human hepatoblastoma 2.2.15 cells | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system. |
| AID322840 | Antiviral activity against Lamivudine -adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V/M204V mutant | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1191974 | Selectivity index, ratio of CC50 for mock-infected human HeLa cells to EC50 for HIV2 ROD infected in human MT4 cells | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6 | Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity. |
| AID1363964 | Antiviral activity against lamivudine-resistant hepatitis B virus harboring reverse transcriptase M204I mutant infected in human Huh7 cells assessed as reduction in intracellular DNA levels measured on day 7 by real-time PCR analysis | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 | Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). |
| AID322831 | Fold resistance, ratio of EC50 for adenofir-resistant HBV with reverse transcriptase N236T mutant to EC50 for wild-type HBV | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID322850 | Fold resistance, ratio of Lamivudine -adenofir-resistant with HBV reverse transcriptase V173L/L180M/A181V/N236T mutant to wildtype HBV genotype E | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID541159 | Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 8 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID682495 | Cytotoxicity against PHA-stimulated human PBMC incubated for 6 hrs followed by compound-wash out measured after 6 days | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID1901998 | Cytotoxicity against human HepG2 2.2.15 cells infected with Hepatitis B virus assessed as reduction in cell growth by CCK8 assay | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231 | Design and synthesis of novel quinazolinone derivatives as anti-HBV agents with TLR8 agonist effect. |
| AID340711 | AUC (0 to 12 hrs) in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID301051 | Antiviral activity against HBV transfected Hep G2.2.15 cells assessed as inhibition of surface antigen HBsAg secretion | 2007 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19 | Two new alkaloids and active anti-hepatitis B virus constituents from Hypserpa nitida. |
| AID1351354 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication at 20 uM after 6 days by RT-PCR method relative to control | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID580188 | Cytotoxicity against human HepG2 cells after 3 days by neutral red dye uptake assay | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV). |
| AID358595 | Antiviral activity against Hepatitis B virus cell culture assay | 2001 | Journal of natural products, Nov, Volume: 64, Issue:11 | Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp. |
| AID1226091 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID410752 | Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID1869627 | Antiviral activity against wild type HBV infected in human HepG2 2.2.15 cells assessed as reduction in viral replication pre incubated for 3 days followed by replacement with fresh compounds for another 3 days prior to pronase treatment by RT-qPCR analysi | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID1815380 | Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID464070 | Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | 2010 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5 | Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. |
| AID1187820 | Antiviral activity against hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral replication | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | A new series of HAPs as anti-HBV agents targeting at capsid assembly. |
| AID1156487 | Cytotoxicity against human MT4 cells after 5 days by MTT assay | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. |
| AID323408 | Reduction in dexelvucitabine diphosphate choline level in human CEM cells at 1 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID1535522 | Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2019 | Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3 | Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. |
| AID625939 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hyb | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID582425 | Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver sorbitol dehydrogenase activity at 15 mg/kg, po qd measured on 4 to 24 weeks on 48 week study | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID517941 | Antiviral activity against HIV1 subtype C isolate 7 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID572774 | Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID417250 | Cmin in HIV-infected human assessed as Lamivudine triphosphate level in PBMC at 300 mg QD for 7 days measured per 10'6 cells in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID557050 | Antiviral activity against HIV1 clade H harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID682493 | Antiviral activity against NRTI-resistant HIV1 71361-1 clade B clinical isolate infected in PHA-stimulated human PBMC assessed as inhibition of viral replication incubated for 6 hrs followed by compound-wash out measured after 6 days by liquid scintillati | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID1888691 | Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay | |||
| AID464072 | Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | 2010 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5 | Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. |
| AID246791 | In vitro effective concentration against Lamivudine resistant HIV-1 mutant M184V in human peripheral blood mononuclear cells | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides. |
| AID322834 | Antiviral activity against wild type HBV genotype H assessed as inhibition of replication | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID437963 | Cytotoxicity against human HepG2(2.2.15) cells | 2009 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23 | Anti-HBV agents. Part 3: preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors. |
| AID200001 | In vitro antiviral activity against HIV-1 Reverse transcriptase M184V mutant | 2003 | Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12 | The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V). |
| AID340716 | Ratio of Cmax to Cmin in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1191294 | Decrease in HBV viral DNA replication in human HepG2(2.2.15) cells at 0.75 to 3 uM after 72 hrs by real-time PCR analysis | 2015 | European journal of medicinal chemistry, Jan-27, Volume: 90 | Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents. |
| AID1152370 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay | 2014 | Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12 | Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. |
| AID1631596 | Antiviral activity against HIV-1 NL4-3 infected in human U87 cells expressing CD4.CXCR4 assessed as inhibition of p24 production at 10 uM measured after 4 days by p24 ELISA | 2016 | Bioorganic & medicinal chemistry, 09-01, Volume: 24, Issue:17 | Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA. |
| AID417064 | Drug metabolism in HIV-infected human PBMC assessed as zidovudine diphosphate level at 300 mg administered in two courses, first BID for 7 to 14 days followed by QD for 7 days and second course the subjects were switched to the other regimen measured per | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID105370 | In vitro concentration required to cause death of uninfected MT-4 cell | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs? |
| AID675188 | Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. |
| AID322829 | Antiviral activity against lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant assessed as inhibition of replication | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1741378 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in HBeAg secretion incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by ELISA | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. |
| AID574195 | Cytotoxicity against human skeletal muscle Myoblast assessed as change in Tfam mitochondrial RNA level on day 2 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID580186 | Cytotoxicity against human HuH7 cells after 4 days by neutral red dye uptake assay | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV). |
| AID1729159 | Antiviral activity against HIV1 harboring Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID340717 | AUC (0 to 12 hrs) in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID218241 | In vitro cytotoxicity against Vero cells | 2000 | Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21 | Synthesis and antiviral activity of oxaselenolane nucleosides. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID548577 | Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID520605 | Cytotoxicity against human WI38 cells by neutral red assay | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Anti-BK virus activity of nucleoside analogs. |
| AID358067 | Antiviral activity against HBV in mouse ayw wild type HBV-Met cells assessed as inhibition of viral DNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID572769 | Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID340712 | Half life in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID558394 | Ratio of drug level in HIV-infected pregnant woman amniotic fluid to maternal blood plasma at 150 mg, po BID by LC/MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. |
| AID519883 | Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1741375 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in intracellular viral DNA level | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. |
| AID1661349 | Elimination half life in monkey plasma at 20 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID297680 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 at 100 uM by microplate alamar blue assay | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19 | Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. |
| AID1902003 | Antiviral activity against lamivudine/entecavir- resistant Hepatitis B virus infected in human HepG2 A64 cells assessed as inhibition of DNA replication | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231 | Design and synthesis of novel quinazolinone derivatives as anti-HBV agents with TLR8 agonist effect. |
| AID519861 | Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID246535 | Effective concentration to inhibit 50 % of herpes simplex virus type 1 replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID574200 | Cytotoxicity against human skeletal muscle Myoblast at 100 uL on day 5 by WST-1 assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID691385 | Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication at 0.5 to 1 ug/mL | 2012 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20 | A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses. |
| AID1401769 | Cytotoxicity against human HepG2.2.15 cells after 9 days by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID492272 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus | 2010 | Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14 | Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus. |
| AID541160 | Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 9 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID517942 | Antiviral activity against HIV1 subtype D isolate 8 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID576238 | AUC (0 to tau) in HIV-1 infected children aged 2.5 to 4.8 years at 4 mg/kg, po every 12 hrs by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID548584 | Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID541150 | Selectivity ratio of EC50 for antiviral activity against 3TC-resistant HIV1 selected after 4 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID322830 | Antiviral activity against lamivudine-adefovir-resistant HBV with reverse transcriptase L180M/M204V/N236T mutant assessed as inhibition of replication | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID548830 | Antiviral activity against HIV1 isolate 192 harboring reverse transcriptase M41L/T215Y mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1199052 | Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay | 2014 | Journal of natural products, Jun-27, Volume: 77, Issue:6 | Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead. |
| AID1565092 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay | |||
| AID1192273 | Antiviral activity against hepatitis B viral in human HepG2(2.2.15) cells assessed as decrease in surface antigen HBsAg secretion at 25 ug/ml after 7 days | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | A coumarin lignanoid from the stems of Kadsura heteroclita. |
| AID405002 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I/L180M/M204I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID565982 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Structure-activity relationships study of 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives as novel non-nucleoside anti-hepatitis B virus agents. |
| AID340697 | Renal clearance in healthy human at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1661348 | AUC (0 to 24 hrs) in monkey plasma at 20 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID1869718 | Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 3 days by MTT assay | |||
| AID406546 | Selectivity index, ratio of TC50 for human HepG2.2.15 cells to IC50 for HBV DNA replication | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Synthesis and anti-hepatitis B virus evaluation of novel ethyl 6-hydroxyquinoline-3-carboxylates in vitro. |
| AID572778 | Ratio of IC50 for HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID417245 | Tmax in HIV-infected human assessed as Lamivudine diphosphate level in PBMC at 300 mg QD for 7 days in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID548832 | Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID392504 | Antiviral activity against Cowpox virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID423283 | Selectivity ratio of EC50 for wild type HIV2 ROD to EC50 for wild type HIV1 NL4-3 M184V variant | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. |
| AID1387674 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 1 mM supplemented with fresh medium containing compound every 3 days for 9 days measured after 9 days by ELISA relative to control | 2018 | Journal of natural products, 10-26, Volume: 81, Issue:10 | Matrine-Type Alkaloids from the Roots of Sophora flavescens and Their Antiviral Activities against the Hepatitis B Virus. |
| AID105716 | Antiviral activity against HIV-1 (strain RF) infected MT-4 cells | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10 | Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. |
| AID1199053 | Selectivity index, ratio of CC50 for human MT4 cells to IC50 for Human immunodeficiency virus 1 3b infected in human MT4 cells | 2014 | Journal of natural products, Jun-27, Volume: 77, Issue:6 | Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead. |
| AID246536 | Effective concentration to inhibit 50 % of herpes simplex virus type 2 replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID444056 | Fraction escaping gut-wall elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID155793 | In vitro anti-HIV activity in peripheral blood mononuclear cells. | 1997 | Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19 | Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. |
| AID1363962 | Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 | Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). |
| AID517940 | Antiviral activity against HIV1 subtype C isolate 6 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID1771367 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral replication incubated for 8 days by southern blotting analysis | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. |
| AID89029 | Antiviral activity against wild type HIV virus(xxBRU) in Human peripheral blood mononuclear (PBM) cells | 2004 | Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7 | Synthesis, structure-activity relationships, and mechanism of drug resistance of D- and L-beta-3'-fluoro-2',3'-unsaturated-4'-thionucleosides as anti-HIV agents. |
| AID217731 | Cytotoxicity was determined in the vero cells infected with HIV-I | 1993 | Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2 | Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents. |
| AID596754 | Antiviral activity against HBV transfected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion by ELISA | 2011 | Journal of natural products, Apr-25, Volume: 74, Issue:4 | Homoflavonoid glucosides from Ophioglossum pedunculosum and their anti-HBV activity. |
| AID323411 | Reduction in dexelvucitabine diphosphate choline level in human PBMC at 33.3 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID732670 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD4+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 13.6 +/-2.7%) | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID1401791 | Antiviral activity against DHBV infected in duck assessed as inhibition of viral DNA level in serum at 10 mg/kg, po administered once daily measured on day 10 by SYBR Green I dye-based FQ-PCR analysis relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID675187 | Antiviral activity against HIV-1 subtype B US/92/727 infected in PBMC assessed as inhibition of viral replication after 7 days by XTT assay | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. |
| AID517938 | Antiviral activity against HIV1 subtype B isolate 4 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID1649795 | Cytotoxicity in human HepG2 cells assessed as induction of cell killing | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | Discovery of (1 |
| AID423157 | Antiviral activity against wild type HIV1 NL4-3 produced from full length pR9deltaApa infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. |
| AID417240 | AUC in HIV-infected human assessed as Lamivudine monophosphate level in PBMC at 300 mg QD for 7 days in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID1535525 | Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay | 2019 | Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3 | Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1228536 | Volume of distribution in Sprague-Dawley rat at 2.5 mg/kg, iv | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID212881 | Toxic activity against peripheral blood mononuclear cells. | 1997 | Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19 | Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. |
| AID664470 | Antiviral activity against wild type HIV1 clade C 98USMSC5016 clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infect | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors. |
| AID582426 | Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver alanine aminotransferase activity at 15 mg/kg, po qd measured on 4 to 24 weeks on 48 week study | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID614130 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBsAg antigen secretion after 72 hrs by ELISA | 2011 | Journal of natural products, Aug-26, Volume: 74, Issue:8 | Swerilactones L-O, secoiridoids with C₁₂ and C₁₃ skeletons from Swertia mileensis. |
| AID1729151 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID541158 | Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 6 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID781025 | Cytotoxicity against human MT4 cells after 5 days by MTT assay | 2013 | Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22 | Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. |
| AID582429 | Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver alanine aminotransferase activity at 15 mg/kg, po qd for 48 weeks | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1599856 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in cytoplasmic DNA synthesis by reed and munch method | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs. |
| AID664472 | Antiviral activity against multidrug-resistant HIV1 clade B 4775-5 clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround i | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors. |
| AID582400 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 4.3 +/- 1.5 log10 ng/ml) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID576236 | Cmin in HIV-1 infected children aged 2.5 to 4.8 years at 4 mg/kg, po every 12 hrs by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1320863 | Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. |
| AID1815387 | Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase L100I mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID517831 | Antiviral activity against HBV assessed as inhibition of viral DNA replication | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and |
| AID322835 | Antiviral activity against wild type HBV genotype E assessed as inhibition of replication | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1587129 | Oral bioavailability in human administered once daily | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | A Survey of the Structures of US FDA Approved Combination Drugs. |
| AID404996 | Antiviral activity against HBV genotype D with reverse transcriptase L80I/L180M/M204I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID572995 | Mitochondrial toxicity in human HepG2 cells assessed as percent lactic acid production at 10 uM after 14 days by real-time PCR relative to beta-actin DNA | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID154974 | Concentration required for antiviral activity in PBMC (human peripheral blood mononuclear cells) infected with HIV-1 strain LAV | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Structure-activity relationships of beta-D-(2S,5R)- and alpha-D-(2S,5S)-1,3-oxathiolanyl nucleosides as potential anti-HIV agents. |
| AID586326 | Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Antiviral activity of seed extract from Citrus bergamia towards human retroviruses. |
| AID572779 | Ratio of IC50 for HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID548820 | Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1544317 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM measured on day 3 by FQ-PCR analysis relative to control | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID422691 | Ratio of IC50 for HIV1 with reverse transcriptase K70E/M184V mutation to IC50 for wild type HIV1 | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase. |
| AID1191399 | Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3 | Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. |
| AID444051 | Total clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID322839 | Antiviral activity against lamivudine-adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V mutant | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1729152 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV 3B infected in human MT4 cells | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID576251 | Apparent oral clearance in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 24 hrs coadministered with 8 mg/kg abacavir by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1351357 | Antiviral activity against lamivudine/entecavir resistant HBV harboring reverse transcriptase L180M/M204V/T184L mutant infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication at 100 uM after 72 hrs by RT-PCR method relative t | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID423281 | Selectivity ratio of EC50 for multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase to EC50 for wild type HIV1 NL4-3 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. |
| AID1377846 | Inhibition of capsid in HBV infected in human HepAD38 cells assessed as reduction in tetracycline-induced cccDNA formation by measuring reduction in HBe antigen secretion after 14 days by ELISA | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID1152374 | Selectivity index, ratio CC50 for human MT4 cells to EC50 for HIV 1 3B | 2014 | Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12 | Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. |
| AID404986 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1226119 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 75 uM after 9 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID257336 | Inhibition of synthesis of intracellular HBV DNA replicative intermediates in cultured human hepatoblastoma 2.2.15 cells | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system. |
| AID519886 | Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1191971 | Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6 | Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity. |
| AID404984 | Antiviral activity against HBV genotype D with reverse transcriptase L80I/L180M/M204I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID727265 | Mitochondrial toxicity in human HepG2 cells assessed as lactate dehydrogenase release up to 200 uM | 2013 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2 | 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. |
| AID358068 | Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral pre-genomic RNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID417061 | Drug metabolism in HIV-infected human PBMC assessed as zidovudine monophosphate level at 300 mg administered in two courses, first QD for 7 days followed by BID for 7 to 14 days and second course the subjects were switched to the other regimen measured pe | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID1555311 | Inhibition of capsid protein in Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in viral DNA level supplemented with fresh medium containing compound every 2 days and measured after 6 days by RT-PCR analysis relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. |
| AID1203823 | Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method | 2015 | Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8 | β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms. |
| AID404979 | Antiviral activity against HBV genotype D in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1449516 | Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | 2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. |
| AID404993 | Antiviral activity against HBV genotype D with reverse transcriptase M204I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1555320 | Inhibition of capsid protein in lamivudine/entecavir-resistant Hepatitis B virus harboring rtL180M/rtM204V/rt184L mutant infected in human HepG2.2.15 cells assessed as reduction in viral DNA level measured after 72 hrs by PCR analysis | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. |
| AID152654 | In vitro cytotoxicity against PBM cells | 2000 | Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21 | Synthesis and antiviral activity of oxaselenolane nucleosides. |
| AID410756 | Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1226105 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as cell survival at 300 uM after 9 days (Rvb = 100%) | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID47429 | In vitro cytotoxicity against CEM cells | 2000 | Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21 | Synthesis and antiviral activity of oxaselenolane nucleosides. |
| AID1503177 | Cytotoxicity against human SupT1 cells assessed as decrease in cell viability after 48 hrs by CCK-8 assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities. |
| AID417234 | Drug metabolism in HIV-infected human PBMC assessed as zidovudine triphosphate level at 300 mg administered in two courses, first QD for 7 days followed by BID for 7 to 14 days and second course the subjects were switched to the other regimen measured per | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID1815385 | Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID266284 | Antiviral activity against duck HBV in primary duck hepatocytes | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication. |
| AID557047 | Antiviral activity against HIV1 clade D harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID523460 | Decrease in HscA70-mRNA expression in Hepatitis B virus infected in human HepG2(2.2.15) cells at 13 uM after 24-36 hrs by RT-PCR analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus. |
| AID598201 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for Hepatitis B virus | 2011 | Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10 | Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus. |
| AID417251 | Cmin in HIV-infected human assessed as Lamivudine diphosphate level in PBMC at 300 mg QD for 7 days measured per 10'6 cells in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID1694157 | Antiviral activity against Hepatitis B virus infected in human HePAD38 cells assessed as reduction in viral DNA replication incubated for 7 days by RT-PCR analysis | 2021 | Bioorganic & medicinal chemistry, 02-01, Volume: 31 | Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. |
| AID576248 | Cmin in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 24 hrs coadministered with 8 mg/kg abacavir by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID246787 | In vitro effective concentration against Lamivudine resistant wild type HIV-1 in human peripheral blood mononuclear cells | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides. |
| AID407142 | Selectivity index, ratio of CC50 for human Hep G2.2.15 cells to IC50 for HBV e antigen secretion | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13 | Synthesis and in vitro anti-hepatitis B virus activities of 4-aryl-6-chloro-quinolin-2-one and 5-aryl-7-chloro-1,4-benzodiazepine derivatives. |
| AID405001 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L180M/M204I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1330730 | Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by CCK-8 assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID1649791 | Inhibition of reverse transcriptase in HBV infected in human HepG2.2.15 cells assessed as induction of intracellular viral RNA accumulation at 2 uM for 4 days by qPCR or qRT-PCR relative to control | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | Discovery of (1 |
| AID1544341 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID1457761 | Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring extracellular viral DNA copy number after 6 days by real-time qPCR method | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID1401787 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as intracellular HBV DNA levels at 20 uM measured on day 6 by FQ-PCR analysis | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID548576 | Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID341757 | Drug level in human phytohemagglutininin-activated PBMC assessed as Lamivudine diphosphate level at 2.6 uM after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID1888694 | Antiviral activity against HIV1 with RT L100I mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay | |||
| AID1228735 | Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay | 2015 | Journal of natural products, May-22, Volume: 78, Issue:5 | Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata. |
| AID1380574 | Resistance index, ratio of IC50 for antiviral activity against HIV1 virions containing reverse transcriptase E138K/M184V mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells to IC50 for antiviral activ | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents. |
| AID1226117 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 300 uM after 9 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1661387 | Inhibition of HIV1 HA-tagged Vif expressed in HEK293T cells co-expressing eGFP-tagged pcDNA-APOBEC3G assessed as reduction in Vif-mediated A3G degradation at 10000 nM measured after 48 hrs by flow cytometry | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID301050 | Cytotoxicity against human Hep G2.2.15 cells | 2007 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19 | Two new alkaloids and active anti-hepatitis B virus constituents from Hypserpa nitida. |
| AID1743621 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID548829 | Antiviral activity against HIV1 isolate 188 harboring reverse transcriptase T215Y/M184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID582396 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 1495 +/- 890 pg) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1631598 | Antiviral activity against HIV-1 NL4-3 infected in human U87 cells expressing CD4.CXCR4 assessed as inhibition of p24 production at 100 uM measured after 4 days by p24 ELISA | 2016 | Bioorganic & medicinal chemistry, 09-01, Volume: 24, Issue:17 | Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA. |
| AID519858 | Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID588209 | Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset | 2010 | Chemical research in toxicology, Jul-19, Volume: 23, Issue:7 | Developing structure-activity relationships for the prediction of hepatotoxicity. |
| AID358080 | Cytotoxicity against HBV transfected human HepG2 cells by MTT assay | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID358065 | Antiviral activity against HBV in adriamycin-resistant wild type HepW10 cells assessed as inhibition of viral DNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID1449524 | Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | 2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. |
| AID1226086 | Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTT assay | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID664469 | Antiviral activity against wild type HIV1 clade B 94US3393IN clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infecti | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors. |
| AID1226115 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 75 uM after 6 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID437965 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV surface antigen secretion | 2009 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23 | Anti-HBV agents. Part 3: preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors. |
| AID565914 | Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion after 6 days by ELISA | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Structure-activity relationships study of 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives as novel non-nucleoside anti-hepatitis B virus agents. |
| AID410754 | Antiviral activity against lamivudine-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID478520 | Cytotoxicity against human HepG2(2.2.15) cells after 9 days by MTT assay | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Synthesis and antiviral activity of new acrylamide derivatives containing 1,2,3-thiadiazole as inhibitors of hepatitis B virus replication. |
| AID1693338 | Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as inhibition of pregenomic RNA expression at 1 uM measured after incubation of 6 by RT-PCR analysis relative to control | 2021 | Bioorganic & medicinal chemistry, 01-01, Volume: 29 | Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. |
| AID1661335 | Cytotoxicity against HEK293 cells assessed as cell viability by MTT assay | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID464067 | Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | 2010 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5 | Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. |
| AID740215 | Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-HBV active constituents from Piper longum. |
| AID384984 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV surface antigen secretion | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Periglaucines A-D, anti-HBV and -HIV-1 alkaloids from Pericampylus glaucus. |
| AID417244 | Tmax in HIV-infected human assessed as Lamivudine triphosphate level in PBMC at 300 mg QD for 7 days in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID322828 | Antiviral activity against adenofir-resistant HBV with reverse transcriptase N236T mutant assessed as inhibition of replication | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1351364 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for antiviral activity against lamivudine/entecavir resistant HBV harboring reverse transcriptase L180M/M204V/T184L mutant infected in human HepG2(2.2.15) cells | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID1457789 | Selectivity index, ratio of CC50 for HepG2.2.15 cells to EC50 for HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring intracellular viral DNA copy | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID586277 | Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. |
| AID664467 | Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors. |
| AID540220 | Clearance in human after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID1377842 | Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in viral replication by RT-PCR method | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID1422387 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in extracellular viral DNA levels after 6 days by qPCR/TaqMan assay | 2018 | Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23 | Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action. |
| AID417256 | Cmax in HIV-infected human assessed as Lamivudine triphosphate level in PBMC at 300 mg QD for 7 days measured per 10'6 cells in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID574194 | Cytotoxicity against human skeletal muscle Myoblast assessed as change in POLG mitochondrial RNA level on day 2 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID105557 | In vitro concentration required to inhibit the cytopathicity of HIV-1 IIIB on MT-4 cell | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs? |
| AID105880 | Concentration required to inhibit syntica formation by 50% in HIV-1 infected MT-4 cells | 1994 | Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14 | Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates. |
| AID358079 | Cytotoxicity against HBV transfected mouse ayw wild type HBV-Met cells by MTT assay | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID1055520 | Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID1888699 | Antiviral activity against HIV1 with RT RES056 mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay | |||
| AID1316334 | Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID89158 | Effective concentration against M184V HIV-1 virus in human peripheral blood mononuclear cells | 2004 | Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13 | Synthesis, structure-activity relationships, and drug resistance of beta-d-3'-fluoro-2',3'-unsaturated nucleosides as anti-HIV Agents. |
| AID1729160 | Antiviral activity against HIV1 harboring E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID586318 | Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression at 0.23 ug/ml after 5 days post infection by quantitative real time RT-PCR | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Antiviral activity of seed extract from Citrus bergamia towards human retroviruses. |
| AID1661366 | Ratio of Cmax in monkey plasma at 20 mg/kg, po administered as single dose measured after 1 hr to Cmax in monkey plasma at 20 mg/kg, po administered as single dose measured after 24 hrs | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID519867 | Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID548819 | Antiviral activity against HIV1 isolate 070 harboring reverse transcriptase 65R/S68G mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1377854 | Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in intracellular viral DNA level at 10 uM by RT-PCR method relative to control | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID1055518 | Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID1565094 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV RES056 | |||
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1320776 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID1555310 | Cytotoxicity against human HepG2.2.15 cells assessed as cell viability measured after 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. |
| AID1070444 | Antiviral activity against HIV-1 3B/H9 infected in human HOG.R5 cells transfected with HIV1 LTR-GFP assessed as inhibition of viral replication by fluorescence analysis | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Bioactive compounds from Vitex leptobotrys. |
| AID1661351 | Cmax in monkey plasma at 20 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID618859 | Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. |
| AID152626 | Activity against Lamivudine-resistant virus (HIV-1M184V) in human PBM cells, expressed as EC90 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance. |
| AID1869626 | Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay to EC50 for anti-HIV activity against wild type HIV-2 ROD infected in human MT4 cells assessed as inhibition of HIV-induced cyto | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID328845 | Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3 | Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. |
| AID675189 | Cytotoxicity against human CEM-SS cells by XTT method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. |
| AID1555312 | Inhibition of capsid protein in Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in viral DNA level at 4 uM supplemented with fresh medium containing compound every 2 days and measured after 6 days by RT-PCR analysis | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. |
| AID358066 | Antiviral activity against HBV in adriamycin-resistant HepD2 cells with RTM20V and RTV180M mutation assessed as inhibition of viral DNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID1226106 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as cell survival at 150 uM after 9 days (Rvb = 100%) | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1729158 | Antiviral activity against HIV1 harboring Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID152967 | Concentration required to cause death of PBMC cells was determined in vitro | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID405007 | Effect on replication efficiency of HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I/M204I mutation in human Huh7 cells assessed as decrease in viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID625276 | FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI | 2011 | Drug discovery today, Aug, Volume: 16, Issue:15-16 | FDA-approved drug labeling for the study of drug-induced liver injury. |
| AID1687683 | Antiviral activity against HIV-1 E138K mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. |
| AID548827 | Antiviral activity against HIV1 isolate 180 harboring reverse transcriptase K65R mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID781024 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells | 2013 | Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22 | Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. |
| AID282662 | Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. |
| AID614564 | Cytotoxicity against human HepG2(2.2.15) cells after 24 hours following 9 days of treatment by neutral red dye uptake assay | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18 | Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents. |
| AID1507018 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 8 days by ELISA | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. |
| AID1351353 | Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID582398 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd for 48 weeks measured on 60th week | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1888690 | Antiviral activity against HIV1 3B infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay | |||
| AID527284 | Antiviral activity against HBV infected in human 2.2.15 cell | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus. |
| AID1320785 | Selectivity ratio of CC50 for human HepG2(2.2.15) cells to EC50 for reduction in HBV ayw1 intracellular DNA copy number | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID323406 | Reduction in [3H]dexelvucitabine triphosphate in human CEM cells per 10^6 cells at 33.3 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID1888704 | Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT F227L + V106A mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells | |||
| AID598199 | Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 4 days by RT-PCR analysis | 2011 | Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10 | Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus. |
| AID548803 | Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1636440 | Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. |
| AID89159 | Effective concentration against Wild Type HIV-1 virus in human peripheral blood mononuclear cells | 2004 | Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13 | Synthesis, structure-activity relationships, and drug resistance of beta-d-3'-fluoro-2',3'-unsaturated nucleosides as anti-HIV Agents. |
| AID586325 | Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Antiviral activity of seed extract from Citrus bergamia towards human retroviruses. |
| AID1055519 | Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID1199054 | Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay | 2014 | Journal of natural products, Jun-27, Volume: 77, Issue:6 | Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead. |
| AID384986 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV e-antigen secretion | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Periglaucines A-D, anti-HBV and -HIV-1 alkaloids from Pericampylus glaucus. |
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID404983 | Antiviral activity against HBV genotype D with reverse transcriptase L180M/M204I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID341759 | Drug level in human phytohemagglutininin-activated PBMC assessed as Lamivudine triphosphate level at 2.6 uM after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID1226098 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 150 uM after 6 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID738968 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-hepatitis B virus lignans from the root of Streblus asper. |
| AID1743622 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV1 RES056 infected in human MT4 cells | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID1152372 | Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay | 2014 | Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12 | Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. |
| AID520604 | Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Anti-BK virus activity of nucleoside analogs. |
| AID614565 | Selectivity index, ratio of TC50 for human HepG2(2.2.15) cells to IC50 for HBV | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18 | Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents. |
| AID541154 | Selectivity ratio of EC50 for antiviral activity against APV-resistant HIV1 selected after 2 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID1199051 | Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay | 2014 | Journal of natural products, Jun-27, Volume: 77, Issue:6 | Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead. |
| AID2997 | In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells | 1997 | Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19 | Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. |
| AID410601 | Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as replication intermediates after 24 hrs | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID560903 | Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. |
| AID740216 | Cytotoxicity against human HepG2(2.2.15) cells | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-HBV active constituents from Piper longum. |
| AID340703 | Apparent total oral clearance in healthy human at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID580187 | Antiviral activity against Hepatitis B virus infected in human HepG2 cells assessed as reduction in viral DNA after 3 days by Southern blotting | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV). |
| AID1741367 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in intracellular viral DNA level at 100 uM incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by fluorogenic probe | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. |
| AID261857 | Inhibition of wild type HBV transfected in human hepatoblastoma 2.2.15 cells | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6 | Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV. |
| AID86871 | Cytotoxic concentration against Hepatitis B virus in human hepatoblastoma cell line | 1998 | Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12 | Does the anti-hepatitis B virus activity of (+)-5'-noraristeromycin exist in its 4'-epimer and 4'-deoxygenated derivatives? |
| AID1743620 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID358076 | Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID519887 | Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID658564 | Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay | 2012 | Journal of natural products, Mar-23, Volume: 75, Issue:3 | Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium. |
| AID423211 | Antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as inhibition of HBsAg secretion at 200 ug/mL after 9 days by ELISA | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Schisanwilsonenes A-C, anti-HBV Carotane sesquiterpenoids from the fruits of Schisandra wilsoniana. |
| AID1649794 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | Discovery of (1 |
| AID301054 | Selectivity index, ratio of CC50 for human Hep G2.2.15 cells to IC50 for HBV e antigen secretion in HBV transfected Hep G2.2.15 cells | 2007 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19 | Two new alkaloids and active anti-hepatitis B virus constituents from Hypserpa nitida. |
| AID548838 | Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID340709 | Cmin in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1377841 | Cytotoxicity against African green monkey Vero cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID1156488 | Selectivity index, ratio of CC50 for human MT4 cells to IC50 for wild type HIV1 3B | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. |
| AID1330732 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion by ELISA | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID1072514 | Antiviral activity against Hepatitis B virus assessed as inhibition of Hepatitis B virus DNA replication | 2014 | European journal of medicinal chemistry, Mar-21, Volume: 75 | A review of non-nucleoside anti-hepatitis B virus agents. |
| AID1226100 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 37.5 uM after 6 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID322842 | Antiviral activity against lamivudine-adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V/N236T mutant | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID572776 | Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID626002 | Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hybri | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID582430 | Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver aspartate aminotransferase activity at 15 mg/kg, po qd for 48 weeks | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1434728 | Cytotoxicity against human CEM cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. |
| AID519868 | Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID301052 | Antiviral activity against HBV transfected Hep G2.2.15 cells assessed as inhibition of e antigen HBsAg secretion | 2007 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19 | Two new alkaloids and active anti-hepatitis B virus constituents from Hypserpa nitida. |
| AID417238 | AUC in HIV-infected human assessed as Lamivudine triphosphate level in PBMC at 300 mg QD for 7 days in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID527720 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication at 0.5 to 1 ug/ml after 2 days relative to control | 2010 | Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21 | Synthesis and in vitro antiviral activities of 3'-fluoro (or chloro) and 2',3'-difluoro 2',3'-dideoxynucleoside analogs against hepatitis B and C viruses. |
| AID519863 | Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID582415 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd for 48 weeks | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID548831 | Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1197447 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of surface antigen secretion by EIA | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4 | Synthesis and anti-hepatitis B virus activity of C4 amide-substituted isosteviol derivatives. |
| AID1888689 | Antiviral activity against HIV1 with RT F227L + V106A mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay | |||
| AID478524 | Antiviral activity against HBV infected in HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 8 days by radio immunoassay | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Synthesis and antiviral activity of new acrylamide derivatives containing 1,2,3-thiadiazole as inhibitors of hepatitis B virus replication. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1661392 | Antiviral activity against JRFL pseudotyped HIV1 infected in human Hut/CCR5 cells assessed as time needed to reach 50% reduction of virus infection at 1000 nM incubated with cells for 4 hrs prior to compound washout followed by viral infection and measure | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID425652 | Total body clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID1330731 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion by ELISA | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID410602 | Cytotoxicity against human HepG2(2.2.15) cells assessed as uptake of neutral red dye after 24 hrs | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID444052 | Hepatic clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1694158 | Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay | 2021 | Bioorganic & medicinal chemistry, 02-01, Volume: 31 | Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. |
| AID1507021 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication at 4 uM after 8 days by real time fluorescent PCR method relative to control | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. |
| AID732680 | Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID1742102 | Antiviral activity against lamivudine and entecavir-resistant HBV harboring rtL180 M/rtM204V/rtT184L mutant infected in human HepG2.2.15 cells assessed as inhibition of DNA replication at 100 uM supplemented with fresh medium containing compound every 2 d | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. |
| AID563944 | Antiviral activity against HIV1 pNL4-3 harboring chimeric pTKD infected in TZM-bl cells after 72 hrs by luciferase assay | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. |
| AID1226096 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 37.5 uM after 3 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1687684 | Antiviral activity against HIV-1 RES056 mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. |
| AID519971 | Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT to EC50 for 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1303216 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | Design, synthesis and anti-HIV activity of novel quinoxaline derivatives. |
| AID1226087 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1771364 | Inhibition of capsid protein in HBV infected in human HepDES19 cells assessed as inhibition of viral replication by measuring minus polarity DNA level at 5 uM incubated for 3 days by strand preferential qPCR analysis relative to control | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. |
| AID1377853 | Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in intracellular viral DNA level by RT-PCR method | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID519961 | Selectivity ratio of EC50 for 0.02 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.02 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID582397 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd measured on 12th week on 48 weeks study | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID519856 | Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID558380 | Drug level in HIV-infected pregnant woman amniotic fluid at 150 mg, po BID by LC/MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. |
| AID517836 | Antiviral activity against HBV assessed as inhibition of viral DNA replication at 0.5 to 1 ug/mL | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and |
| AID218507 | Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells; ND means Not determined | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID548816 | Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID682492 | Antiviral activity against NNTRI-resistant HIV1 A-17 clade B clinical isolate infected in PHA-stimulated human PBMC assessed as inhibition of viral replication incubated for 6 hrs followed by compound-wash out measured after 6 days by liquid scintillation | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID1055513 | Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID574189 | Cytotoxicity against human skeletal muscle Myoblast assessed as change in MTCYB mitochondrial RNA level on day 2 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID586354 | Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I, K82N mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysi | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. |
| AID548840 | Antiviral activity against HIV1 isolate 217 harboring reverse transcriptase D67N/K70E/M184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID548821 | Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID410759 | Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID1743630 | Antiviral activity against HIV1 harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID1869634 | Selectivity index, ratio of CC50 cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability to EC50 for antiviral activity against wild type HBV infected in human HepG2 2.2.15 cells assessed as reduction in viral replication by DN | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID1544304 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days and measured on day 9 by ELISA relative to contro | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID576256 | AUC in HIV-1 infected children with body weight <17 kg at 10 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID257338 | Selectivity index (CC50/EC50) for inhibition of HBV virion DNA synthesis in human hepatoblastoma 2.2.15 cells | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system. |
| AID476929 | Human intestinal absorption in po dosed human | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Neural computational prediction of oral drug absorption based on CODES 2D descriptors. |
| AID1503175 | Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells at 100 uM after 48 hrs by luciferase reporter gene assay relative to control | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities. |
| AID1888698 | Antiviral activity against HIV1 with RT E138K mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay | |||
| AID586319 | Antiviral activity against Human T-cell leukemia/lymphoma virus type 1 infected in human PBMC assessed as inhibition of tax/rex gene expression after 3 weeks post infection by quantitative real time RT-PCR | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Antiviral activity of seed extract from Citrus bergamia towards human retroviruses. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1226118 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 150 uM after 9 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1187821 | Cytotoxicity against human HepG2.2.15 cells after 48 hrs | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | A new series of HAPs as anti-HBV agents targeting at capsid assembly. |
| AID405412 | Antiviral activity against PERV infected in human 293T cells assessed as inhibition of proximal DNA synthesis after 24 hrs by RT-PCR | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates. |
| AID548836 | Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID588220 | Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset | 2008 | Toxicology mechanisms and methods, , Volume: 18, Issue:2-3 | Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. |
| AID307877 | Selectivity index, ratio of CC50 for HepG2.2.15 cells to IC50 for HBV | |||
| AID340695 | AUC (0 to 24 hrs) in healthy human at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID548806 | Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID548822 | Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID574190 | Cytotoxicity against human skeletal muscle Myoblast assessed as change in MTCO3 mitochondrial RNA level on day 2 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID1228521 | Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in serum at 20 mg/kg/day, po measured after 3 days of treatment withdrawal | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID548587 | Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1769750 | Cytotoxicity against human H9 cells assessed as cell viability incubated for 7 days by MTT colorimetric assay | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis. |
| AID1197834 | Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. |
| AID727270 | Antiviral activity against wild type Hepatitis B virus infected in human HuH7 cells | 2013 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2 | 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. |
| AID582404 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks (Rvb = 995 +/- 736 pg) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID417252 | Cmin in HIV-infected human assessed as Lamivudine monophosphate level in PBMC at 300 mg QD for 7 days measured per 10'6 cells in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID1457764 | Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring intracellular viral DNA copy number after 6 days byr by real-time qPCR assay | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID1741374 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in intracellular viral DNA level incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by fluorogenic probe based RT-q | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. |
| AID1661381 | Binding affinity to HIV1 Vif and CBFbeta-ELOB-ELOC complex (unknown origin) by CM5 chip based assay | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID1769749 | Antiviral activity against HIV13B infected in human H9 cells assessed as p24 level incubated for 7 days by ELISA | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis. |
| AID340696 | Apparent total oral clearance in healthy human at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID322826 | Effect on cell viability in human Huh7 cells | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID567091 | Drug absorption in human assessed as human intestinal absorption rate | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Prediction of drug intestinal absorption by new linear and non-linear QSPR. |
| AID572780 | Ratio of IC50 for HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID1165076 | Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay | 2014 | European journal of medicinal chemistry, Nov-24, Volume: 87 | Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. |
| AID582414 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd measured on 36th week on 48 weeks study | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID519889 | Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.005 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID781026 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay | 2013 | Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22 | Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. |
| AID664471 | Antiviral activity against NNRTI-resistant HIV1 clade B A-17 clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infecti | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors. |
| AID1226128 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 37.5 uM after 6 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1449528 | Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | 2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. |
| AID246417 | Effective concentrations at which 10-fold depression of intracellular intermediates of HBV DNA was observed in 2.2.15 Cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | 5'-Homoneplanocin A inhibits hepatitis B and hepatitis C. |
| AID1238542 | Binding affinity to human serum albumin with excitation at 280 nm after 2 hrs by spectrofluorimetric analysis | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase. |
| AID1862267 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors. |
| AID557023 | Antiviral activity against HIV1 clade A harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID397589 | Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique | 2001 | Journal of natural products, Feb, Volume: 64, Issue:2 | Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. |
| AID417263 | Half life in HIV-infected human adult | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID1401765 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 20 uM after 9 days by ELISA relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID410757 | Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID1544305 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days and measured on day 9 by ELISA relative to contro | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID576249 | Cmax in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 24 hrs coadministered with 8 mg/kg abacavir by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID325079 | Drug level in human PBMC assessed as concentration of Lamivudine triphosphate per 10^6 cells | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. |
| AID1320782 | Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability by MTS assay | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID464071 | Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | 2010 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5 | Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. |
| AID527283 | Antiviral activity against HBV infected in human 2.2.15 cell at 10 ug/ml | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus. |
| AID548575 | Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID209952 | Concentration required to reduce the proliferation of PHA stimulated human peripheral blood T lymphocytes to 50% of untreated PHA Stimulated control | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID582401 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 3.8 +/- 1.3 log10 ng/ml) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID548581 | Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID541156 | Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 5 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID1316331 | Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. |
| AID244629 | Selectivity index of intracellular intermediates as the ratio of CC50 and EC90 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | 5'-Homoneplanocin A inhibits hepatitis B and hepatitis C. |
| AID1226125 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 300 uM after 6 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1543319 | Therapeutic index, ratio of CC50 for toxicity in C8166 cells to EC50 for antiviral activity against HIV1 3B infected in human C8166 cells | 2019 | Journal of natural products, 07-26, Volume: 82, Issue:7 | Dimeric Pyranonaphthoquinone Glycosides with Anti-HIV and Cytotoxic Activities from a Soil-Derived |
| AID582410 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 55 +/- 32 %) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID548579 | Antiviral activity against HIV1 isolate 069 harboring reverse transcriptase D67E/T69SSG/V75M/M184V/L210W/T215Y mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1351356 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID517829 | Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication at 0.01 to 0.05 ug/mL | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and |
| AID572992 | Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of mitochondrial DNA at 100 uM after 14 days by real-time PCR | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID565915 | Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion after 6 days by ELISA | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Structure-activity relationships study of 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives as novel non-nucleoside anti-hepatitis B virus agents. |
| AID405000 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I/M204I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID576230 | Cmax in HIV-1 infected children aged 2.5 to 14 years at 8 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1614368 | Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level at 10 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. |
| AID340710 | Ratio of Cmax to Cmin in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID527717 | Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication after 2 days | 2010 | Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21 | Synthesis and in vitro antiviral activities of 3'-fluoro (or chloro) and 2',3'-difluoro 2',3'-dideoxynucleoside analogs against hepatitis B and C viruses. |
| AID1636356 | Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. |
| AID618793 | Antiviral activity against HIV1 LAV1 infected in phytohemagglutininin-stimulated human PBMC assessed as RT level after 6 days by microdilution plate assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. |
| AID414791 | Selectivity index, ratio of TC50 for human HepG2(2.2.15) cells to IC50 for HBV | 2009 | Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8 | Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID563939 | Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. |
| AID323407 | Reduction in [3H]dexelvucitabine triphosphate in human CEM cells per 10^6 cells at 100 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID1661334 | Antiviral activity against VSVG pseudotyped HIV1 infected in HEK293 cells preincubated for 3 hrs followed by compound washout and subsequent compound redosing and measured after 72 hrs by luciferase reporter gene based assay | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID358069 | Antiviral activity against HBV in human HepW10 cells assessed as inhibition of viral pre genomic RNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID682491 | Antiviral activity against HIV1 98USMSC5016 clade C clinical isolate infected in PHA-stimulated human PBMC assessed as inhibition of viral replication incubated for 6 hrs followed by compound-wash out measured after 6 days by liquid scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID1401795 | Antiviral activity against DHBV infected in duck assessed as inhibition of viral DNA level in serum at 10 mg/kg, po administered once daily measured on day 15 by SYBR Green I dye-based FQ-PCR analysis relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID548573 | Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1380573 | Antiviral activity against HIV1 virions containing reverse transcriptase E138K/M184V mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre- | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents. |
| AID574199 | Cytotoxicity against human skeletal muscle Myotube assessed as change in Tfam mitochondrial RNA level on day 5 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID582412 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd for 48 weeks study (Rvb = 35 +/- 27 %) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID588964 | Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT1 | 2010 | Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3 | Membrane transporters in drug development. |
| AID1815377 | Anti-HIV activity against HIV-1 IIIB infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID410604 | Antiviral activity against lamivudine-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID341753 | Drug level in human phytohemagglutininin-activated PBMC at 2.6 uM after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID1055517 | Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID1401799 | Antiviral activity against DHBV infected in duck assessed as inhibition of viral DNA level in liver at 10 mg/kg, po administered once daily measured on day 10 by SYBR Green I dye-based FQ-PCR analysis relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID1447282 | Inhibition of HIV1 3B dinucleoside reverse transcriptase infected in human P4R5 MAGI cells assessed as reduction in viral infection after 2 hrs by Galacto-Star beta-galactosidase reporter gene assay | 2017 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9 | Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. |
| AID1320778 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID519965 | Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1226131 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 75 uM after 9 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID106422 | Therapeutic index was measured as concentration required to cause 50% death of uninfected MT-4- cells to IC50 concentration required to inhibit syncytia formation by 50% in HIV-1 infected MT-4 cells | 1994 | Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14 | Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates. |
| AID1200844 | Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. |
| AID1351365 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of intracellular viral pregenomic RNA expression at 1 uM after 6 days by TRIzol reagent based RT-PCR method relative to control | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID1544335 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID740213 | Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBeAg secretion | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-HBV active constituents from Piper longum. |
| AID261858 | Inhibition of HBV M204I mutant transfected in B1 cell line at 10 ug/mL | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6 | Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV. |
| AID563938 | Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase T165A mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. |
| AID540221 | Volume of distribution at steady state in human after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID1363968 | Antiviral activity against lamivudine-resistant hepatitis B virus harboring reverse transcriptase M204I/V173L double mutant infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 | Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). |
| AID576253 | Apparent oral clearance in HIV-1 infected children with body weight >17 kg at 8 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1226101 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 300 uM after 9 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID576235 | AUC (0 to tau) in HIV-1 infected children aged 6.9 years at 4 mg/kg, po every 12 hrs coadministered with nevirapine and stavudine by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID458527 | Antiviral activity against Hepatitis B virus ayw in human M33 cells containing Lamivudine resistant HBV genome with DNA polymerase L515M/M539V mutation genome cells assessed as reduction of viral DNA level after 6 days by RT-PCR | 2010 | Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3 | Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents. |
| AID685499 | Antiviral activity against HIV1 BaL assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID226232 | Fold increase of EC50 HIV M184v to that of EC90 HIV-1xxBRU was determined | 2004 | Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7 | Synthesis, structure-activity relationships, and mechanism of drug resistance of D- and L-beta-3'-fluoro-2',3'-unsaturated-4'-thionucleosides as anti-HIV agents. |
| AID1320781 | Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring extracellular viral DNA copy number after 6 days by real-time qPCR method | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID1771360 | Selectivity index, ratio of CC50 for human HepDES19 cells to EC50 for inhibition of capsid protein-mediated antiviral activity against HBV infected in human HepDES19 cells assessed as inhibition of DNA replication | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. |
| AID417235 | Half life in HIV-infected human assessed as Lamivudine triphosphate level in PBMC at 300 mg QD for 7 days in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID1363967 | Antiviral activity against lamivudine-resistant hepatitis B virus harboring reverse transcriptase M204I mutant infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 | Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). |
| AID586353 | Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis | 2011 | Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2 | In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. |
| AID1226109 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 300 uM after 3 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1387678 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 1 mM supplemented with fresh medium containing compound every 3 days for 9 days measured after 9 days by ELISA relative to control | 2018 | Journal of natural products, 10-26, Volume: 81, Issue:10 | Matrine-Type Alkaloids from the Roots of Sophora flavescens and Their Antiviral Activities against the Hepatitis B Virus. |
| AID1320865 | Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID417062 | Drug metabolism in HIV-infected human PBMC assessed as zidovudine monophosphate level at 300 mg administered in two courses, first BID for 7 to 14 days followed by QD for 7 days and second course the subjects were switched to the other regimen measured pe | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID548837 | Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1587128 | Half-life in human serum administered once daily | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | A Survey of the Structures of US FDA Approved Combination Drugs. |
| AID572993 | Mitochondrial toxicity in human HepG2 cells assessed as percent mitochondrial DNA production at 10 uM after 14 days by real-time PCR relative to control | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID246456 | Effective concentration to inhibit 50 % of hepatitis C virus replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID353551 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV surface antigen secretion | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Anti-HBV agents. Part 2: synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives. |
| AID1192274 | Antiviral activity against hepatitis B viral in human HepG2(2.2.15) cells assessed as decrease in surface antigen HBeAg secretion at 25 ug/ml after 7 days | 2015 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7 | A coumarin lignanoid from the stems of Kadsura heteroclita. |
| AID572767 | Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID1507023 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication at 0.16 uM after 8 days by real time fluorescent PCR method relative to control | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. |
| AID548834 | Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1743627 | Antiviral activity against HIV1 harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID1869629 | Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability by neutral red uptake assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID1228538 | Tmax in Sprague-Dawley rat at 32 mg/kg, po | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID1869630 | Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID1072523 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production | 2014 | European journal of medicinal chemistry, Mar-21, Volume: 75 | A review of non-nucleoside anti-hepatitis B virus agents. |
| AID301053 | Selectivity index, ratio of CC50 for human Hep G2.2.15 cells to IC50 for surface antigen HBsAg secretion in HBV transfected Hep G2.2.15 cells | 2007 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19 | Two new alkaloids and active anti-hepatitis B virus constituents from Hypserpa nitida. |
| AID86718 | Effective concentration to inhibit hepatitis B virus cytopathicity in HepG2.2.15 cells was determined in vitro | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept. |
| AID1535524 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2019 | Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3 | Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1729149 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID548583 | Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1649792 | Antiviral activity against HBV infected in human HepG2.A64 cells containing reverse transcriptase L180M/T184L/M204V mutant assessed as reduction in viral replication incubated for 6 days by PCR analysis | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | Discovery of (1 |
| AID437964 | Antiviral activity against HBV assessed as inhibition of viral surface antigen secretion | 2009 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23 | Anti-HBV agents. Part 3: preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors. |
| AID46753 | The cytotoxicity against CEM cells | 1997 | Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19 | Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. |
| AID1661362 | Cmax in monkey PBMC assessed as 3TC-TP level at 20 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID1228736 | Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay | 2015 | Journal of natural products, May-22, Volume: 78, Issue:5 | Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata. |
| AID341748 | Drug level in human resting PBMC assessed as Lamivudine monophosphate level at 2.6 uM after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID152628 | Antiviral activity against HIV-1xxBRU mutant strain in human PBM cells | 2002 | Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22 | Stereoselective synthesis and antiviral activity of D-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thionucleosides. |
| AID1228737 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1-3B | 2015 | Journal of natural products, May-22, Volume: 78, Issue:5 | Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata. |
| AID417257 | Cmax in HIV-infected human assessed as Lamivudine diphosphate level in PBMC at 300 mg QD for 7 days measured per 10'6 cells in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID548801 | Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID582405 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 979 pg) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID548811 | Antiviral activity against HIV1 isolate 220 harboring reverse transcriptase K70E/M184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1228738 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV2-ROD | 2015 | Journal of natural products, May-22, Volume: 78, Issue:5 | Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata. |
| AID1351363 | Antiviral activity against lamivudine/entecavir resistant HBV harboring reverse transcriptase L180M/M204V/T184L mutant infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 72 hrs by RT-PCR method | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID447658 | Antiviral activity against Hepatitis B virus infected human HepG2.2.15 cells assessed as HBsAg secretion at 200 ug/kg after 9 days by ELISA | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17 | Schisanwilsonins A-G and related anti-HBV lignans from the fruits of Schisandra wilsoniana. |
| AID1743637 | Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID261854 | Inhibition of duck HBV transfected in primary duck hepatocytes at 10 ug/mL | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6 | Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV. |
| AID1741368 | Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability at 100 uM incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay relative to control | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. |
| AID519960 | Selectivity ratio of EC50 for 0.01 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.01 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID354458 | Cytotoxicity against human CEM-SS cells at 40 ug/ml after 6 days by MTS assay | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | New 3-O-acyl betulinic acids from Strychnos vanprukii Craib. |
| AID540100 | Antiviral activity against Hepatitis B virus infected in HepG2.2.15 assessed as inhibition of HBV replication by quantitative Southern blot hybridization analysis | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24 | Synthesis and biological evaluation of 1H-benzimidazol-5-ols as potent HBV inhibitors. |
| AID576254 | AUC in HIV-1 infected children with body weight <17 kg at 8 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1742097 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication supplemented with fresh medium containing compound every 2 days for 6 days by RT-PCR analysis | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. |
| AID519967 | Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells by phenosense assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1661385 | Inhibition of HIV1 HA-tagged Vif expressed in HEK293T cells co-expressing Myc-tagged pcDNA-APOBEC3G assessed as reduction in Vif-mediated A3G degradation at 10000 nM measured after 48 hrs by Western blot analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID297676 | Antimycobacterial activity against Mycobacterium bovis BCG at 100 uM by microplate alamar blue assay | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19 | Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. |
| AID548833 | Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID235642 | Selectivity index was evaluated [Selectivity = (CC50 / EC50) against Hepatitis B virus in human hepatoblastoma cell line] | 1998 | Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12 | Does the anti-hepatitis B virus activity of (+)-5'-noraristeromycin exist in its 4'-epimer and 4'-deoxygenated derivatives? |
| AID626000 | Fold resistance, ratio of EC90 for lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant to EC90 for wild type Hepatitis B virus | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID517934 | Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID681296 | TP_TRANSPORTER: inhibition of Calcein efflux (Calcein: 0.05 micro;M, Lamivudine: 0.55 uM) in UMCC-1/VP cells | 2002 | AIDS (London, England), Sep-06, Volume: 16, Issue:13 | The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). |
| AID1888695 | Antiviral activity against HIV1 with RT K103N mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay | |||
| AID781022 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-2 ROD infected in human MT4 cells | 2013 | Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22 | Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. |
| AID1869628 | Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 1 to 4 hrs by MTS uptake assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID558387 | Ratio of drug level in HIV-infected pregnant woman cord blood plasma to maternal blood plasma at 150 mg, po BID by LC/MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. |
| AID1743638 | Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT E138K mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID625996 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hyb | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID1156484 | Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. |
| AID574201 | Cytotoxicity against human skeletal muscle Myotube at 100 uL on day 5 by WST-1 assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID106425 | Concentration required to cause death of MT-4 cells was determined in vitro | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept. |
| AID1869741 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication at 20 uM measured after 6 days by FQ-PCR analysis relative to control | |||
| AID1565097 | Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | |||
| AID1364091 | Antiviral activity against hepatitis B virus infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by real time PCR analysis | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 | Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). |
| AID249056 | Cytotoxicity against CEM cell lines of human | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID548808 | Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID447663 | Antiviral activity against Hepatitis B virus infected human HepG2.2.15 cells assessed as HBeAg secretion at 200 ug/kg after 9 days by ELISA | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17 | Schisanwilsonins A-G and related anti-HBV lignans from the fruits of Schisandra wilsoniana. |
| AID1431334 | Antiviral activity against Hepatitis B virus subtype adw2 infected in human HuH7 cells assessed as reduction in HBcAg level at 5 ug/ml after 2 days by immunoblot method relative to control | 2016 | Journal of natural products, Dec-23, Volume: 79, Issue:12 | Synthesis of C-4-Substituted Steviol Derivatives and Their Inhibitory Effects against Hepatitis B Virus. |
| AID519881 | Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1165074 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay | 2014 | European journal of medicinal chemistry, Nov-24, Volume: 87 | Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. |
| AID625937 | Fold resistance, ratio of EC90 for lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant to EC90 for wild type Hepatitis B virus | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID556526 | Antiviral activity against Human immunodeficiency virus 1 clone Q9016 harboring K122E, Q145M, I202V, F214L mutation in reverse transcriptase by phenosense assay relative to wild type | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility. |
| AID1572521 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells | |||
| AID86873 | Effective concentration against Hepatitis B virus in human hepatoblastoma cell line | 1998 | Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12 | Does the anti-hepatitis B virus activity of (+)-5'-noraristeromycin exist in its 4'-epimer and 4'-deoxygenated derivatives? |
| AID217737 | Inhibition of cell growth in vero cells | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Structure-activity relationships of beta-D-(2S,5R)- and alpha-D-(2S,5S)-1,3-oxathiolanyl nucleosides as potential anti-HIV agents. |
| AID1743634 | Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT L100I mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID478525 | Selectivity index, ratio of TC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus DNA replication | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Synthesis and antiviral activity of new acrylamide derivatives containing 1,2,3-thiadiazole as inhibitors of hepatitis B virus replication. |
| AID444057 | Fraction escaping hepatic elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1902002 | Selectivity index, ratio of CC50 for human HepG2.2.2.15 cells to IC50 for Hepatitis B virus infected in human HepG2.2.2.15 cells | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231 | Design and synthesis of novel quinazolinone derivatives as anti-HBV agents with TLR8 agonist effect. |
| AID1743629 | Antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID1320864 | Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. |
| AID1203825 | Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 10 uM incubated for 14 days | 2015 | Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8 | β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms. |
| AID384982 | Cytotoxicity against human HepG2.2.15 cells by MTT assay | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Periglaucines A-D, anti-HBV and -HIV-1 alkaloids from Pericampylus glaucus. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID548813 | Antiviral activity against HIV1 isolate 060 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID625998 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID1226111 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 75 uM after 3 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID540114 | Antiviral activity against Hepatitis B virus infected in HepG2.2.15 assessed as inhibition of HBsAg production at <2183.1 +/- 4.1 by EIA | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24 | Synthesis and biological evaluation of 1H-benzimidazol-5-ols as potent HBV inhibitors. |
| AID1742096 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication at 0.8 uM supplemented with fresh medium containing compound every 2 days for 6 days by RT-PCR analysis relative to control | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. |
| AID404907 | Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level at 0.3 uM by PCR | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues. |
| AID560905 | Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. |
| AID1320777 | Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID560907 | Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. |
| AID404912 | Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues. |
| AID540217 | Volume of distribution at steady state in dog after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID53755 | Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures | 2002 | Journal of medicinal chemistry, May-09, Volume: 45, Issue:10 | Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus. |
| AID548582 | Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID55962 | Concentration required to reduce the proliferation of Daudi cells to 50% of untreated controls; ND means not determined | 2002 | Journal of medicinal chemistry, May-09, Volume: 45, Issue:10 | Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus. |
| AID1152373 | Cytotoxicity against human MT4 cells by MTT assay | 2014 | Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12 | Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. |
| AID558366 | Drug level in HIV-infected pregnant woman maternal blood plasma at 150 mg, po BID by LC/MS/MS analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. |
| AID576231 | AUC (0 to tau) in HIV-1 infected children aged 2.5 to 14 years at 8 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID82124 | Antiviral activity against Immunodeficiency virus type-1 (HIV-1) in peripheral blood mononuclear cells | 2000 | Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21 | Synthesis and antiviral activity of oxaselenolane nucleosides. |
| AID1401767 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 20 uM after 9 days by ELISA relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID576234 | Cmax in HIV-1 infected children aged 6.9 years at 4 mg/kg, po every 12 hrs coadministered with nevirapine and stavudine by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1743636 | Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID1055512 | Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID1457762 | Cytotoxicity against human HepG2.2.15 cells assessed as cell viability by tetrazolium dye uptake assay | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID81903 | Cytotoxic concentration required to reduce the uptake of neutral red stain by uninfected cell monolayers to 50% of untreated uninfected human foreskin fibroblasts (HFF); ND means not determined | 2002 | Journal of medicinal chemistry, May-09, Volume: 45, Issue:10 | Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus. |
| AID1228535 | Total blood clearance rate in Sprague-Dawley rat at 2.5 mg/kg, iv | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID570170 | Antiviral activity against lamivudine-resistant HBV infected in human Huh7.5 cells assessed as reduction of viral replication at 0.16 ug/ml after 36 hrs | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70. |
| AID576245 | Cmax in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 12 hrs coadministered with 8 mg/kg abacavir by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1862265 | Inhibition of wild-type recombinant HIV-1 group M subtype B BH10 reverse transcriptase RNase-associated RNase H activity expressed in Escherichia coli XL1 blue using 32P-labeled 5'-UUUUUUUUUAGGAUACAUAUGGUUAAAGUAU-3'/5'-ATACTTTAACCATATGTATCC-3' RNA/DNA tem | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors. |
| AID323409 | Reduction in dexelvucitabine diphosphate choline level in human CEM cells at 33.3 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID557048 | Antiviral activity against HIV1 clade F1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID246785 | Effective concentrations at which 2-fold depression of extracellular virion DNA (HBV) was observed in 2.2.15 Cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | 5'-Homoneplanocin A inhibits hepatitis B and hepatitis C. |
| AID618860 | Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. |
| AID582411 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 41 +/- 25 %) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1743618 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect incubated for 5 days by MTT assay | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID574196 | Cytotoxicity against human skeletal muscle Myoblast assessed as change in POLG mitochondrial RNA level on day 5 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID358084 | Inhibition of HBV promoter in human HepG2(2.2.15) cells by luciferase reporter gene assay | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID572997 | Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of beta-actin DNA at 10 uM after 14 days by real-time PCR | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID781023 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay | 2013 | Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22 | Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. |
| AID1565095 | Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | |||
| AID1191402 | Cytotoxicity against human MT4 cells after 5 days MTT assay | 2015 | Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3 | Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. |
| AID1191403 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells | 2015 | Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3 | Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. |
| AID392536 | Antiviral activity against Vaccinia virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1200845 | Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. |
| AID1769751 | Therapeutic index, ratio of CC50 for cytotoxicity against human H9 cells to EC50 for antiviral activity against HIV13B | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis. |
| AID1869631 | Antiviral activity against wild type HBV infected in human HepG2 2.2.15 cells assessed as reduction in viral replication by DNA HYB (Vision)/neutral red (Tox) assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID582431 | Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver alkaline phosphatase activity at 15 mg/kg, po qd for 48 weeks | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID340698 | Volume of distribution at steady state in healthy human at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID576239 | Apparent oral clearance in HIV-1 infected children aged 2.5 to 4.8 years at 4 mg/kg, po every 12 hrs by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1487262 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay | 2017 | Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16 | Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. |
| AID1815390 | Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 of Anti-HIV activity against HIV-1 IIIB infected in human MT4 | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID519874 | Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID618866 | Cytotoxicity against human HepAD38 cells | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. |
| AID323397 | Antiviral activity against HIV1 LAI in human PBM cells | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID691382 | Antiviral activity against Duck hepatitis B virus infected in pekin duck primary hepatocytes assessed as inhibition of viral replication at 0.5 to 1 ug/mL | 2012 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20 | A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses. |
| AID548572 | Antiviral activity against HIV1 isolate 057 expressing wild type reverse transcriptase gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID341752 | Drug level in human resting PBMC assessed as Lamivudine triphosphate level at 2.6 uM after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID1320775 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID81902 | Concentration required to reduce the proliferation of HFF (human foreskin fibroblasts) cells to 50% of untreated controls; ND means not determined | 2002 | Journal of medicinal chemistry, May-09, Volume: 45, Issue:10 | Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus. |
| AID527281 | Antiviral activity against HBV infected in duck primary hepatocytes at 10 ug/ml | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus. |
| AID1447283 | Inhibition of HIV1 BaL dinucleoside reverse transcriptase infected in human P4R5 MAGI cells assessed as reduction in viral infection after 2 hrs by Galacto-Star beta-galactosidase reporter gene assay | 2017 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9 | Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. |
| AID1627277 | Antiviral activity against HBV infected in human HepG2.2.15.7 cells assessed as inhibition of viral DNA level after 9 days by real time PCR method | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Synthesis and anti-HBV activity of α-stereoisomer of aristeromycin based analogs. |
| AID1599883 | Toxicity against Pekin duck infected with HBV assessed as change in body weight at 0.2 to 0.4 mmol/kg, po once daily for 14 days and measured every day during compound dosing | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs. |
| AID1228537 | Cmax in Sprague-Dawley rat at 32 mg/kg, po | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID691392 | Cytotoxicity against human HuH7 cells after 2 days by XTT assay | 2012 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20 | A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses. |
| AID519859 | Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID576252 | Apparent oral clearance in HIV-1 infected children with body weight <17 kg at 8 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID152644 | Cytotoxicity against human peripheral blood mononuclear (PBM) cells infected with HIV-I | 1993 | Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2 | Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents. |
| AID1401803 | Antiviral activity against DHBV infected in duck assessed as inhibition of viral DNA level in liver at 10 mg/kg, po administered once daily measured on day 15 by SYBR Green I dye-based FQ-PCR analysis relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID576241 | Cmax in HIV-1 infected children aged 8.5 to 12.3 years at 4 mg/kg, po every 12 hrs by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID1241025 | Antiviral activity against HBV infected in human HepG22.2.15 cells after 3 days by neutral red dye-based plaque reduction assay | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | 2- and 3-Fluoro-3-deazaneplanocins, 2-fluoro-3-deazaaristeromycins, and 3-methyl-3-deazaneplanocin: Synthesis and antiviral properties. |
| AID1226093 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 300 uM after 3 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1226122 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 150 uM after 3 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1434727 | Cytotoxicity against human PBMC assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID738970 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2.2.15 cells assessed as HBeAg secretion inhibition assay | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-hepatitis B virus lignans from the root of Streblus asper. |
| AID1320779 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV2 ROD infected in human MT4 cells | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID353550 | Antiviral activity against HBV assessed as inhibition of viral surface antigen secretion | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Anti-HBV agents. Part 2: synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives. |
| AID548574 | Antiviral activity against HIV1 isolate 060 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219E mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1687680 | Antiviral activity against wild type HIV-1 strain 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. |
| AID625938 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID1191400 | Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3 | Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. |
| AID664468 | Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors. |
| AID1363965 | Antiviral activity against lamivudine-resistant hepatitis B virus harboring reverse transcriptase M204I/V173L double mutant infected in human Huh7 cells assessed as reduction in intracellular DNA levels measured on day 7 by real-time PCR analysis | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 | Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID152975 | Effective concentration to inhibit HIV-1 LAI cytopathicity in PBMC cells was determined in vitro | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept. |
| AID153114 | In vitro concentration required to inhibit the HIV-1 LA1 replication on PBMCs cell (peripheral blood mononuclear cells) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs? |
| AID1228517 | Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in serum at 20 mg/kg/day, po treatment initiated at day 10 after infection relative to control | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID1544338 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM measured on day 3 by FQ-PCR analysis relative to control | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID658566 | Resistance factor, ratio of EC50 for multidrug-resistant HIV1 695-RT infected in HEK293T cells to wildtype HIV1 infected in HEK293T cells | 2012 | Journal of natural products, Mar-23, Volume: 75, Issue:3 | Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium. |
| AID540219 | Volume of distribution at steady state in monkey after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID410603 | Antiviral activity against lamivudine-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID1555313 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for capsid protein in Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in viral DNA level | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. |
| AID323415 | Reduction in dexelvucitabine diphosphate choline level in PHA-stimulated human PBMC at 1 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID1228513 | Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in serum at 20 mg/kg/day, po treatment initiated at day 5 after infection relative to control | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID249057 | Cytotoxicity against MT-2 cell lines of human | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID732681 | Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID1544306 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM measured on day 3 by FQ-PCR analysis relative to control | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID417063 | Drug metabolism in HIV-infected human PBMC assessed as zidovudine diphosphate level at 300 mg administered in two courses, first QD for 7 days followed by BID for 7 to 14 days and second course the subjects were switched to the other regimen measured per | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID322827 | Antiviral activity against wild type HBV assessed as inhibition of replication | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1197448 | Selectivity index, ratio of TC50 for human HepG2(2.2.15) cells to IC50 for HBV infected in human HepG2(2.2.15) cells assessed as inhibition of surface antigen secretion | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4 | Synthesis and anti-hepatitis B virus activity of C4 amide-substituted isosteviol derivatives. |
| AID266278 | Antiviral activity against duck HBV in primary duck hepatocytes at 10 ug/mL | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication. |
| AID1743619 | Antiviral activity against HIV1 RES056 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID464069 | Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | 2010 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5 | Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. |
| AID268267 | Inhibition of HBV DNA replication | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15 | Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. |
| AID340705 | Volume of distribution at steady state in healthy human at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID519873 | Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID340694 | Tmax in healthy human at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID614134 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBeAg antigen secretion in HBV infected in human HepG2(2.2.15) cells | 2011 | Journal of natural products, Aug-26, Volume: 74, Issue:8 | Swerilactones L-O, secoiridoids with C₁₂ and C₁₃ skeletons from Swertia mileensis. |
| AID560906 | Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. |
| AID417261 | Half life in HIV-infected children | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID576244 | Cmin in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 12 hrs coadministered with 8 mg/kg abacavir by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1649793 | Antiviral activity against multidrug-resistant HBV infected in human HepG2.1403F cells assessed as reduction in viral replication incubated for 6 days by PCR analysis | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | Discovery of (1 |
| AID626005 | Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative So | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID323410 | Reduction in dexelvucitabine diphosphate choline level in human CEM cells at 100 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID1742100 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication at 100 uM supplemented with fresh medium containing compound every 2 days for 6 days by RT-PCR analysis relative to control | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. |
| AID1447284 | Cytotoxicity against human P4R5 MAGI cells after 2 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9 | Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. |
| AID407139 | Antiviral activity against hepatitis B virus infected Hep G2.2.15 cells assessed as inhibition of HBsAg secretion | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13 | Synthesis and in vitro anti-hepatitis B virus activities of 4-aryl-6-chloro-quinolin-2-one and 5-aryl-7-chloro-1,4-benzodiazepine derivatives. |
| AID1544323 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 9 days measured post-last dose by FQ-P | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID519884 | Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID572777 | Antiviral activity against HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID1377844 | Cytotoxicity against human PBMC by CellTiter 96 non-radioactive cell proliferation colorimetric assay | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID425653 | Renal clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID576232 | Apparent oral clearance in HIV-1 infected children aged 2.5 to 14 years at 8 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID732672 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IL-2 level in serum at 100 mg/kg qd for 1 month by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID1380567 | Antiviral activity against HIV1 virions derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre-mixed virions followed by incubation with target cel | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents. |
| AID246366 | Effective concentration required to inhibit hepatitis B virus replication in 2.2.15 cells in DNA hybridization assay | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. |
| AID576233 | Cmin in HIV-1 infected children aged 6.9 years at 4 mg/kg, po every 12 hrs coadministered with nevirapine and stavudine by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID406547 | Antiviral activity against HBV assessed as inhibition of viral DNA replication by Southern blot | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Synthesis and anti-hepatitis B virus evaluation of novel ethyl 6-hydroxyquinoline-3-carboxylates in vitro. |
| AID527285 | Cytotoxicity against human HuH7 cells | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus. |
| AID340708 | Cmax in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1055509 | Cytotoxicity against human CEM cells | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID340714 | Cmax in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1888701 | Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells | |||
| AID404987 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase M204I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID732679 | Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID1503176 | Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities. |
| AID1055515 | Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID548814 | Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID322846 | Fold resistance, ratio of lamivudine-resistant HBV with reverse transcriptase V173L/L180/M204V mutant to wild-type HBV genotype H | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1377851 | Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in extracellular viral DNA level by RT-PCR method | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID1226110 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 150 uM after 3 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID664466 | Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay | 2012 | Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6 | Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors. |
| AID540101 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for inhibition of Hepatitis B virus DNA replication | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24 | Synthesis and biological evaluation of 1H-benzimidazol-5-ols as potent HBV inhibitors. |
| AID407140 | Cytotoxicity against human Hep G2.2.15 cells | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13 | Synthesis and in vitro anti-hepatitis B virus activities of 4-aryl-6-chloro-quinolin-2-one and 5-aryl-7-chloro-1,4-benzodiazepine derivatives. |
| AID1693333 | Cytotoxicity against human HepG2 2.2.15 cell line assessed as cell viability measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 01-01, Volume: 29 | Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. |
| AID582408 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks (Rvb = 34 +/- 20 pg) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID340713 | Tmax in healthy human PBMC assessed as intracellular apricitabine triphosphate level at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1614371 | Mitochondrial toxicity in human HepG2 cells 10 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. |
| AID614133 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBsAg antigen secretion in HBV infected in human HepG2(2.2.15) cells | 2011 | Journal of natural products, Aug-26, Volume: 74, Issue:8 | Swerilactones L-O, secoiridoids with C₁₂ and C₁₃ skeletons from Swertia mileensis. |
| AID86850 | Compound concentration required to inhibit the viral cell proliferation by 50% against HBV | 1998 | Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13 | Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides. |
| AID407141 | Selectivity index, ratio of CC50 for human Hep G2.2.15 cells to IC50 for HBV surface antigen secretion | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13 | Synthesis and in vitro anti-hepatitis B virus activities of 4-aryl-6-chloro-quinolin-2-one and 5-aryl-7-chloro-1,4-benzodiazepine derivatives. |
| AID1565098 | Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | |||
| AID1199055 | Selectivity index, ratio of CC50 for human MT4 cells to IC50 for Human immunodeficiency virus type 2 ROD infected in human MT4 cells | 2014 | Journal of natural products, Jun-27, Volume: 77, Issue:6 | Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead. |
| AID341760 | Antiviral activity against HIV1 with reverse transcriptase M184V mutation in human phytohemagglutininin-activated PBMC assessed as inhibition of viral replication | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID358073 | Antiviral activity against HBV in human HepW10 cells assessed as inhibition of viral 2.4/2.1RNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID563940 | Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S/T165A mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. |
| AID1165077 | Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay | 2014 | European journal of medicinal chemistry, Nov-24, Volume: 87 | Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. |
| AID323416 | Reduction in [3H]dexelvucitabine triphosphate in human CEM cells at 1 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID354455 | Antiviral activity against HIV1 3B infected in human HOG.R5 cells after 4 days | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | New 3-O-acyl betulinic acids from Strychnos vanprukii Craib. |
| AID572998 | Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of beta-actin DNA at 100 uM after 14 days by real-time PCR | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID1815388 | Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID340700 | Cmax in healthy human at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1687685 | Antiviral activity against HIV-2 ROD strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. |
| AID519892 | Selectivity ratio of EC50 for 0.05 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.05 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID322832 | Fold resistance, ratio of EC50 for lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant to EC50 for wild-type HBV | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID675190 | Therapeutic index, ratio of TC50 for human CEM-SS cells to EC50 for HIV-1 subtype 3B infected in CEM-SS cells | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. |
| AID1363966 | Antiviral activity against lamivudine-resistant wild type hepatitis B virus infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 | Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). |
| AID576247 | Apparent oral clearance in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 12 hrs coadministered with 8 mg/kg abacavir by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1197833 | Resistance index, ratio of EC50 for HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant to EC50 for wild type HIV1 3B | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. |
| AID1431325 | Selectivity index, ratio of TC50 for human HuH7 cells to IC50 for Hepatitis B virus subtype adw2 infected in human HuH7 cells assessed as inhibition of viral DNA replication | 2016 | Journal of natural products, Dec-23, Volume: 79, Issue:12 | Synthesis of C-4-Substituted Steviol Derivatives and Their Inhibitory Effects against Hepatitis B Virus. |
| AID548586 | Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID582403 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 3.3 +/- 1.6 log10 ng/ml) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID541151 | Selectivity ratio of EC50 for antiviral activity against 3TC-resistant HIV1 selected after 8 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID740212 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBeAg secretion | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-HBV active constituents from Piper longum. |
| AID1226103 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 75 uM after 9 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID523465 | Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA level at 13 uM after 72 hrs by RT-PCR analysis | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus. |
| AID556527 | Antiviral activity against Human immunodeficiency virus 1 clone 14682 harboring 122E, 135V, Q145V, 200A mutation in reverse transcriptase by phenosense assay relative to wild type | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility. |
| AID582402 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd for 48 weeks (Rvb = 3.8 +/- 1.3 log10 ng/ml) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1197453 | Selectivity index, ratio of TC50 for human HepG2(2.2.15) cells to IC50 for HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4 | Synthesis and anti-hepatitis B virus activity of C4 amide-substituted isosteviol derivatives. |
| AID738971 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2.2.15 cells by HBsAg secretion inhibition assay | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-hepatitis B virus lignans from the root of Streblus asper. |
| AID89027 | Antiviral activity against drug-resistant HIV-1 virus (M184v) in Human peripheral blood mononuclear (PBM) cells | 2004 | Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7 | Synthesis, structure-activity relationships, and mechanism of drug resistance of D- and L-beta-3'-fluoro-2',3'-unsaturated-4'-thionucleosides as anti-HIV agents. |
| AID540218 | Clearance in monkey after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID392501 | Antiviral activity against Human adenovirus 2 | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID625997 | Fold resistance, ratio of EC90 for lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant to EC90 for wild type Hepatitis B virus | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID548825 | Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID517837 | Antiviral activity against drug resistant HBV infected in M204I cells assessed as inhibition of viral DNA replication | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and |
| AID519888 | Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID417258 | Cmax in HIV-infected human assessed as Lamivudine monophosphate level in PBMC at 300 mg QD for 7 days measured per 10'6 cells in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID574187 | Cytotoxicity against human skeletal muscle Myoblast assessed as increase in mitochondrial DNA on day 5 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID1203824 | Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 1 uM incubated for 14 days | 2015 | Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8 | β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms. |
| AID1226108 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as cell survival at 37.5 uM after 9 days (Rvb = 100%) | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID732671 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD3+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 30.1 +/-2.9%) | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID548799 | Antiviral activity against HIV1 isolate 188 harboring reverse transcriptase T215Y/M184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID53757 | In vitro antiviral activity against Hepatitis B virus in primary duck hepatocyte (DHBV) cultures and expressed as percent inhibition of viral DNA at 10 ug/mL | 2002 | Journal of medicinal chemistry, May-09, Volume: 45, Issue:10 | Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus. |
| AID548571 | Antiviral activity against HIV1 isolate 056 expressing wild type reverse transcriptase gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1156486 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. |
| AID153103 | In vitro concentration required to cause death of uninfected PBMCs cell (peripheral blood mononuclear cells) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs? |
| AID322848 | Fold resistance, ratio of Lamivudine -adenofir-resistant with HBV reverse transcriptase V173L/L180M/A181V/M204V mutant to wildtype HBV genotype E | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID582424 | Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as effect on hematological parameters at 15 mg/kg, po qd for 48 weeks measured up to 60 weeks | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID246406 | In vitro effective concentration against Lamivudine resistant wild type HIV-1 in human peripheral blood mononuclear cells | 2005 | Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11 | Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides. |
| AID328843 | Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3 | Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. |
| AID1862268 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors. |
| AID548585 | Antiviral activity against HIV1 isolate 162 harboring reverse transcriptase A62V/V75I/F77L/Y115F/F116Y/Q151M/M184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1203822 | Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method | 2015 | Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8 | β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms. |
| AID576237 | Cmax in HIV-1 infected children aged 2.5 to 4.8 years at 4 mg/kg, po every 12 hrs by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID1351355 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 6 days by RT-PCR method | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. |
| AID417060 | Drug metabolism in HIV-infected human PBMC assessed as zidovudine parent-drug level at 300 mg administered in two courses, first BID for 7 to 14 days followed by QD for 7 days and second course the subjects were switched to the other regimen measured per | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID548802 | Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID340704 | Renal clearance in healthy human at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID323413 | Reduction in dexelvucitabine diphosphate choline level in human CEM cells at 1 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID218505 | Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells; ND means Not determined | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID1815379 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID1599880 | Antiviral activity against HBV infected in pekin duck assessed as reduction in serum viral DNA level at 0.4 mmol/kg, po once daily for 14 days and measured on days 7, 14 post treatment and on day 3 after treatment cessation by qRT-PCR analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs. |
| AID1869622 | Anti-HIV activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as inhibition of HIV-induced cytopathic effect measured after 5 days by MTT assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID598075 | Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication at 10 nM by p24 HIV antigen capture assay relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis of 5-thiodidehydropyranylcytosine derivatives as potential anti-HIV agents. |
| AID328842 | Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3 | Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1888702 | Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells | |||
| AID404985 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID548818 | Antiviral activity against HIV1 isolate 069 harboring reverse transcriptase D67E/T69SSG/V75M/M184V/L210W/T215Y mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID548824 | Antiviral activity against HIV1 isolate 162 harboring reverse transcriptase A62V/V75I/F77L/Y115F/F116Y/Q151M/M184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID582407 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 33 +/- 21 pg) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1771356 | Inhibition of capsid protein in HBV infected in human HepDES19 cells assessed as inhibition of viral replication incubated for 3 days by strand preferential qPCR analysis | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. |
| AID675191 | Cytotoxicity against human PBMC | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. |
| AID1377840 | Cytotoxicity against human CEM cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID91036 | Cytotoxic concentration of compound required for 50% extinction of HuH-6 cells | 2002 | Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14 | 2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents. |
| AID519891 | Selectivity ratio of EC50 for 0.02 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.02 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1729157 | Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID517937 | Antiviral activity against HIV1 subtype B isolate 3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID1729153 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID1741373 | Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. |
| AID417246 | Tmax in HIV-infected human assessed as Lamivudine monophosphate level in PBMC at 300 mg QD for 7 days in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID154955 | Activity against Lamivudine-resistant virus (HIV-1XXBRU) in human PBM cells, expressed as EC50 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance. |
| AID557021 | Antiviral activity against HIV1 CRF02_AG harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID1544320 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days measured post-last dose by FQ-P | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID1771359 | Cytotoxicity against human HepDES19 cells assessed as reduction in cell viability measured after 3 days by by MTS assay | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. |
| AID1191298 | Selectivity index, ratio of TC50 for human HepG2(2.2.15) cells to IC50 for decrease in HBV viral DNA replication in human HepG2(2.2.15) cells | 2015 | European journal of medicinal chemistry, Jan-27, Volume: 90 | Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents. |
| AID358074 | Antiviral activity against HBV in human HepD2 cells assessed as inhibition of viral 2.4/2.1RNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID1649770 | Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | Discovery of (1 |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID557020 | Antiviral activity against HIV1 clade B harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID1614322 | Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. |
| AID548815 | Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1535523 | Antiviral activity against HIV1 RES056 containing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2019 | Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3 | Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. |
| AID1165075 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay | 2014 | European journal of medicinal chemistry, Nov-24, Volume: 87 | Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. |
| AID586314 | Antiviral activity against Human T-cell leukemia/lymphoma virus type 1 infected in human PBMC assessed as inhibition of tax/rex gene expression at 22.93 ug/ml after 3 weeks post infection by quantitative real time RT-PCR | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Antiviral activity of seed extract from Citrus bergamia towards human retroviruses. |
| AID570169 | Antiviral activity against wild type HBV infected in human Huh7.5 cells assessed as reduction of viral replication at 0.16 ug/ml after 36 hrs | 2011 | Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3 | Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70. |
| AID732678 | Antiviral activity against Hepatitis B virus infected in transgenic mouse assessed as decrease in viral DNA level in liver at 100 mg/kg qd for 1 month by qPCR analysis | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID557052 | Antiviral activity against NRTI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID517936 | Antiviral activity against HIV1 subtype A isolate 2 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID1248145 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells | 2015 | Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20 | Synthesis and antiviral activity of maleopimaric and quinopimaric acids' derivatives. |
| AID1401774 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA level at 20 uM measured on day 9 by FQ-PCR analysis | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID417059 | Drug metabolism in HIV-infected human PBMC assessed as zidovudine parent-drug level at 300 mg administered in two courses, first QD for 7 days followed by BID for 7 to 14 days and second course the subjects were switched to the other regimen measured per | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID340702 | AUC (0 to 24 hrs) in healthy human at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID574186 | Cytotoxicity against human skeletal muscle Myoblast assessed as increase in mitochondrial DNA on day 2 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID1226124 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 37.5 uM after 3 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1555317 | Inhibition of capsid protein in lamivudine/entecavir-resistant Hepatitis B virus harboring rtL180M/rtM204V/rt184L mutant infected in human HepG2.2.15 cells assessed as reduction in viral DNA level at 100 uM measured after 72 hrs by PCR analysis relative t | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors. |
| AID1226097 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 300 uM after 6 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID322844 | Fold resistance, ratio of lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant to wild-type HBV genotype E | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1197449 | Cytotoxicity against human HepG2(2.2.15) cells | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4 | Synthesis and anti-hepatitis B virus activity of C4 amide-substituted isosteviol derivatives. |
| AID1743639 | Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT F227L/V106A mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID580183 | Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV). |
| AID358082 | Effect on virus RNA stability on doxycyclin-induced HBV pre genomic RNA production in Met-On-TRE HBV cells treated with 3 uM drug after doxycycline removal | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID1661360 | AUC (0 to 24 hrs) in monkey PBMC assessed as 3TC-TP level at 20 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID325077 | Drug level in human RBC assessed as concentration of Lamivudine triphosphate per 10^6 cells | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. |
| AID322845 | Fold resistance, ratio of lamivudine-resistant HBV with reverse transcriptase L180M/A181V mutant to wild-type HBV genotype E | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1565091 | Antiviral activity against drug resistant HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | |||
| AID1320783 | Selectivity ratio of CC50 for human HepG2(2.2.15) cells to EC50 for reduction in HBV ayw1 extracellular DNA copy number | 2016 | Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20 | Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication. |
| AID548805 | Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1226094 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 150 uM after 3 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID548588 | Antiviral activity against HIV1 isolate 180 harboring reverse transcriptase K65R mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID246455 | Effective concentration to inhibit 50 % of hepatitis B virus replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID519890 | Selectivity ratio of EC50 for 0.01 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.01 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1742095 | Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. |
| AID1888696 | Antiviral activity against HIV1 with RT Y181C mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay | |||
| AID244625 | Selectivity index of virion as the ratio of CC50 and EC90 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | 5'-Homoneplanocin A inhibits hepatitis B and hepatitis C. |
| AID1535527 | Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 RES056 containing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells | 2019 | Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3 | Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. |
| AID1226095 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 75 uM after 3 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID404981 | Antiviral activity against HBV genotype D with reverse transcriptase M204I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1661365 | Cmax in monkey plasma at 20 mg/kg, po administered as single dose measured after 72 hrs by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID1661374 | Cytotoxicity against human Hut/CCR5 cells assessed as reduction in cell viability at 1000 to 10000 nM measured after 120 hrs by MTT assay | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID1535526 | Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells | 2019 | Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3 | Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. |
| AID235453 | Selectivity (CC50/EC50) for death of uninfected PBMCs to that of inhibition of cytopathicity of HIV-1 LA1 on PBMCs (peripheral blood mononuclear cells) | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs? |
| AID572996 | Mitochondrial toxicity in human HepG2 cells assessed as percent lactic acid production at 100 uM after 14 days by real-time PCR relative to beta-actin DNA | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID322833 | Fold resistance, ratio of EC50 for lamivudine-adefovir-resistant HBV with reverse transcriptase L180M/M204V/N236T mutant to EC50 for wild-type HBV | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID405005 | Effect on replication efficiency of HBV genotype D with reverse transcriptase L80I/L180M/M204I mutation in human Huh7 cells assessed as decrease in viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1771358 | Inhibition of capsid protein in HBV infected in human HepDES19 cells assessed as inhibition of viral replication by measuring plus polarity DNA level at 5 uM incubated for 3 days by strand preferential qPCR analysis relative to control | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. |
| AID519964 | Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID414789 | Cytotoxicity against human HepG2(2.2.15) cells treated for 9 days measured after 24 hrs of last treatment by neutral red uptake assay | 2009 | Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8 | Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives. |
| AID358071 | Antiviral activity against HBV in HBV-Met cells assessed as inhibition of viral pre genomic RNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID1380569 | Antiviral activity against HIV1 virions containing reverse transcriptase K103N mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre-mixed | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents. |
| AID341761 | Antiviral activity against HIV1 with reverse transcriptase M184V mutation in human phytohemagglutininin-activated PBMC assessed as inhibition of viral replication at 60 uM | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID1869633 | Selectivity index, ratio of CC50 cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability to EC50 for antiviral activity against wild type HBV infected in human HepG2 2.2.15 cells assessed as reduction in viral replication by DN | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID437967 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for HBV early antigen secretion | 2009 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23 | Anti-HBV agents. Part 3: preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors. |
| AID1565099 | Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | |||
| AID1661350 | Tmax in monkey plasma at 20 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID1226116 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 37.5 uM after 6 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1228539 | Oral bioavailability in Sprague-Dawley rat at 32 mg/kg | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID154954 | Activity against Lamivudine-resistant virus (HIV-1M184V) in human PBM cells, expressed as EC50 | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance. |
| AID560908 | Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. |
| AID582409 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 27 pg) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID464068 | Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization | 2010 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5 | Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. |
| AID548810 | Antiviral activity against HIV1 isolate 217 harboring reverse transcriptase D67N/K70E/M184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1165078 | Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells | 2014 | European journal of medicinal chemistry, Nov-24, Volume: 87 | Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. |
| AID1687686 | Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. |
| AID540214 | Clearance in rat after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID614131 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBeAg antigen secretion after 72 hrs by ELISA | 2011 | Journal of natural products, Aug-26, Volume: 74, Issue:8 | Swerilactones L-O, secoiridoids with C₁₂ and C₁₃ skeletons from Swertia mileensis. |
| AID297672 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 100 uM by microplate alamar blue assay | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19 | Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. |
| AID1228734 | Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay | 2015 | Journal of natural products, May-22, Volume: 78, Issue:5 | Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata. |
| AID1303215 | Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay | 2016 | European journal of medicinal chemistry, Jul-19, Volume: 117 | Design, synthesis and anti-HIV activity of novel quinoxaline derivatives. |
| AID1197832 | Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. |
| AID200002 | In vitro antiviral activity against HIV-1 Reverse transcriptase wild type | 2003 | Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12 | The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V). |
| AID341762 | Antiviral activity against HIV1 with reverse transcriptase M184V mutation in human phytohemagglutininin-activated PBMC assessed as inhibition of viral replication at 200 uM | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID1888693 | Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT L100I mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells | |||
| AID354464 | Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay | 2004 | Journal of natural products, Jun, Volume: 67, Issue:6 | New 3-O-acyl betulinic acids from Strychnos vanprukii Craib. |
| AID1377839 | Inhibition of capsid in HBV infected in human HepAD38 cells assessed as reduction in cccDNA formation by measuring reduction in HBe antigen secretion at 10 uM after 14 days by ELISA relative to control | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID450973 | Lipophilicity, log P of the compound | 2009 | Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17 | Synthesis and anti-HIV activity of novel 2',3'-dideoxy-3'-thiacytidine prodrugs. |
| AID1507016 | Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability after 8 days by CCK-8 assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. |
| AID397590 | Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique | 2001 | Journal of natural products, Feb, Volume: 64, Issue:2 | Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. |
| AID1431324 | Antiviral activity against Hepatitis B virus subtype adw2 infected in human HuH7 cells assessed as inhibition of viral DNA replication by RT-PCR method | 2016 | Journal of natural products, Dec-23, Volume: 79, Issue:12 | Synthesis of C-4-Substituted Steviol Derivatives and Their Inhibitory Effects against Hepatitis B Virus. |
| AID519872 | Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1661361 | Tmax in monkey PBMC assessed as 3TC-TP level at 20 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID574197 | Cytotoxicity against human skeletal muscle Myoblast assessed as change in Tfam mitochondrial RNA level on day 5 by RT-PCR relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. |
| AID691386 | Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication | 2012 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20 | A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses. |
| AID1487263 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells | 2017 | Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16 | Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. |
| AID1815383 | Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID358072 | Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral 2.4/2.1RNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID253330 | Cytotoxic concentration against HBV replication in 2.2.15 cell culture | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | 5'-Homoneplanocin A inhibits hepatitis B and hepatitis C. |
| AID1434729 | Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. |
| AID410751 | Antiviral activity against lamivudine-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID1694159 | Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay | 2021 | Bioorganic & medicinal chemistry, 02-01, Volume: 31 | Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. |
| AID557051 | Antiviral activity against PI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID548841 | Antiviral activity against HIV1 isolate 220 harboring reverse transcriptase K70E/M184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID79629 | Antiviral activity against Hepatitis B virus (HBV) in 2.2.15 cells | 2000 | Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21 | Synthesis and antiviral activity of oxaselenolane nucleosides. |
| AID1228525 | Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in liver at 20 mg/kg/day, po treatment initiated at day 5 after infection relative to control | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID406541 | Cytotoxicity against human HepG2.2.15 cells after 9 days by MTT assay | 2008 | Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13 | Synthesis and anti-hepatitis B virus evaluation of novel ethyl 6-hydroxyquinoline-3-carboxylates in vitro. |
| AID322847 | Fold resistance, ratio of Lamivudine -adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V mutant to wildtype HBV genotype E | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID541153 | Selectivity ratio of EC50 for antiviral activity against EFV-resistant HIV1 selected after 7 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID682487 | Cytotoxicity against human HeLa P4/R5 cells incubated for 2 hrs followed by compound-wash out measured after 46 hrs by MTS assay | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID246358 | Effective concentrations at which 2-fold depression of extracellular virion DNA (HBV) was observed in 2.2.15 Cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | 5'-Homoneplanocin A inhibits hepatitis B and hepatitis C. |
| AID1572522 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells | |||
| AID1902000 | Cytotoxicity against human HepG2 2.2.15 cells infected with Hepatitis B virus assessed as inhibition of cell growth at 0.4 uM incubated for 6 days by RT PCR analysis relative to control | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231 | Design and synthesis of novel quinazolinone derivatives as anti-HBV agents with TLR8 agonist effect. |
| AID358064 | Antiviral activity against HBV in ayw wild type HepG2(2.2.15) cells assessed as inhibition of viral DNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID266285 | Antiviral activity against wild type HBV in human hepatoma 2.2.15 cells | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication. |
| AID557022 | Antiviral activity against HIV1 CRF01_AE harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID257337 | Cytotoxicity against human hepatoblastoma 2.2.15 cells | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system. |
| AID323414 | Reduction in dexelvucitabine diphosphate choline level in human PBMC at 1 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID1434726 | Cytotoxicity against human HepG2 cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. |
| AID527721 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 2 days | 2010 | Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21 | Synthesis and in vitro antiviral activities of 3'-fluoro (or chloro) and 2',3'-difluoro 2',3'-dideoxynucleoside analogs against hepatitis B and C viruses. |
| AID261860 | Inhibition of HBV L180M/ M204V mutant transfected in D88 cell line at 10 ug/mL | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6 | Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID404982 | Antiviral activity against HBV genotype D with reverse transcriptase L80I/M204I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID625941 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID582423 | Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as change in body weight at 15 mg/kg, po qd for 48 weeks measured up to 60 weeks | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1815384 | Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID407138 | Antiviral activity against hepatitis B virus infected Hep G2.2.15 cells assessed as inhibition of HBeAg secretion | 2008 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13 | Synthesis and in vitro anti-hepatitis B virus activities of 4-aryl-6-chloro-quinolin-2-one and 5-aryl-7-chloro-1,4-benzodiazepine derivatives. |
| AID586320 | Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression after 5 days post infection by quantitative real time RT-PCR | 2011 | Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6 | Antiviral activity of seed extract from Citrus bergamia towards human retroviruses. |
| AID266286 | Antiviral activity against HBV L180M/M204V mutant transfected in D88 cell line at 10 ug/mL | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication. |
| AID353552 | Antiviral activity against HBV assessed as inhibition of viral early antigen secretion | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Anti-HBV agents. Part 2: synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives. |
| AID517830 | Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and |
| AID681387 | TP_TRANSPORTER: uptake in Xenopus laevis oocytes | 2000 | The Journal of pharmacology and experimental therapeutics, Sep, Volume: 294, Issue:3 | Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. |
| AID548817 | Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID422693 | Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by antivirogram biological cutoffs assay relative to wild type HIV1 | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID89635 | Concentration required to reduce the proliferation of PHA stimulated human peripheral blood T lymphocytes to 50% of untreated PHA stimulated control | 2002 | Journal of medicinal chemistry, May-09, Volume: 45, Issue:10 | Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus. |
| AID548804 | Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1200843 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. |
| AID519876 | Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID450972 | Selectivity index, ratio of CCID50 for human PBMC to IC50 for HIV1 infected in human PBMC | 2009 | Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17 | Synthesis and anti-HIV activity of novel 2',3'-dideoxy-3'-thiacytidine prodrugs. |
| AID81557 | In vitro concentration required to inhibit HBV DNA secretion by HepG2.2.15 transfected by HBV | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs? |
| AID1693337 | Antiviral activity against lamivudine/entecavir-resistant HBV rtL180M/rtM204V/rtT184L mutant infected in human HepG2 2.2.15 cells assessed as inhibition of viral DNA replication measured after incubation of 72 hrs by RT-PCR analysis | 2021 | Bioorganic & medicinal chemistry, 01-01, Volume: 29 | Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. |
| AID1191973 | Cytotoxicity against mock-infected human HeLa cells by MTT assay | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6 | Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity. |
| AID322841 | Antiviral activity against Lamivudine -adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V/M204V/N236T mutant | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID688917 | Antiviral activity against Hepatitis B virus infected in HepG2(2.2.15) cells assessed as reduction in HBsAg level at 20 uM after 9 days by ELISA | 2012 | Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19 | Synthesis and biological evaluation of novel homochiral carbocyclic nucleosides from 1-amino-2-indanols. |
| AID325078 | Drug level in human RBC assessed as concentration of Lamivudine triphosphate per 10^6 cells after 0.3 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. |
| AID427244 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV surface antigen at < TC50 | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Synthesis and in vitro anti-hepatitis B virus activity of 6H-[1]benzothiopyrano[4,3-b]quinolin-9-ols. |
| AID550166 | Cytotoxicity against human HepG2(2.2.15) cells | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and in vitro anti-hepatitis B virus activity of six-membered azanucleoside analogues. |
| AID598200 | Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay | 2011 | Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10 | Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus. |
| AID548839 | Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1152371 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay | 2014 | Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12 | Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. |
| AID423158 | Antiviral activity against wild type HIV2 ROD produced from full length pROD9 infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. |
| AID340718 | Half life in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID384983 | Antiviral activity against HBV assessed as inhibition of viral surface antigen secretion in HepG2.2.15 cells by ELISA | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Periglaucines A-D, anti-HBV and -HIV-1 alkaloids from Pericampylus glaucus. |
| AID1431337 | Antiviral activity against Hepatitis B virus subtype adw2 infected in human HuH7 cells assessed as reduction in HBx level at 5 ug/ml after 2 days by immunoblot method relative to control | 2016 | Journal of natural products, Dec-23, Volume: 79, Issue:12 | Synthesis of C-4-Substituted Steviol Derivatives and Their Inhibitory Effects against Hepatitis B Virus. |
| AID682490 | Antiviral activity against HIV1 94US3393IN clade B clinical isolate infected in PHA-stimulated human PBMC assessed as inhibition of viral replication incubated for 6 hrs followed by compound-wash out measured after 6 days by liquid scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID540216 | Clearance in dog after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID572781 | Ratio of IC50 for HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID548580 | Antiviral activity against HIV1 isolate 070 harboring reverse transcriptase 65R/S68G mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1226088 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1815389 | Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID1627278 | Cytotoxicity against human HepG2.2.15.7 cells assessed as reduction in cell viability after 9 days by tetrazolium dye based method | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Synthesis and anti-HBV activity of α-stereoisomer of aristeromycin based analogs. |
| AID519871 | Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID588210 | Human drug-induced liver injury (DILI) modelling dataset from Ekins et al | 2010 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12 | A predictive ligand-based Bayesian model for human drug-induced liver injury. |
| AID322836 | Antiviral activity against lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1771363 | Inhibition of capsid protein in HBV infected in human HepDES19 cells assessed as inhibition of viral replication by measuring minus polarity DNA level at 20 uM incubated for 3 days by strand preferential qPCR analysis relative to control | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. |
| AID1320868 | Solubility of the compound | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. |
| AID625936 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hyb | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID211486 | Toxic activity against VERO cells. | 1997 | Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19 | Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. |
| AID1191288 | Cytotoxicity against human HepG2(2.2.15) cells assessed as decrease in cell viability after 72 hrs by MTS assay | 2015 | European journal of medicinal chemistry, Jan-27, Volume: 90 | Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents. |
| AID517943 | Antiviral activity against HIV1 expressing reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID1599857 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV infected in human HepG2.2.15 cells | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs. |
| AID679629 | TP_TRANSPORTER: Anti-HIV-1 activity in MT-4 and MT-4/DOX500 | 2003 | Molecular pharmacology, Jan, Volume: 63, Issue:1 | Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID557046 | Antiviral activity against HIV1 clade C harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID261856 | Inhibition of wild type HBV transfected in human hepatoblastoma 2.2.15 cells at 10 ug/mL | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6 | Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV. |
| AID1742098 | Selectivity index, ratio of CC50 for human HepG2 2.2.15 cells to IC50 for antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. |
| AID519885 | Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID328841 | Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3 | Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. |
| AID738973 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-hepatitis B virus lignans from the root of Streblus asper. |
| AID548812 | Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID582427 | Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver sorbitol dehydrogenase activity at 15 mg/kg, po qd measured on 28 to 48 weeks on 48 week study | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1693336 | Selectivity index, ratio of CC50 for human HepG2 2.2.15 to IC50 of antiviral activity against HBV infected in human HepG2 2.2.15 cells assessed as decrease in extracellular viral DNA level measured after incubation of 6 days by RT-PCR analysis | 2021 | Bioorganic & medicinal chemistry, 01-01, Volume: 29 | Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. |
| AID404908 | Cytotoxicity against human HL60 cells after 3 days by MTT assay | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues. |
| AID423280 | Antiviral activity against multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. |
| AID261855 | Inhibition of duck HBV transfected in primary duck hepatocytes | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6 | Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV. |
| AID79635 | Concentration required to inhibit 50% of cytoplasmic HBV-DNA synthesis | 2002 | Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14 | 2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents. |
| AID422692 | Ratio of IC50 for HIV1 with reverse transcriptase K70G/M184V mutation to IC50 for wild type HIV1 | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase. |
| AID1226129 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 300 uM after 9 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1815381 | Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID246491 | Effective concentration to inhibit 50% of cytomegalovirus (CMV) replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID1614367 | Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level at 10 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. |
| AID1771357 | Inhibition of capsid protein in HBV infected in human HepDES19 cells assessed as inhibition of viral replication by measuring plus polarity DNA level at 20 uM incubated for 3 days by strand preferential qPCR analysis relative to control | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. |
| AID358070 | Antiviral activity against HBV in human HepD2 cells assessed as inhibition of viral pre genomic RNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID519973 | Antiviral activity against HIV1 NL4-3 harboring M184V mutant RT at 2.5 uM after 6 days | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID246341 | Effective concentration to inhibit 50 % of Epstein Barr virus replication in a cell culture model | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID520606 | Selectivity index, ratio of CC50 for human WI38 cells to EC50 for BK polyomavirus ATCC VR837 | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Anti-BK virus activity of nucleoside analogs. |
| AID1377845 | Cytotoxicity against human HepG2 cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. |
| AID548800 | Antiviral activity against HIV1 isolate 192 harboring reverse transcriptase M41L/T215Y mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID572768 | Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID1854347 | Antiviral activity against HIV-1 | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | HIV nucleoside reverse transcriptase inhibitors. |
| AID492270 | Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay | 2010 | Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14 | Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID576242 | AUC (0 to tau) in HIV-1 infected children aged 8.5 to 12.3 years at 4 mg/kg, po every 12 hrs by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID519862 | Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1888692 | Selectivity index, ratio of CC50 for toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells cells assessed as protection against viral-induc | |||
| AID517939 | Antiviral activity against HIV1 subtype BF isolate 5 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID563942 | Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase T165A/M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. |
| AID738967 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected human HepG2.2.15 cells by DNA replication assay | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-hepatitis B virus lignans from the root of Streblus asper. |
| AID1544329 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM measured on day 3 by FQ-PCR analysis relative to control | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID405004 | Effect on replication efficiency of HBV genotype D with reverse transcriptase L80I/M204I mutation in human Huh7 cells assessed as increase in viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1572520 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay | |||
| AID1743635 | Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT K103N mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID404980 | Antiviral activity against HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1869742 | Antiviral activity against Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in serum at 25 mg/kg, IG administered once daily for 28 days and measured on day 21 | |||
| AID548826 | Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID322838 | Antiviral activity against lamivudine-resistant HBV with reverse transcriptase V173L/L180/M204V mutant | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID246559 | Effective concentration to inhibit 50 % of Human immunodeficiency virus replication in a cell culture model;ND=Not determined | 2005 | Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 | Synthesis and antiviral activity of helioxanthin analogues. |
| AID519893 | Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.005 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1401783 | Antiviral activity against Hepatitis B virus harboring rtV173L/L180M/M204V mutant infected in HepGRL1 cells assessed as inhibition of intracellular HBV DNA level at 20 uM measured on day 6 by FQ-PCR analysis relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents. |
| AID1543318 | Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytial cell formation incubated for 72 hrs | 2019 | Journal of natural products, 07-26, Volume: 82, Issue:7 | Dimeric Pyranonaphthoquinone Glycosides with Anti-HIV and Cytotoxic Activities from a Soil-Derived |
| AID576255 | AUC in HIV-1 infected children with body weight >17 kg at 8 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID675192 | Therapeutic index, ratio of TC50 for human PBMC to EC50 for HIV-1 subtype B US/92/727 infected in PBMC | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. |
| AID86872 | Effective concentration against Hepatitis B virus in human hepatoblastoma cell line | 1998 | Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12 | Does the anti-hepatitis B virus activity of (+)-5'-noraristeromycin exist in its 4'-epimer and 4'-deoxygenated derivatives? |
| AID560904 | Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. |
| AID1226089 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1661372 | Antiviral activity against JRFL pseudotyped HIV1 infected in human Hut/CCR5 cells assessed as time needed to reach 50% reduction of virus infection at 10000 nM incubated with cells for 4 hrs prior to compound washout followed by viral infection and measur | 2020 | Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15 | Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention. |
| AID1226121 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 300 uM after 3 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1380571 | Antiviral activity against HIV1 virions containing reverse transcriptase Y181C mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre-mixed | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents. |
| AID1228534 | Half life in Sprague-Dawley rat at 2.5 mg/kg, iv | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID614562 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by measuring HBsAg and HBeAg production after 9 days by EIA | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18 | Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents. |
| AID1507017 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 8 days by ELISA | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. |
| AID1226090 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID572775 | Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID1316333 | Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. |
| AID732676 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IL-2 mRNA level in liver at 100 mg/kg qd for 1 month by qPCR analysis | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1694161 | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay | 2021 | Bioorganic & medicinal chemistry, 02-01, Volume: 31 | Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. |
| AID1614323 | Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. |
| AID1815382 | Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID625999 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Sout | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID444055 | Fraction absorbed in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID625940 | Fold resistance, ratio of EC90 for lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant to EC90 for wild type Hepatitis B virus | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID517935 | Antiviral activity against HIV1 subtype A isolate 1 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. |
| AID1197831 | Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. |
| AID1197830 | Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. |
| AID405003 | Effect on replication efficiency of HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as decrease in viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID427242 | Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Synthesis and in vitro anti-hepatitis B virus activity of 6H-[1]benzothiopyrano[4,3-b]quinolin-9-ols. |
| AID732673 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IFN gamma level in serum at 100 mg/kg qd for 1 month by ELISA | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID404995 | Antiviral activity against HBV genotype D with reverse transcriptase L180M/M204I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID541152 | Selectivity ratio of EC50 for antiviral activity against EFV-resistant HIV1 selected after 3 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID732669 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in CD8+ population in peripheral blood at 100 mg/kg qd for 1 month by flow cytometry (Rvb = 14.1 +/-1.4%) | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID1226113 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 300 uM after 6 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID582413 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 26 %) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID340847 | Apparent terminal half life in healthy human at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID450970 | Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 days by ELISA | 2009 | Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17 | Synthesis and anti-HIV activity of novel 2',3'-dideoxy-3'-thiacytidine prodrugs. |
| AID1226130 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 150 uM after 9 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1729161 | Antiviral activity against HIV1 harboring F227L/V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID1693341 | Antiviral activity against lamivudine/entecavir-resistant HBV rtL180M/rtM204V/rtT184L mutant infected in human HepG2 2.2.15 cells assessed as inhibition of viral DNA replication at 100 uM measured after incubation of 72 hrs by RT-PCR analysis relative to | 2021 | Bioorganic & medicinal chemistry, 01-01, Volume: 29 | Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. |
| AID732677 | Immunoregulatory activity in Hepatitis B virus infected transgenic mouse assessed as increase in cytokine IFN gamma mRNA level in liver at 100 mg/kg qd for 1 month by qPCR analysis | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5 | Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). |
| AID519877 | Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID273057 | Cytotoxicity against 2.2.15 cells | 2006 | Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20 | 9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. |
| AID218359 | Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID353549 | Cytotoxicity against human HepG2(2.2.15) cells | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Anti-HBV agents. Part 2: synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives. |
| AID1316330 | Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17 | Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. |
| AID727269 | Cytotoxicity against human HuH7 cells | 2013 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2 | 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1320867 | Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. |
| AID404994 | Antiviral activity against HBV genotype D with reverse transcriptase L80I/M204I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID576229 | Cmin in HIV-1 infected children aged 2.5 to 14 years at 8 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID540215 | Volume of distribution at steady state in rat after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID1226099 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 75 uM after 6 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID358075 | Antiviral activity against HBV in mouse HBV-Met cells assessed as inhibition of viral 2.4/2.1RNA replication | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID404998 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1694160 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay | 2021 | Bioorganic & medicinal chemistry, 02-01, Volume: 31 | Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. |
| AID519865 | Antiviral activity against HIV1 subtype B-NL4-3 infected in 3 hrs pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID625932 | Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID1387650 | Antiviral activity against HIV1 infected in human PBMC incubated for 24 hrs in presence of 10% NHS by GFP based single cycle HIV replication assay | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20 | Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4'-Ethynyl-2-fluoro-2'-deoxyadenosine). |
| AID1565090 | Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | |||
| AID1055516 | Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis | 2013 | European journal of medicinal chemistry, , Volume: 70 | Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. |
| AID1228529 | Antiviral activity against duck Hepatitis B virus infected in duck assessed as inhibition of viral DNA replication in liver at 20 mg/kg/day, po treatment initiated at day 10 after infection relative to control | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9 | Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection. |
| AID519882 | Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID576250 | AUC (0 to tau) in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 24 hrs coadministered with 8 mg/kg abacavir by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID328846 | Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3 | Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. |
| AID422695 | Ratio of IC50 for HIV1 with reverse transcriptase K70G mutation to IC50 for wild type HIV1 | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase. |
| AID618858 | Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. |
| AID1226092 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID273056 | Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay | 2006 | Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20 | 9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. |
| AID548823 | Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID340707 | Tmax in healthy human PBMC assessed as intracellular apricitabine triphosphate level at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1743631 | Antiviral activity against HIV1 harboring RT F227L/V106Amutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID422694 | Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by vircotype clinical cutoffs assay relative to wild type HIV1 | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase. |
| AID576243 | Apparent oral clearance in HIV-1 infected children aged 8.5 to 12.3 years at 4 mg/kg, po every 12 hrs by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID369218 | Antiviral activity against woodchuck hepatitis virus infected woodchucks assessed as log reduction of serum viral DNA per ml of serum after 4 weeks | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection. |
| AID563943 | Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S/T165A/M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. |
| AID340715 | Cmin in healthy human PBMC assessed as intracellular apricitabine triphosphate level per 10'6 cells at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID218018 | Cytotoxic concentration required to reduce the viability of Vero cells as determined by MTT assay | 2002 | Journal of medicinal chemistry, May-09, Volume: 45, Issue:10 | Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus. |
| AID1507015 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication at 20 uM after 8 days by real time fluorescent PCR method relative to control | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. |
| AID740214 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-HBV active constituents from Piper longum. |
| AID614132 | Cytotoxicity in human HepG2(2.2.15) cells after 72 hrs by MTT assay | 2011 | Journal of natural products, Aug-26, Volume: 74, Issue:8 | Swerilactones L-O, secoiridoids with C₁₂ and C₁₃ skeletons from Swertia mileensis. |
| AID1729156 | Antiviral activity against HIV1 harboring L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID1449527 | Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | 2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. |
| AID410755 | Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID626004 | Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot h | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID341755 | Drug level in human phytohemagglutininin-activated PBMC assessed as Lamivudine monophosphate level at 2.6 uM after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID582406 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 46 +/- 25 pg) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID519875 | Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID576246 | AUC (0 to tau) in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 12 hrs coadministered with 8 mg/kg abacavir by HPLC | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? |
| AID384985 | Antiviral activity against HBV assessed as inhibition of viral e-antigen secretion in HepG2.2.15 cells by ELISA | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Periglaucines A-D, anti-HBV and -HIV-1 alkaloids from Pericampylus glaucus. |
| AID358078 | Cytotoxicity against HBV transfected human adriamycin-resistant HepD2 cells with RTM20V and RTV180M mutation by MTT assay | 2007 | Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20 | Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. |
| AID404989 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L180M/M204I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID322843 | Antiviral activity against entecavir-resistant HBV with reverse transcriptase L180M/S202G/M204V mutant | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID519962 | Selectivity ratio of EC50 for 0.05 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.05 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1815392 | Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase Y188L mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID417237 | Drug metabolism in HIV-infected human PBMC assessed as zidovudine triphosphate level at 300 mg administered in two courses, first BID for 7 to 14 days followed by QD for 7 days and second course the subjects were switched to the other regimen measured per | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID1544344 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of extracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID557053 | Antiviral activity against NRTI-, PI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID268269 | Selectivity index, CC50 for HepG2.2.15 cells/IC50 for HBV | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15 | Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. |
| AID1742099 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg production supplemented with fresh medium containing compound every 3 days for 6 days by EIA relative to control | 2020 | European journal of medicinal chemistry, Nov-01, Volume: 205 | Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. |
| AID550165 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by semi-quantitative EIA | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and in vitro anti-hepatitis B virus activity of six-membered azanucleoside analogues. |
| AID1544309 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 6 days measured post-last dose by FQ-P | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID1572519 | Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay | |||
| AID1226132 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 37.5 uM after 9 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID235451 | Selectivity (CC50/EC50) for death of uninfected MT4 cell to that of inhibition of cytopathicity of HIV-1 IIIB on MT-4 cell | 2003 | Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15 | Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs? |
| AID519869 | Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID405008 | Effect on replication efficiency of HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I/L180M/M204I mutation in human Huh7 cells assessed as increase in viral replication yield at 1 uM after 5 days relative to contro | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1815386 | Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase Y181C mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID23457 | Partition coefficient (logP) | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept. |
| AID618794 | Antiviral activity against Hepatitis B virus infected in human HepAD38 assessed as reduction of viral DNA level on day 7 by quantitative-PCR assay analysis | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. |
| AID340693 | Cmax in healthy human at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1226127 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 75 uM after 6 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1815393 | Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase E138K mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID1487261 | Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay | 2017 | Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16 | Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. |
| AID1869624 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID444054 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1071715 | Antiviral activity against Hepatitis B virus assessed as inhibition of viral infection by DNA virion assay | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues. |
| AID1869623 | Anti-HIV activity against wild type HIV-2 ROD infected in human MT4 cells assessed as inhibition of HIV-induced cytopathic effect measured after 5 days by MTT assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID1743628 | Antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID325080 | Drug level in human PBMC assessed as concentration of Lamivudine triphosphate per 10^6 cells after 0.3 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. |
| AID47456 | Compound concentration required to inhibit cell growth by 50% against CEM cells | 1998 | Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13 | Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides. |
| AID404990 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I/L180M/M204I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID88983 | Compound concentration required to inhibit the viral cell proliferation by 50% against HIV; Range = 2-3 | 1998 | Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13 | Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides. |
| AID580184 | Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV). |
| AID1743626 | Antiviral activity against HIV1 harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. |
| AID268268 | Cytotoxicity against HepG2.2.15 cells | 2006 | Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15 | Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. |
| AID1687687 | Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells reduction in cell viability by MTT assay to EC50 for antiviral activity against wild type HIV-1 strain IIIB infected in human MT4 cells assessed as reduction in virus-induced cytopa | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. |
| AID1741376 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in HBsAg secretion incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by ELISA | 2020 | European journal of medicinal chemistry, Sep-15, Volume: 202 | Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. |
| AID261859 | Inhibition of HBV M204I mutant transfected in B1 cell line | 2006 | Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6 | Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV. |
| AID1226114 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 150 uM after 6 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID323412 | Reduction in dexelvucitabine diphosphate choline level in human PBMC at 100 uM | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. |
| AID1902001 | Antiviral activity against Hepatitis B virus infected in human HepG2 2.2.15 cells assessed as inhibition of DNA replication | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231 | Design and synthesis of novel quinazolinone derivatives as anti-HBV agents with TLR8 agonist effect. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1226123 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA copies per uL at 75 uM after 3 days by real-time fluorescence quantitative PCR analysis | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1191401 | Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay | 2015 | Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3 | Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. |
| AID519870 | Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1888705 | Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT RES056 mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells | |||
| AID557049 | Antiviral activity against HIV1 clade G harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID582428 | Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of serum gamma-glutamyltransferase activity at 15 mg/kg, po qd for 48 weeks | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID1687682 | Antiviral activity against HIV-1 Y181C mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. |
| AID307875 | Inhibition of cytoplasmic HBV DNA synthesis in HepG2.2.15 cells after 8 days | |||
| AID106426 | Effective concentration to inhibit HIV-1 IIIB cytopathicity in MT-4 cells was determined in vitro | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept. |
| AID1387651 | Cytotoxicity in human MT4 cells expressing GFP assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20 | Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4'-Ethynyl-2-fluoro-2'-deoxyadenosine). |
| AID405582 | Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates. |
| AID478523 | Antiviral activity against HBV infected in HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion after 8 days by radio immunoassay | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Synthesis and antiviral activity of new acrylamide derivatives containing 1,2,3-thiadiazole as inhibitors of hepatitis B virus replication. |
| AID548835 | Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID565983 | Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Structure-activity relationships study of 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives as novel non-nucleoside anti-hepatitis B virus agents. |
| AID63717 | Percent inhibition of viral DNA in the presence of 10 mg/mL compound compared to untreated infected controls in duck hepatocytes | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID738972 | Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 | Anti-hepatitis B virus lignans from the root of Streblus asper. |
| AID519864 | Antiviral activity against HIV1 subtype B-NL4-3 infected in 2 hrs pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID580185 | Antiviral activity against Hepatitis B virus infected in human Huh7 cells assessed as reduction in viral DNA after 1 day by Southern blotting | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV). |
| AID582395 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 1132 +/- 738 pg) | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID200144 | Ratio for inhibition of HIV-1 RT to that of type and HIV-1 RT M184V mutant was determined | 2003 | Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12 | The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V). |
| AID625933 | Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hybridization assay | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID625935 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. |
| AID328844 | Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay | 2007 | Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3 | Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. |
| AID548578 | Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID1544312 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every 3 days for 9 days measured post-last dose by FQ-P | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID527561 | Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication at 0.5 to 1 ug/ml after 2 days relative to control | 2010 | Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21 | Synthesis and in vitro antiviral activities of 3'-fluoro (or chloro) and 2',3'-difluoro 2',3'-dideoxynucleoside analogs against hepatitis B and C viruses. |
| AID556524 | Antiviral activity against Human immunodeficiency virus 1 clone pNL4-3-Q145M harboring K102Q, Q145M, S162C, K277R, I293V mutation in reverse transcriptase by phenosense assay relative to wild type | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility. |
| AID405207 | Effect on replication efficiency of HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as decrease viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID727268 | Antiviral activity against entecavir-resistant Hepatitis B virus harboring L180M/M204V/S202G triple mutant infected in human HuH7 cells | 2013 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2 | 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. |
| AID1226107 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as cell survival at 75 uM after 9 days (Rvb = 100%) | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID444050 | Fraction unbound in human plasma | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1572518 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay | |||
| AID582419 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in lobular hepatitis at 15 mg/kg, po qd measured on 12th week on 48 weeks study | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID467612 | Fraction unbound in human plasma | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID1431320 | Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 3 days by MTS assay | 2016 | Journal of natural products, Dec-23, Volume: 79, Issue:12 | Synthesis of C-4-Substituted Steviol Derivatives and Their Inhibitory Effects against Hepatitis B Virus. |
| AID257342 | Selectivity index (CC50/EC50) for inhibition of HBV replicative intermediate synthesis in human hepatoblastoma 2.2.15 cells | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system. |
| AID519966 | Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells by phenosense assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. |
| AID1200847 | Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. |
| AID550167 | Selectivity index, ratio of TC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1 | Synthesis and in vitro anti-hepatitis B virus activity of six-membered azanucleoside analogues. |
| AID1888697 | Antiviral activity against HIV1 with RT Y188L mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay | |||
| AID63719 | Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls. | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity. |
| AID1320866 | Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B expressing wild type reverse transcriptase | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. |
| AID417239 | AUC in HIV-infected human assessed as Lamivudine diphosphate level in PBMC at 300 mg QD for 7 days in presence of zidovudine | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. |
| AID1888703 | Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT E138K mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells | |||
| AID152627 | Antiviral activity against (HIV-1M184V) mutant strain in human PBM cells | 2002 | Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22 | Stereoselective synthesis and antiviral activity of D-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thionucleosides. |
| AID556525 | Antiviral activity against Human immunodeficiency virus 1 clone 38086 harboring K49R, V60I, I135V, Q145M, Q174H, G196E, Q207E, R211K, V245K mutation in reverse transcriptase by phenosense assay relative to wild type | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility. |
| AID1565096 | Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | |||
| AID427243 | Selectivity index, ratio of TC50 for human HepG2(2.2.15) cells to IC50 for inhibition of HBV DNA replication | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Synthesis and in vitro anti-hepatitis B virus activity of 6H-[1]benzothiopyrano[4,3-b]quinolin-9-ols. |
| AID246789 | Effective concentrations at which 10-fold depression of intracellular intermediates of HBV DNA was observed in 2.2.15 Cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | 5'-Homoneplanocin A inhibits hepatitis B and hepatitis C. |
| AID325082 | Ratio of drug level in human RBC to human PBMC assessed as concentration of Lamivudine triphosphate after 0.3 hrs | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. |
| AID1203826 | Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 50 uM incubated for 14 days | 2015 | Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8 | β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms. |
| AID1815395 | Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells | 2021 | European journal of medicinal chemistry, Dec-15, Volume: 226 | Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. |
| AID1207746 | Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits | 2013 | Scientific reports, , Volume: 3 | MICE models: superior to the HERG model in predicting Torsade de Pointes. |
| AID1869625 | Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay to EC50 for anti-HIV activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as inhibition of HIV-induced cyt | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound. |
| AID404988 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I/M204I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1197829 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID1543317 | Toxicity in human C8166 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2019 | Journal of natural products, 07-26, Volume: 82, Issue:7 | Dimeric Pyranonaphthoquinone Glycosides with Anti-HIV and Cytotoxic Activities from a Soil-Derived |
| AID1721279 | Antiviral activity against HBV infected in human HepAD38 cells assessed as inhibition of viral DNA at 10 uM incubated for 4 days by SYBR green dye based RT-PCR analysis relative to control | 2020 | Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16 | Junceellolide B, a novel inhibitor of Hepatitis B virus. |
| AID1241034 | Cytotoxicity against human HepG2(2.2.1) cells | 2015 | Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17 | 2- and 3-Fluoro-3-deazaneplanocins, 2-fluoro-3-deazaaristeromycins, and 3-methyl-3-deazaneplanocin: Synthesis and antiviral properties. |
| AID1449531 | Mitochondrial toxicity in human HepG2 cells assessed as lactic acid production at 10 uM measured on day 14 by spectrophotometric method relative to control | 2017 | Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13 | 2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. |
| AID563937 | Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID1565100 | Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | |||
| AID548828 | Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay relative to wild type | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID548809 | Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID492271 | Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis after 8 days by RT-PCR analysis | 2010 | Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14 | Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus. |
| AID582399 | Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in portal hepatitis at 15 mg/kg, po qd measured on 12th week on 48 weeks study | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. |
| AID340701 | Tmax in healthy human at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1507024 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication after 8 days by real time fluorescent PCR method | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. |
| AID1363963 | Antiviral activity against lamivudine-resistant wild type hepatitis B virus infected in human Huh7 cells assessed as reduction in intracellular DNA levels measured on day 7 by real-time PCR analysis | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 | Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). |
| AID104417 | Compound was tested for anti-HIV activity in MT-2/ IIIB cells and the ratio of the drug concentration (ID50) required to inhibit cell growth was reported. | 1998 | Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13 | Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides. |
| AID1457763 | Selectivity index, ratio of CC50 for HepG2.2.15 cells to EC50 for HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring extracellular viral DNA copy | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. |
| AID322837 | Antiviral activity against lamivudine-resistant HBV with reverse transcriptase L180M/A181V mutant | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID572994 | Mitochondrial toxicity in human HepG2 cells assessed as percent mitochondrial DNA production at 100 uM after 14 days by real-time PCR relative to control | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID541155 | Selectivity ratio of EC50 for antiviral activity against APV-resistant HIV1 selected after 4 passages to EC50 for antiviral activity against wild-type HIV1 3B | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. |
| AID404992 | Antiviral activity against HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID266279 | Antiviral activity against wild type HBV in human hepatoma 2.2.15 cells at 10 ug/mL | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication. |
| AID410600 | Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as extracellular HBV virion DNA level after 24 hrs | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID1072521 | Selectivity index, ratio of cytotoxicity towards human HepG2.2.15 cells to IC50 for HBV DNA production | 2014 | European journal of medicinal chemistry, Mar-21, Volume: 75 | A review of non-nucleoside anti-hepatitis B virus agents. |
| AID1434725 | Antiviral activity against HBV infected in human HepAD38 cells assessed as inhibition of DNA replication after 5 days by RT-PCR method | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. |
| AID596753 | Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay | 2011 | Journal of natural products, Apr-25, Volume: 74, Issue:4 | Homoflavonoid glucosides from Ophioglossum pedunculosum and their anti-HBV activity. |
| AID404997 | Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation in human Huh7 cells assessed as viral replication yield at 1 uM after 5 days relative to control | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
| AID1191972 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6 | Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity. |
| AID1226102 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 150 uM after 9 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID437966 | Antiviral activity against HBV assessed as inhibition of viral early antigen secretion | 2009 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23 | Anti-HBV agents. Part 3: preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors. |
| AID340699 | Apparent terminal half life in healthy human at 300 mg, po administered once daily for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. |
| AID1693339 | Antiviral activity against wild type HBV infected in human HepG2 2.2.15 cells assessed as inhibition of viral DNA replication at 100 uM measured after incubation of 72 hrs by RT-PCR analysis relative to control | 2021 | Bioorganic & medicinal chemistry, 01-01, Volume: 29 | Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. |
| AID682488 | Antiviral activity against HIV1 by cell-based assay | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. |
| AID322849 | Fold resistance, ratio of lamivudine -adenofir-resistant with HBV reverse transcriptase V173L/L180M/A181V/M204V/N236T mutant to wild-type HBV genotype E | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. |
| AID1544332 | Antiviral activity against lamivudine-resistant Hepatitis B virus harboring L180M/M204V mutant infected in human HepG2.2.15 cells assessed as inhibition of intracellular HBV DNA replication at 20 uM supplemented with fresh medium containing compound every | 2019 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11 | Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-fluoro-2'-C-methyl 8-azanebularine derivatives as potent anti-HBV agents. |
| AID410753 | Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1 | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. |
| AID517838 | Antiviral activity against drug resistant HBV infected in M204I cells assessed as inhibition of viral DNA replication at 10 ug/mL | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19 | Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and |
| AID572991 | Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of mitochondrial DNA at 10 uM after 14 days by real-time PCR | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. |
| AID1226120 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 37.5 uM after 9 days by ELISA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID1888700 | Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT K103N mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells | |||
| AID341750 | Drug level in human resting PBMC assessed as Lamivudine diphosphate level at 2.6 uM after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro interactions between apricitabine and other deoxycytidine analogues. |
| AID548798 | Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID282656 | Cytotoxicity against CEM cells | 2004 | Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27 | (Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. |
| AID691383 | Antiviral activity against Duck hepatitis B virus infected in pekin duck primary hepatocytes assessed as inhibition of viral replication | 2012 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20 | A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses. |
| AID565981 | Cytotoxicity against human HepG2(2.2.15) cells | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Structure-activity relationships study of 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives as novel non-nucleoside anti-hepatitis B virus agents. |
| AID21031 | Partition coefficient was measured in the solution of 1-octanol with a phosphate buffer (0.2) at pH 7.4 | 1994 | Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14 | Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates. |
| AID548807 | Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. |
| AID307876 | Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay | |||
| AID325081 | Ratio of drug level in human RBC to human PBMC assessed as concentration of Lamivudine triphosphate | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1729150 | Antiviral activity against HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1745855 | NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1745854 | NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1391719 | Selectivity index, ratio of CC50 for human HepG2.215 cells to IC50 for Hepatitis B virus infected in human HepG2.215 cells assessed as inhibition of HBsAg secretion | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Design, synthesis and biological evaluation of seco-A-pentacyclic triterpenoids-3,4-lactone as potent non-nucleoside HBV inhibitors. |
| AID1754645 | Antiviral activity against HIV1 harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1391717 | Antiviral activity against Hepatitis B virus infected in human HepG2.215 cells assessed as inhibition of HBeAg secretion after 3 days by ELISA | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Design, synthesis and biological evaluation of seco-A-pentacyclic triterpenoids-3,4-lactone as potent non-nucleoside HBV inhibitors. |
| AID1506330 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 3.13 ug/ml after 8 days by ELISA relative to control | 2017 | MedChemComm, Jan-01, Volume: 8, Issue:1 | Synthesis and biological activity evaluation of novel peroxo-bridged derivatives as potential anti-hepatitis B virus agents. |
| AID1391724 | Antiviral activity against Hepatitis B virus infected in human HepG2.215 cells assessed as reduction in cellular viral DNA level at 25 uM after 9 days by real time QF-PCR analysis relative to control | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Design, synthesis and biological evaluation of seco-A-pentacyclic triterpenoids-3,4-lactone as potent non-nucleoside HBV inhibitors. |
| AID1292008 | Selectivity index, ratio of CC50 for mock infected human MT4 cells to EC50 for HIV2 ROD infected in human MT4 cells | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. |
| AID1389502 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to EC50 for HBV infected in human HepG2.2.15 cells | 2018 | Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8 | 2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors. |
| AID1754647 | Antiviral activity against HIV1 harboring RT RES056 mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1754638 | Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1292012 | Selectivity index, ratio of CC50 for mock infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. |
| AID1754641 | Antiviral activity against HIV1 harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1754640 | Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect measured after 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1298247 | Inhibition of HIV1 wild type reverse transcriptase p66/p51 using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry | 2016 | Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11 | 1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus. |
| AID1754644 | Antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1754642 | Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1391725 | Selectivity index, ratio of CC50 for human HepG2.215 cells to IC50 for Hepatitis B virus infected in human HepG2.215 cells assessed as reduction in covalently closed circular DNA level | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Design, synthesis and biological evaluation of seco-A-pentacyclic triterpenoids-3,4-lactone as potent non-nucleoside HBV inhibitors. |
| AID1292007 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. |
| AID1754646 | Antiviral activity against HIV1 harboring RT F227L/V106A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1389500 | Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA levels after 72 hrs by qRT-PCR analysis | 2018 | Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8 | 2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors. |
| AID1391726 | Antiviral activity against Hepatitis B virus infected in human HepG2.215 cells assessed as reduction in covalently closed circular DNA level after 9 days by real time QF-PCR analysis | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Design, synthesis and biological evaluation of seco-A-pentacyclic triterpenoids-3,4-lactone as potent non-nucleoside HBV inhibitors. |
| AID1391718 | Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Design, synthesis and biological evaluation of seco-A-pentacyclic triterpenoids-3,4-lactone as potent non-nucleoside HBV inhibitors. |
| AID1292011 | Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. |
| AID1506329 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 3.13 ug/ml after 8 days by ELISA relative to control | 2017 | MedChemComm, Jan-01, Volume: 8, Issue:1 | Synthesis and biological activity evaluation of novel peroxo-bridged derivatives as potential anti-hepatitis B virus agents. |
| AID1298246 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells | 2016 | Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11 | 1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus. |
| AID1754643 | Antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1298245 | Cytotoxicity against human MT4 cells after 5 days MTT assay | 2016 | Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11 | 1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus. |
| AID1391716 | Antiviral activity against Hepatitis B virus infected in human HepG2.215 cells assessed as inhibition of HBsAg secretion after 3 days by ELISA | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Design, synthesis and biological evaluation of seco-A-pentacyclic triterpenoids-3,4-lactone as potent non-nucleoside HBV inhibitors. |
| AID1506328 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 3.13 ug/ml after 4 days by ELISA relative to control | 2017 | MedChemComm, Jan-01, Volume: 8, Issue:1 | Synthesis and biological activity evaluation of novel peroxo-bridged derivatives as potential anti-hepatitis B virus agents. |
| AID1298243 | Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay | 2016 | Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11 | 1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus. |
| AID1506327 | Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 3.13 ug/ml after 4 days by ELISA relative to control | 2017 | MedChemComm, Jan-01, Volume: 8, Issue:1 | Synthesis and biological activity evaluation of novel peroxo-bridged derivatives as potential anti-hepatitis B virus agents. |
| AID1391720 | Selectivity index, ratio of CC50 for human HepG2.215 cells to IC50 for Hepatitis B virus infected in human HepG2.215 cells assessed as inhibition of HBeAg secretion | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Design, synthesis and biological evaluation of seco-A-pentacyclic triterpenoids-3,4-lactone as potent non-nucleoside HBV inhibitors. |
| AID1292009 | Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay | 2016 | European journal of medicinal chemistry, Jun-10, Volume: 115 | Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. |
| AID1754637 | Antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect measured after 5 days by MTT assay | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1754639 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for Antiviral activity against HIV-1 IIIB infected in human MT4 cells | 2021 | Bioorganic & medicinal chemistry, 07-15, Volume: 42 | Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. |
| AID1389499 | Cytotoxicity against human HepG2.2.15 cells after 72 hrs by MTT assay | 2018 | Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8 | 2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 794 (11.98) | 18.2507 |
| 2000's | 3355 (50.60) | 29.6817 |
| 2010's | 2052 (30.95) | 24.3611 |
| 2020's | 429 (6.47) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (91.24) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,425 (20.28%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 755 (10.75%) | 6.00% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 753 (10.72%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 77 (1.10%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4,015 (57.15%) | 84.16% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy [NCT01059422] | Phase 4 | 10 participants (Anticipated) | Interventional | 2010-10-31 | Recruiting | ||
| Randomized Phase 3 Trial to Evaluate Two Simplified Antiretroviral Treatment Strategies in HIV Infected Children, Treated by Antiretroviral Triple Therapy Before One Year of Age, in Virological Success in Africa (Burkina Faso, Côte d'Ivoire, Rwanda) [NCT01127204] | Phase 2/Phase 3 | 161 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-t [NCT00307151] | Phase 2 | 452 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China [NCT01340950] | Phase 4 | 250 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Randomized, Pilot Estimation Study to Compare the Safety and Efficacy of Raltegravir+TDF+3TC Versus TDF+3TC+EFV in HBV/HIV Co-infected Patients [NCT01318096] | 60 participants (Anticipated) | Interventional | 2011-03-31 | Not yet recruiting | |||
| UNCPM 22314 - Evaluating the Safety of Pregnancy, Infant and Maternal Health Outcomes Among PrEP Users in Malawi [NCT06158126] | 621 participants (Anticipated) | Observational [Patient Registry] | 2024-01-01 | Not yet recruiting | |||
| Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers [NCT01125696] | Phase 2 | 45 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Open-Label, Fixed-Sequence, Crossover Study To Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects [NCT01220232] | Phase 1 | 14 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression [NCT01174914] | Phase 2 | 171 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| An Open-label, Randomized, Single Dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine Versus Dolutegravir and Lamivudine Single Entities and Food Effect Assessment in Healthy Volunteers [NCT03078556] | Phase 1 | 154 participants (Actual) | Interventional | 2017-03-27 | Completed | ||
| A Single Arm, Phase 3 Study, Exploring the Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV, a Pilot Switch Study Strategy in South Africa [NCT04433780] | Phase 3 | 133 participants (Actual) | Interventional | 2021-01-04 | Completed | ||
| Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study [NCT01210287] | Phase 2/Phase 3 | 110 participants (Anticipated) | Interventional | 2010-10-31 | Active, not recruiting | ||
| Pre-exposure Prophylaxis of HIV Infection Among Men Who Have Sex With Men (MSM) and Transgender Women (TG) in Suburban Yangon, Myanmar [NCT04781426] | 200 participants (Actual) | Observational | 2020-10-28 | Completed | |||
| Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Lamivudine Plus Adefovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir Combination Therapy - Multicenter Randomiz [NCT03236584] | Phase 3 | 76 participants (Actual) | Interventional | 2015-09-01 | Active, not recruiting | ||
| NEVIRAPINE Plus LAMIVUDINE (3TC) for HIV Maintenance Therapy - A Single Center Pilot Study [NCT03223402] | 20 participants (Actual) | Interventional | 2016-12-23 | Completed | |||
| Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis) [NCT01376154] | 342 participants (Actual) | Observational | 2006-06-30 | Completed | |||
| The Effects of Maraviroc Versus Efavirenz in Combination With Zidovudine/Abacavir on the CD4/CD8 Ratio in Treatment-naïve HIV-infected Individuals [NCT03178084] | Phase 3 | 721 participants (Actual) | Interventional | 2014-10-15 | Completed | ||
| A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adu [NCT04900038] | Phase 2 | 85 participants (Actual) | Interventional | 2021-08-18 | Terminated(stopped due to Company decision to stop compound development. The decision was not based on any safety or efficacy concerns. It reflected the company strategy for portfolio progression.) | ||
| A Pilot Clinical Trial of Reverse Transcriptase Inhibitors in Children With Aicardi-Goutières Syndrome (AGS) [NCT02363452] | Phase 2 | 11 participants (Actual) | Interventional | 2015-09-10 | Completed | ||
| A Randomized, Open-Label, Single-Dose, 3-Period, Crossover Evaluation of the Relative Bioavailability of Two Experimental Fixed-Dose Combination Tablet Formulations of Dolutegravir 50 mg/Abacavir 600 mg/Lamivudine 300 mg Compared to Co-Administered Dolute [NCT01366547] | Phase 1 | 18 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Body Composition Sub-study of the D2EFT Trial [NCT03675815] | Phase 4 | 155 participants (Actual) | Interventional | 2019-12-05 | Active, not recruiting | ||
| "Safeguard the Household - A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country" [NCT00255840] | 812 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir®) and Dolutegravir(Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol [NCT02527096] | Phase 2 | 110 participants (Actual) | Interventional | 2015-09-17 | Completed | ||
| Impact of DOlutegravir+Lamivudine Simplification on TIssue and Blood Latent Replication-competent HIV-1 Reservoirs (IDOLTIB Study) [NCT04034862] | Phase 3 | 36 participants (Actual) | Interventional | 2019-10-01 | Active, not recruiting | ||
| Efficacy of Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy in Patients With Viral Suppression. Randomized, Open-label 96 Weeks Non-inferiority Trial [NCT01307488] | Phase 4 | 286 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects [NCT00118898] | Phase 3 | 1,864 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine [NCT00099632] | Phase 2 | 484 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Phase 3, Randomized, Multicenter Study of the Treatment of Antiretroviral-Naive HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs Combivir (Lamivudine/Zidovudine) and Efavirenz [NCT00112047] | Phase 3 | 517 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2 to Less Than 18) With Chronic Hepatitis B [NCT00095121] | Phase 3 | 173 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects [NCT01263015] | Phase 3 | 844 participants (Actual) | Interventional | 2011-02-01 | Completed | ||
| An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 ≥ 250 Cells/mm3 and HIV Virus Load ≥ 50,000 cp/mL [NCT01583439] | 11 participants (Actual) | Interventional | 2012-09-30 | Terminated(stopped due to Low Accrual.) | |||
| DOR/TDF/3TC Maintenance Therapy Among Patients Harboring M184V/I Mutation: a Pilot Open-label Study [NCT06034938] | Phase 2 | 32 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| A Prospective Randomised Open Label Clinical Trial to Determine the Efficacy of Nevirapine, Compared With a Combination of ZDV + 3TC, in Decreasing the Peripartum Mother to Child Transmission of HIV. Women, Who Present After 38 Weeks Gestation or in Labou [NCT02181933] | Phase 3 | 2,648 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay®) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq®) in HIV-1- Infected Patients [NCT02596334] | Phase 3 | 158 participants (Actual) | Interventional | 2015-12-23 | Terminated(stopped due to 5 patients on tivicay had virological failure) | ||
| Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT) [NCT01352715] | Phase 3 | 515 participants (Actual) | Interventional | 2012-03-13 | Completed | ||
| Pilot 24week Clinical Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Raltegravir/Lamivudine Combination, Replacing Standard Combination Therapy in HIV-infected Pts With Prolonged Virological Suppression. [NCT02284035] | Phase 3 | 75 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Daily Antiretroviral Therapy (DART 1): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Didanosine Enteric Coated (Ddl-EC) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti [NCT00116415] | 65 participants | Interventional | 2002-03-31 | Completed | |||
| A Phase 3 Study Switching HIV-1 Infected Subjects With an Undetectable Viral Load From a HAART Regimen Dosed Twice Daily or More Frequently to a Once-Daily HAART Regimen [NCT00135369] | Phase 3 | 300 participants | Interventional | 2002-09-30 | Completed | ||
| Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet (SCRUM) [NCT02569346] | Phase 1 | 22 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Is Dual Therapy as Effective as Triple Therapy Regarding CD4+/CD8+ Ratio Recovery and Improvement of Immune Activation and Inflammation in HIV-infected Patients With Consistent Plasma Viral Load Suppression (Tridual) [NCT03447873] | Phase 4 | 153 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| A Randomised Non-inferiority Trial With Nested PK to Assess DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old [NCT04337450] | Phase 2/Phase 3 | 370 participants (Anticipated) | Interventional | 2022-04-22 | Recruiting | ||
| A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose [NCT01489046] | Phase 2 | 297 participants (Actual) | Interventional | 2011-02-28 | Terminated | ||
| Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults Without Baseline Genotyping Test (D2ARLING Study) [NCT04549467] | Phase 4 | 244 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | ||
| The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy [NCT00005918] | Phase 3 | 730 participants | Interventional | 2000-06-30 | Completed | ||
| Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF) [NCT04054089] | Phase 4 | 66 participants (Anticipated) | Interventional | 2019-09-30 | Not yet recruiting | ||
| A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With Lamivudine/Zidovudine (Combivir) Background Therapy In Hiv/Hepatitis C Virus (H [NCT00141284] | Phase 4 | 12 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Elimination of Paediatric HIV-1 Infection: Evaluation of the Prevention Programme and Rescue Intervention Based on the Expanded Programme on Immunization (EPI). ANRS 12388 PREVENIR-PEV Study. [NCT03869944] | Phase 2 | 97 participants (Actual) | Interventional | 2019-12-04 | Active, not recruiting | ||
| The Effect of Anti-viral Drugs Used in Late Pregnancy in Mothers With Hepatitis B Virus Infection on Long-term Development of Children [NCT02301650] | 400 participants (Anticipated) | Observational | 2014-10-31 | Enrolling by invitation | |||
| A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting [NCT00102960] | Phase 3 | 377 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of Lamivudine and Adefovir Dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg) [NCT01353742] | Phase 1 | 40 participants (Actual) | Interventional | 2011-02-21 | Completed | ||
| A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-n [NCT02831764] | Phase 3 | 722 participants (Actual) | Interventional | 2016-07-18 | Completed | ||
| A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects With Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations [NCT02629822] | Phase 2 | 10 participants (Actual) | Interventional | 2016-01-14 | Completed | ||
| A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Vir [NCT02831673] | Phase 3 | 719 participants (Actual) | Interventional | 2016-07-21 | Completed | ||
| A Prosp., Multic., Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From SOC ART in HIV-patients With Sustained Virological Suppr. [NCT02486133] | Phase 3 | 269 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults [NCT02607930] | Phase 3 | 631 participants (Actual) | Interventional | 2015-11-13 | Completed | ||
| HIV Drug Resistance Profiles Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil [NCT04453436] | 2,500 participants (Anticipated) | Observational [Patient Registry] | 2020-09-01 | Not yet recruiting | |||
| A Study to Compare Long-Term Safety and Tolerability of Stavudine (d4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulations, Each In Combination With Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studie [NCT00116298] | Phase 3 | 900 participants | Interventional | 2001-01-31 | Completed | ||
| Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program [NCT03394196] | 152 participants (Actual) | Interventional | 2018-07-04 | Terminated(stopped due to COVID-19 and Funding) | |||
| Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age [NCT03760458] | Phase 1/Phase 2 | 57 participants (Actual) | Interventional | 2020-09-09 | Completed | ||
| Multicenter, Double-Blind, Randomized, Dose Ranging Study to Compare the Safety and Activity of MK0518 Plus Tenofovir and Lamivudine (3TC) Versus Efavirenz Plus Tenofovir and Lamivudine (3TC) in ART-Naive, HIV-Infected Patients [NCT00100048] | Phase 2 | 206 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission [NCT00099359] | Phase 3 | 1,735 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Prospective, Randomised, Open-label, Multi-centre Study to Compare Three Chronic Hepatitis B (CHB) Treatment Strategies Over a 2year Period in Chinese HBeAg Positive CHB Patients [NCT01088009] | Phase 4 | 366 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), and Nevirapine (NVP) as GPO-Vir Z30 Pediatric Tablets Versus the Individual Liquid Formulations in HIV-Infected Children Greater Than [NCT00672412] | Phase 1/Phase 2 | 42 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Phase III, Randomized, 2x2 Factorial Trial to Assess the Efficacy of Antiviral Therapy in Women and Infants in Reducing Vertical Transmission of Hepatitis B in Africa [NCT04704024] | Phase 3 | 450 participants (Anticipated) | Interventional | 2021-09-03 | Recruiting | ||
| Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release (d4T XR) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in An [NCT00116116] | Phase 4 | 70 participants | Interventional | 2002-03-31 | Completed | ||
| 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor [NCT04019873] | 1 participants (Actual) | Observational | 2019-11-18 | Completed | |||
| Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019 [NCT03016533] | Phase 3 | 300 participants (Anticipated) | Interventional | 2017-06-07 | Recruiting | ||
| Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 [NCT04880395] | Phase 4 | 230 participants (Anticipated) | Interventional | 2021-05-20 | Recruiting | ||
| A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) [NCT03272347] | Phase 2 | 123 participants (Actual) | Interventional | 2017-11-27 | Completed | ||
| [NCT01139203] | 300 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | |||
| Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study. [NCT04707326] | 480 participants (Anticipated) | Observational [Patient Registry] | 2019-11-01 | Recruiting | |||
| The Effect of Telbivudine on Renal Function in Chronic Hepatitis B Patients With Mild to Moderate Renal Impairment [NCT03778567] | Phase 4 | 31 participants (Actual) | Interventional | 2013-08-01 | Completed | ||
| Pilot Single-Arm Clinical Trial to Evaluate the Efficacy, PK Interactions and Safety of Dolutegravir Plus 2 NRTIs in HIV-1-Infected Solid Organ Transplant Patients [NCT03360682] | Phase 4 | 20 participants (Anticipated) | Interventional | 2018-04-12 | Active, not recruiting | ||
| The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection [NCT03205566] | Phase 4 | 38 participants (Actual) | Interventional | 2017-09-19 | Completed | ||
| Pharmacokinetics of EFV 400mg Once Daily During Pregnancy in HIV+ Women [NCT02499874] | Phase 1 | 26 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| A Randomized, Open Label Study Evaluating the Efficacy and Safety of Glucocorticoids in Patients With Pre-ACLF-HBV [NCT01344174] | 200 participants (Anticipated) | Interventional | 2011-05-31 | Recruiting | |||
| Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients [NCT00872417] | Phase 4 | 750 participants (Anticipated) | Interventional | 2009-03-31 | Not yet recruiting | ||
| Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir [NCT01023217] | Phase 4 | 90 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA [NCT00637663] | Phase 4 | 72 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women [NCT00993031] | Phase 3 | 389 participants (Actual) | Interventional | 2009-12-15 | Completed | ||
| A Randomised Controlled Trial Comparing the Efficacy of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir (LPV/r) Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding [NCT00640263] | Phase 3 | 1,500 participants (Anticipated) | Interventional | 2009-12-31 | Completed | ||
| Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma [NCT00768157] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-04-30 | Recruiting | ||
| A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe [NCT00834457] | Phase 2/Phase 3 | 49 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Randomized, Open-label Trial to Compare the Efficacy and Safety of Early Initiation of cART With or Without Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in Treatment-Naïve Acute HIV-1 Infected Adults [NCT02231281] | Phase 3 | 65 participants (Anticipated) | Interventional | 2014-08-31 | Active, not recruiting | ||
| A Randomized, Non-comparative, Phase IIb, Unblinded Trial, Evaluating the Efficacy and Safety of Tenofovir-emtricitabine or Lamivudine Plus Zidovudine, Lopinavir/Ritonavir, or Raltegravir, Among ARV-naïve HIV-2 Infected Adult Patients, in West Africa [NCT02150993] | Phase 2/Phase 3 | 210 participants (Actual) | Interventional | 2016-01-26 | Completed | ||
| Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy in Persistently Non-adherent Children, Adolescents, and Young Adults Who Are Failing HAART and Have the M184V Resistance Mutation. [NCT01338025] | Phase 4 | 33 participants (Actual) | Interventional | 2011-03-31 | Terminated(stopped due to Study was halted for lack of accrual) | ||
| Evaluation of the Capacity of a Weekly Strategy of 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV-1 Infected Patients With Undetectable Viral Load for at Least 12 Months, to Maintain a Virological Success With This Intermittent M [NCT02157311] | Phase 3 | 100 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC), and Nevirapine (NVP) as GPO-VIR Pediatric Chewable Tablets Versus the Individual Liquid Formulations in HIV Infected Children 6 Months [NCT00312091] | Phase 1/Phase 2 | 44 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites [NCT04301661] | 25 participants (Actual) | Observational | 2020-03-06 | Completed | |||
| A Randomized Double-Blind Study of Safety, Virologic and Immunological Effects of Stavudine Plus Lamivudine (3TC) Versus Zidovudine Plus Lamivudine in HIV-Infected Subjects Following At Least Six Months of Zidovudine Therapy [NCT00002371] | Phase 3 | 80 participants | Interventional | 1996-06-30 | Completed | ||
| Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppre [NCT02652260] | Phase 2 | 86 participants (Actual) | Interventional | 2016-03-04 | Active, not recruiting | ||
| Efficacy and Safety of Dolutegravir + Lamivudine in Antiretroviral Treatment-naive Adults With HIV-1 Infection in a Multicenter Real-life Cohort Study [NCT04638686] | 185 participants (Actual) | Observational | 2020-06-15 | Completed | |||
| A Prospective Randomized Double-Blind Trial of Three Maintenance Regimens for HIV-Infected Subjects Receiving Induction Therapy With Zidovudine, Lamivudine and Indinavir [NCT00001084] | Phase 2 | 500 participants | Interventional | Completed | |||
| Efficacy and Safety of Early Switching to Dolutegravir/Lamivudine (DTG/3TC) From INSTI-based Three-drug Regimens in HIV-1-infected Adults Previously naïve Who Achieve Virological Suppression [NCT04979468] | Phase 3 | 440 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Phase 2 Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults [NCT02067767] | Phase 2 | 53 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| An Open Label Randomized Clinical Trial, to Evaluate the Treatment With Darunavir/Ritonavir + Lamivudine Once Daily Versus Continuing With Darunavir/Ritonavir Once Daily + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject With Suppres [NCT02159599] | Phase 4 | 249 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologica [NCT02603120] | Phase 3 | 567 participants (Actual) | Interventional | 2015-11-11 | Completed | ||
| Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) [NCT03549689] | Phase 2 | 0 participants (Actual) | Interventional | 2019-08-01 | Withdrawn(stopped due to Withdrawn by drug manufacturer) | ||
| A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants [NCT02582684] | Phase 2 | 122 participants (Actual) | Interventional | 2015-12-08 | Completed | ||
| ProSpective, MultI-Center, Observational PrograM to Assess the Effectiveness of Dual TheraPy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Routine Clinical Settings of the Russian Federation (SIMPLE) [NCT02581202] | 216 participants (Actual) | Observational | 2015-12-21 | Completed | |||
| Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects [NCT00549198] | Phase 4 | 392 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Phase IIb Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Tenofovir+Emtricitabine+Raltegravir or to Lamivudine+Abacavir+Raltegravir in Patients With Optimal Virological Control and Toxicity to the Current Co [NCT00958100] | Phase 2 | 40 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects [NCT00986778] | Phase 4 | 0 participants (Actual) | Interventional | 2009-12-31 | Withdrawn(stopped due to Business Objectives Changed) | ||
| Virologic Outcomes of Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine. [NCT04880785] | Phase 2 | 121 participants (Actual) | Interventional | 2021-07-28 | Active, not recruiting | ||
| Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study) [NCT04636437] | Phase 4 | 222 participants (Anticipated) | Interventional | 2021-05-20 | Recruiting | ||
| A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infecte [NCT00098293] | Phase 3 | 916 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| "A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Response-Guided-Therapy (RGT) Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients" [NCT02560649] | Phase 4 | 324 participants (Anticipated) | Interventional | 2015-05-31 | Active, not recruiting | ||
| A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples [NCT00074581] | Phase 3 | 3,526 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants [NCT04424264] | Phase 1 | 18 participants (Actual) | Interventional | 2019-12-05 | Completed | ||
| A Phase IV Study of the Antiviral Activity and Safety of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen in Korea [NCT00393484] | Phase 4 | 122 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| ADORE: A Single-arm, Phase 3, Pilot Study Investigating the Efficacy of Doravirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With Non-nucleoside Reverse Transcriptase Inhibitor Resistan [NCT04429152] | Phase 3 | 25 participants (Anticipated) | Interventional | 2021-02-09 | Recruiting | ||
| Randomized, Double-Blind Trial of Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis [NCT00076336] | Phase 3 | 232 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| A Randomized, Open-label Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS®) or Adefovir Dipivoxil (ADV) in Patients With Lamivudine-resistant HBeAg Positive Chronic Hepatitis B [NCT02598063] | Phase 4 | 255 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lamivudine Versus Boosted Darunavir and Emtricitabine/Tenofovir or Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects [NCT02770508] | Phase 4 | 145 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Us [NCT02659761] | Phase 4 | 50 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| A Randomized, Open-Label, Third-Party Blinded Study for the Prophylaxis and Treatment of Nelfinavir-associated Diarrhea [NCT00650637] | Phase 3 | 17 participants (Actual) | Interventional | 2003-01-31 | Terminated(stopped due to The study was prematurely discontinued due to administrative reasons on August 18, 2003. There were no safety concerns that led to the decision to terminate.) | ||
| APT-POCT-01: An Open Label, Pharmacokinetic Study of Plasma/Urine/Salivary Drug Concentrations Over Fourteen Days Following Drug Intake Cessation, In HIV-Uninfected Healthy Volunteers Dosing to Steady-state to Further Development of Point of Care Diagnost [NCT04302896] | Early Phase 1 | 30 participants (Actual) | Interventional | 2020-08-31 | Completed | ||
| [NCT00618176] | Phase 4 | 198 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz: An Open-label, Randomized Controlled Trial [NCT02827643] | 48 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | |||
| P1060 Substudy Comparing Differences in Malaria Parasitemia by Real Time Quantitative PCR in HIV-Infected Infants and Children on PI-Based HAART Versus NNRTI-Based HAART [NCT00719602] | Early Phase 1 | 105 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Randomized Study of Lamivudine Prophylaxis or Treatment Against Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen [NCT00201318] | Phase 2 | 50 participants | Interventional | 2001-09-30 | Completed | ||
| A Randomized, Controlled, Open-label, Dose-exploration Study to Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients Who Have Not Received Antiviral Treatment Before. [NCT06061536] | Phase 2 | 64 participants (Anticipated) | Interventional | 2023-11-02 | Recruiting | ||
| A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (R [NCT00002184] | Phase 2 | 120 participants | Interventional | Completed | |||
| Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients [NCT04002323] | 139 participants (Anticipated) | Observational [Patient Registry] | 2019-05-07 | Recruiting | |||
| Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept. [NCT03539224] | Phase 2 | 41 participants (Actual) | Interventional | 2017-11-02 | Active, not recruiting | ||
| Initiation of a Once Daily Regimen of Tenofovir, Lamivudine and Efavirenz After 4 Weeks Versus 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients (Time Study) [NCT01014481] | Phase 4 | 156 participants (Actual) | Interventional | 2009-10-31 | Terminated(stopped due to this study was ended prematurely by ethical committees with a reason of the final outcome was achieved with no longer recruitment was needed.) | ||
| A Randomised, Double-Blinded, Placebo-Controlled Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia) [NCT00338780] | Phase 4 | 0 participants | Interventional | 2000-11-30 | Completed | ||
| The Optimization of HAART for Chinese--a RCT Study [NCT02945163] | Phase 4 | 184 participants (Actual) | Interventional | 2018-03-05 | Completed | ||
| A Pilot Study Of Open-Label Fixed Dose Combination Zidovudine/Lamivudine/Abacavir In HIV-Infected Persons With Tuberculosis In Moshi, Tanzania; Tuberculosis And HIV Immune Reconstitution Syndrome Trial (THIRST) [NCT00851630] | Phase 4 | 70 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Evaluating Responses to Antiretroviral Drugs in Cells and Tissues (The ERADICATE Study): Comprehensive Comparisons of Viral and Cellular Dynamics Among Previously-Untreated Subjects With Acute HIV Infection (Seroconversion Syndrome) or Recently Acquired H [NCT00006443] | 24 participants | Interventional | Completed | ||||
| A Multicenter, Randomized, Controlled Tial of Combination Therapy for Lamivudine-resistant Chronic Hepatitis B Patient: Comparing Clevudine Plus Adefovir With Lamivudine Plus Adefovir [NCT00798460] | Phase 4 | 30 participants (Actual) | Interventional | 2008-12-31 | Terminated(stopped due to could not enroll patients) | ||
| Pharmacokinetics, Safety and Efficacy of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen in Patients With Intolerance and/or Resistance to NRTIs, NNRTIs and RTV: A Pilot Study [NCT02566707] | Phase 2 | 9 participants (Actual) | Interventional | 2015-08-31 | Terminated(stopped due to due to introduction of another integrase inhibitor, recruitement was not feasible anymore.) | ||
| See Detailed Description [NCT00440947] | Phase 3 | 515 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Randomized, Open-Label, Phase IV Trial in Nucleus(t)id-Naive Patients With Chronic Hepatitis B to Examine the Effect of Telbivudine Compared to Lamivudine on the Early Dynamics and Kinetics of Viral Suppression (Early-Viral-Dynamics Study) [NCT00710216] | Phase 4 | 40 participants (Anticipated) | Interventional | Withdrawn(stopped due to Sponsor withdraw) | |||
| Randomized, Open-Labelled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B With Detectable HBV DNA [NCT00625560] | Phase 4 | 72 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia [NCT02652793] | 45 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | |||
| CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics [NCT00666055] | 11 participants (Actual) | Observational | 2008-03-31 | Completed | |||
| [NCT00669487] | Phase 3 | 150 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics) [NCT02832778] | Phase 1 | 35 participants (Anticipated) | Interventional | 2016-11-21 | Recruiting | ||
| A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine Versus Lamivudine in Treatment-experienced HIV-1 Infected Patients With the M184V/I Mutation in Reverse Transcriptase [NCT00612898] | Phase 2/Phase 3 | 239 participants (Actual) | Interventional | 2008-02-29 | Terminated(stopped due to Sponsor decision) | ||
| Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study [NCT05295394] | Phase 4 | 0 participants (Actual) | Interventional | 2019-05-22 | Withdrawn(stopped due to Low recruitment, We did not find participants with the M184V mutation , inclusion criteria , throughout 230 resistance tests carried out) | ||
| Pharmacokinetic and Safety Pilotstudy of RAltegravir and Atazanavir in a Once DAily Dose Regimen in HIV-1 Infected Patients (PRADA) [NCT00943540] | Phase 2 | 20 participants (Anticipated) | Interventional | 2009-07-31 | Completed | ||
| Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa [NCT06138600] | Phase 3 | 200 participants (Anticipated) | Interventional | 2023-11-01 | Active, not recruiting | ||
| Phase 3, Single Center, Controlled, Investigator-blinded, Randomized Matched Pair Design Study of CD4 Cell Recovery in HIV-1 Patients With Sustained Virologic Response Comparing Protease Inhibitor and Non-nucleoside Reverse Transcriptase Inhibitor Based T [NCT00966160] | Phase 3 | 215 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| Pilot Phase IV, Multicenter, Randomized, Open-label and Controlled Study to Assess the Evolution of Peripheral Body Fat Distribution After Switching From Zidovudine Containing Backbone to Truvada in HIV-1-infected Patients on HAART (RECOMB Study). [NCT00324649] | Phase 4 | 80 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Intra-ocular Penetration of Oral Lamivudine and Measurement of Systemic Inflammatory Markers in Patients Undergoing Rhegmatogenous Retinal Detachment Surgery [NCT06056596] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-31 | Recruiting | ||
| A Phase I, Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Lamivudine in Healthy Subjects [NCT02738931] | Phase 1 | 30 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings [NCT02777229] | Phase 3 | 616 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintaine [NCT00724711] | Phase 4 | 312 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet 150 mg (Test) and EPIVIR of Glaxosmithkline in Healthy Volunteers of Both Genders in Fasting Condition [NCT02604004] | Phase 1 | 28 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. [NCT00830856] | 54 participants (Actual) | Interventional | 2006-10-31 | Completed | |||
| Multicenter, International, Prospective, Phase III, Randomized, Superiority Trial Comparing Two Maintenance Strategies With Mono or Bi-therapy of Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antire [NCT01905059] | Phase 3 | 265 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Single Center, Randomized Open Label Study of Initial Interleukin-2 Compared to Delayed Interleukin-2 When Added to Zidovudine, 3TC and Nelfinavir In Order to Modulate Immune Function and to Sustain Suppression of HIV-1 Replication Among Those Persons W [NCT00006441] | 398 participants (Actual) | Interventional | 2003-02-28 | Completed | |||
| A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults [NCT00008554] | Phase 3 | 210 participants | Interventional | 2000-11-30 | Active, not recruiting | ||
| Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual Nucleosides in Initial Therapy of HIV Infection [NCT00000919] | 900 participants | Interventional | Completed | ||||
| A Randomized, Open-Label Study of the Long-Term Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART) Strategies in HAART-Niave, HIV-Infected Persons [NCT00000922] | 1,710 participants | Interventional | Completed | ||||
| A Randomized Comparative Study of Combined Zidovudine-Lamivudine (3TC) vs. the Better of ddI Monotherapy vs. Zidovudine Plus Ddl in Symptomatic HIV-1 Infected Children [NCT00001066] | Phase 2 | 740 participants | Interventional | Completed | |||
| A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease [NCT00001075] | 55 participants | Interventional | Completed | ||||
| A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (D [NCT03945981] | Phase 3 | 131 participants (Actual) | Interventional | 2019-07-02 | Completed | ||
| Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy [NCT00000831] | Phase 2 | 280 participants | Interventional | Completed | |||
| A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone [NCT00000870] | Phase 2 | 200 participants | Interventional | Completed | |||
| A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Ritonavir Co-Administered With Lamivudine (3TC) and Zidovudine (ZDV) in HIV-1-Infected Pregnant Women and Their Infants [NCT00000888] | Phase 1 | 14 participants | Interventional | Completed | |||
| A Phase I Pharmacokinetic Study of Once Versus Twice Daily Dosing With Zidovudine and Lamivudine [NCT00014014] | Phase 1 | 20 participants | Interventional | Completed | |||
| Use of Combination Antiviral Therapy to Delineate the Identity and Longevity of Persistent Reservoirs of HIV-1 Infection and Replication [NCT00001644] | Phase 1 | 42 participants (Actual) | Interventional | 1997-03-03 | Completed | ||
| A Randomized, Double-Blind, Adjuvant-Controlled, Multicenter Study to Compare the Virologic and Immunologic Effect of Highly Active Antiretroviral Therapy (HAART) Plus Remune Versus HAART Plus Incomplete Freund's Adjuvant (IFA) in Antiretroviral-Naive Pat [NCT00005002] | Phase 3 | 688 participants | Interventional | Active, not recruiting | |||
| Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus [NCT02482272] | Phase 4 | 90 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Pharmacokinetics of Plasma Lamivudine (3TC), and Its Active Intracellular Anabolite 3TC-Triphosphate Over a 24 Hour Dosing Interval Following Administration of 3TC 300 mg and 150 mg Once Daily to HIV-Negative Healthy Volunteers [NCT00985647] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection. [NCT00810524] | Phase 4 | 600 participants (Anticipated) | Interventional | 2007-01-31 | Recruiting | ||
| HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health [NCT00164736] | Phase 3 | 2,369 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Optimization of Antiretroviral Therapy [NCT02935075] | Phase 4 | 184 participants (Actual) | Interventional | 2018-03-05 | Completed | ||
| Multicentric Randomised Controlled Trial Assessing the Efficacy of Two Strategies of Structured Treatment Interruption of Highly Active Antiretroviral Therapy (HAART) Compared With a Continuous HAART in HIV- Infected Adults in Abidjan [NCT00158405] | Phase 3 | 840 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase [NCT00823550] | Phase 4 | 462 participants (Anticipated) | Interventional | 2009-01-31 | Active, not recruiting | ||
| Phase III Study of Adefovir Dipivoxil Tablets in Patients With Compensated Chronic Hepatitis B -Comparative Study Against Lamivudine- [NCT00316719] | Phase 3 | 105 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Comparative Study of Entecavir vs. Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-resistant Chronic Hepatitis B Subjects: The DEFINE Study [NCT00410202] | Phase 3 | 629 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Multicenter, Open-Label, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate/d4T/3TC Versus Indinavir Sulfate/Nelfinavir Mesylate/d4T/3TC in HIV-Infected Individuals [NCT00002430] | 220 participants | Interventional | Completed | ||||
| Nucleosides And Darunavir/Dolutegravir In Africa (NADIA): a Randomised Controlled Trial of Darunavir Versus Dolutegravir and Tenofovir Versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa [NCT03988452] | Phase 3 | 465 participants (Actual) | Interventional | 2019-07-30 | Active, not recruiting | ||
| Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PE [NCT00084136] | Phase 4 | 1,571 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| [NCT02202473] | Phase 4 | 192 participants (Actual) | Interventional | Completed | |||
| Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial [NCT01894269] | Phase 4 | 200 participants (Anticipated) | Interventional | 2013-07-31 | Recruiting | ||
| A Prospective, Open-label Trial of Two Abacavir/Lamivudine Based Regimen (ABC/3TC + Darunavir/Ritonavir or ABC/3TC + Raltegravir) in Late Presenter naïve Patients (With CD4 Count <200 Cells/µL - Advanced HIV Disease) [NCT01900106] | Phase 3 | 47 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Virus Reactivation in Patients With Non-Hodgkin Lymphoma on CHOP/R-CHOP: a Randomized Phase II Study [NCT01914744] | Phase 2 | 82 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| Liver Cancer Institiute ,Fudan University [NCT01936233] | Phase 3 | 112 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| A Single-Center, Open-Label Study to Evaluate the Renal Function Improvement in Lamivudine Long Term Used HBsAg Positive Kidney Transplantation Patients After Switch to Telbivudine Treatment. [NCT02894554] | Phase 4 | 19 participants (Actual) | Interventional | 2014-07-31 | Terminated(stopped due to clinical myalgia) | ||
| Pharmacokinetic Study of Twice Daily vs Once Daily Lamivudine and Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV Infection [NCT01982396] | Phase 1 | 19 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Prospective, Randomized, Three-period Crossover, Interaction Study to Evaluate the Pharmacokinetics of Doravirine and Tenofovir Disoproxil Fumarate Co-administered With Cross-sex Hormonal Therapy in Adult HIV-negative Transgender Women [NCT04283656] | Phase 1 | 7 participants (Actual) | Interventional | 2022-02-14 | Completed | ||
| The Study of Mechanisms of Lipodystrophy in HIV-Infected Patients [NCT00006190] | Phase 4 | 0 participants | Interventional | 2000-11-30 | Completed | ||
| A Phase II Trial to Evaluate the Safety and Efficacy of Induction Treatment With Lamivudine Plus Stavudine Plus Abacavir Plus Amprenavir/Ritonavir Followed by Supervised Treatment Interruption in Subjects With Acute HIV Infection or Recent Seroconversion [NCT00000940] | Phase 2 | 121 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| A Phase I/II Study of Ritonavir Therapy in HIV-1 Infected Infants and Children [NCT00000952] | Phase 1 | 60 participants | Interventional | Completed | |||
| Comparison of the Virologic Efficacy of Nelfinavir and/or DMP 266 (Efavirenz, EFV) in Combination With One or Two New Nucleoside Analogs in Nucleoside Experienced Subjects: A Roll-Over Study to ACTG 302/303 [NCT00001087] | Phase 2 | 300 participants | Interventional | Completed | |||
| Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 [NCT00000891] | Phase 2 | 34 participants | Interventional | Completed | |||
| A Phase III Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in Combination With Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and Indinavir (IDV) in HIV-Infected Subjects With Less Than or Equal to 200 CD4 Cells/mm3 or Greater [NCT00000903] | Phase 3 | 444 participants | Interventional | Completed | |||
| Treatment Outcome of Children With HIV Infection [NCT00476606] | 1,000 participants (Anticipated) | Observational | 2003-03-31 | Active, not recruiting | |||
| Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA [NCT00625339] | Phase 4 | 72 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir of Chinese HIV/AIDS Patients In Acute HIV-1 Infection [NCT02219672] | Phase 3 | 18 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Transgender Men and HIV in Uganda: PrEP Uptake and Persistence [NCT04867798] | 75 participants (Actual) | Observational | 2021-09-16 | Completed | |||
| A Randomized, Open Labeled, Multicenter Study Comparing Entecavir Versus Lamivudine as Antiviral Prophylaxis for Patients With Hepatitis B Infection Undergoing Cytotoxic Chemotherapy for Malignant Tumors [NCT01580202] | Phase 3 | 180 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Phase I, Single Dose, Five-period Crossover Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet as Compared to a Co-dose of TIVICAY and EPZICOM in Healthy Subjects [NCT02893488] | Phase 1 | 20 participants (Actual) | Interventional | 2016-09-01 | Completed | ||
| Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis [NCT02273765] | Phase 3 | 460 participants (Actual) | Interventional | 2015-09-11 | Completed | ||
| Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy [NCT01608269] | Phase 4 | 30 participants (Anticipated) | Interventional | 2010-11-30 | Completed | ||
| A Multicenter, Randomized, Controlled Study Comparing the Efficacy and Safety of 48 Weeks of 40kD Branched Pegylated Interferon Alfa-2a (PEG-IFN, RO 25-8310) Versus 96 Weeks of PEG-IFN, Alone or in Combination With 100 mg Lamivudine for 48 Weeks in Patien [NCT01095835] | Phase 3 | 131 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects [NCT00740064] | Phase 4 | 30 participants (Anticipated) | Interventional | 2008-05-31 | Active, not recruiting | ||
| Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent mother-to Child Transmission of HIV-1 o, Resource-limited Settings: A Multicentre Randomized Phase 3 Clinical Trial [NCT00936195] | Phase 3 | 0 participants (Actual) | Interventional | 2010-01-31 | Withdrawn(stopped due to faillure to obtain insurance because of refusal from insurance companies) | ||
| A Randomized Open Label Study Evaluating the Efficacy of Continuous Telbivudine Versus Lamivudine in Patients With HBeAg-negative Chronic Hepatitis B Who Had Previously Achieved an Undetectable Viral Load During 24 Weeks of Telbivudine Therapy [NCT01005238] | Phase 4 | 27 participants (Actual) | Interventional | 2009-09-30 | Terminated(stopped due to unsufficient patient recruitment) | ||
| Phase I Three-way Crossover Bioequivalence Study of Pediatric Formulations of Lamivudine/Zidovudine/Nevirapine Using Healthy Adult Volunteers [NCT01469520] | Phase 1 | 24 participants (Actual) | Interventional | 2010-10-31 | Active, not recruiting | ||
| The Effects of Switching From Dolutegravir/Lamivudine/Abacavir (d/l/a) to Bictegravir/Emtricitabine/Tenofovir Alafenamide (b/f/Taf) in Patients With Suppressed Viral Load on Neuropsychiatric Side Effects and Neurocognitive Function [NCT04155554] | Phase 3 | 100 participants (Anticipated) | Interventional | 2020-01-29 | Recruiting | ||
| Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis [NCT05630872] | Phase 2 | 30 participants (Anticipated) | Interventional | 2024-01-02 | Not yet recruiting | ||
| Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project. [NCT02868580] | Phase 2 | 43 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Adjunctive Therapy With Telmisartan Instituted With ART During Acute HIV Infection to Reduce the Establishment of CNS Reservoirs of HIV and Lymph Node Fibrosis [NCT02750059] | Phase 2 | 21 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis [NCT01075152] | Phase 4 | 177 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects [NCT00000882] | Phase 2 | 300 participants | Interventional | Completed | |||
| ART Drug Dosage Adjustment Using FSCII in Chinese HIV-infected Population [NCT02632474] | Phase 4 | 10 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Prevention of Mother-to-child Transmission of HIV-1: Programme Evaluation and Innovative Responsive Intervention Integrated in the Expanded Programme of Immunization. PROMISE-EPI Study [NCT03870438] | Phase 3 | 1,506 participants (Actual) | Interventional | 2019-12-14 | Completed | ||
| Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere) [NCT01061151] | Phase 3 | 3,747 participants (Actual) | Interventional | 2011-03-01 | Completed | ||
| Determination of Plasma and Intracellular Levels of Nucleoside Reverse Transcriptase Inhibitors (NRTI) and of Nucleotide Analog Tenofovir Disoproxil Fumarate (TDF) in Patients Treated With Abacavir and/or Lamivudine Given With or Without TDF. [NCT00335192] | Phase 4 | 32 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination [NCT00335270] | Phase 4 | 100 participants | Interventional | 2006-03-31 | Completed | ||
| A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glu [NCT00192621] | Phase 4 | 50 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Stru [NCT00192660] | Phase 4 | 80 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Phase III Randomized Trial of the Safety and Antiretroviral Effects of Zidovudine/Lamivudine/Abacavir Versus Zidovudine/Lamivudine/Lopinavir/Ritonavir in the Prevention of Perinatal Transmission of HIV [NCT00086359] | Phase 3 | 19 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Implementing Anti-Retroviral Therapy in Resource-Constrained Settings: A Randomized Controlled Trial to Assess the Effect of Integrated Tuberculosis and HIV Care on the Incidence of AIDS-Defining Conditions or Mortality in Subjects Co-Infected With Tuberc [NCT00091936] | 592 participants (Anticipated) | Interventional | 2009-08-31 | Completed | |||
| A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged >= 6 to <18 Years [NCT00799864] | Phase 2 | 54 participants (Actual) | Interventional | 2011-01-07 | Completed | ||
| The Adult Antiretroviral Treatment and Resistance Study (Tshepo) [NCT00197613] | Phase 3 | 650 participants | Interventional | 2002-12-31 | Completed | ||
| Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load [NCT01013272] | 50 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Effect of Cytoreductive Chemotherapy Combined With Highly Active Antiretroviral Therapy on Lymph Node HIV DNA in HIV-Infected Subjects [NCT00000899] | Phase 1 | 10 participants | Interventional | Completed | |||
| A Randomized, Double-blind, Double-simulated, Active-controlled，Phase III Clinical Study Evaluating the Efficacy and Safety of Azvudine Combined With Tenofovir Fumarate and Efavirenz in Hiv-infected Treatment Naive Patients [NCT04303598] | Phase 3 | 720 participants (Anticipated) | Interventional | 2020-04-01 | Not yet recruiting | ||
| A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients [NCT05332470] | 200 participants (Anticipated) | Observational | 2022-05-01 | Not yet recruiting | |||
| Bioavailability Study of a New Pediatric Formulation of Zidovudine/Lamivudine in Adult Volunteers [NCT00470041] | Phase 1 | 12 participants (Anticipated) | Interventional | 2007-06-30 | Completed | ||
| Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease (ART-AD) [NCT04552795] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2021-02-15 | Active, not recruiting | ||
| Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine in Virologically-suppressed Adults Living With HIV on Bictegravir/Tenofovir Alafenamide/emtricitabine-the DYAD Study [NCT04585737] | Phase 4 | 222 participants (Actual) | Interventional | 2020-09-22 | Completed | ||
| Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation [NCT01848743] | Phase 3 | 120 participants (Anticipated) | Interventional | 2013-04-30 | Recruiting | ||
| A Study on the Viral Kinetics of Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in HBeAg Positive Chronic Hepatitis B [NCT00226447] | Phase 2 | 30 participants | Interventional | 2002-12-31 | Completed | ||
| A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Nelfinavir (Viracept) Co-Administered With Zidovudine (ZDV) and Lamivudine (3TC) in HIV Infected Pregnant Women and Their Infants [NCT00000887] | Phase 1 | 24 participants | Interventional | Completed | |||
| Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) [NCT04826562] | Phase 4 | 40 participants (Actual) | Interventional | 2021-09-26 | Active, not recruiting | ||
| A Phase II, Randomized, Open-Label Comparative Trial of Salvage Antiretroviral Therapies for HIV-Infected Individuals With Virological Evidence of Nelfinavir Treatment Failure as Reflected by Plasma HIV RNA Concentration of >= 1,000 Copies/ml [NCT00000918] | Phase 2 | 300 participants | Interventional | Completed | |||
| Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions: A Follow-up Study to ACTG 175 [NCT00001068] | Phase 2 | 210 participants | Interventional | Completed | |||
| An Open-Label Randomized Study of Delavirdine Mesylate (Rescriptor) in Combination With Zidovudine (Retrovir) and Two Doses of Indinavir (Crixivan) Versus Zidovudine, Lamivudine (Epivir), and Indinavir in HIV-1-Infected Individuals [NCT00002400] | 45 participants | Interventional | Completed | ||||
| A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of Epivir 150 Mg BID Versus Epivir 300 Mg Once-Daily When Administered for 24 Weeks in Combination With FDA-Approved Dosage Regimens of Zerit and Either Crixivan or Viracept in Subjects W [NCT00002442] | Phase 2 | 0 participants | Interventional | 1999-06-30 | Completed | ||
| A Phase II, Open-Label Study of AG1549 in Combination With Other Antiretroviral Agents in Treatment-Naive HIV-Infected Patients [NCT00004998] | Phase 2 | 30 participants | Interventional | 1999-11-30 | Suspended | ||
| Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment [NCT01491295] | Phase 4 | 160 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| Post-Marketing Clinical Study of EPZICOM Tablet (Lamivudine / Abacavir Sulfate) - Pharmacokinetic Study in HIV-Infected Patients - [NCT00337922] | Phase 4 | 8 participants | Interventional | 2006-07-31 | Completed | ||
| Study of Changes in CD4 Lymphocyte Count in Patients With a HAART Regimen Including DDI + Tenofovir and With Viral Suppression Following the Replacement of Tenofovir With Abacavir Once Daily or Following the Double Replacement of DDI + Tenofovir With Abac [NCT00338390] | Phase 3 | 75 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Randomization Trial of Adjuvant Lamivudine/ Adefovir Dipivoxil Against Recurrence in Post-operative HBV-related Hepatocellular Carcinoma [NCT00455091] | 117 participants (Actual) | Observational | 2007-05-31 | Terminated(stopped due to No cases enrollment) | |||
| Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products. [NCT00455585] | Phase 4 | 18 participants | Interventional | 2007-01-31 | Completed | ||
| Prospective Randomized Study for the Comparison of Adding Adefovir Dipivoxil and Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B [NCT00531167] | Phase 4 | 219 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz [NCT04022967] | Phase 3 | 480 participants (Actual) | Interventional | 2020-09-21 | Active, not recruiting | ||
| Multicentre, Open Label, Prospective, Randomised Clinical Trial of an Antiretroviral Simplification Treatment With Efavirenz + Abacavir + 3TC Once Daily [NCT00314626] | Phase 3 | 99 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study [NCT00537966] | 2,017 participants (Anticipated) | Interventional | 2002-01-31 | Recruiting | |||
| A Randomized, Open Label, Multicenter Study Comparing the Safety and Efficacy of Once Daily Regimen Containing Epzicom or Truvada Combined With Ritonavir Boosted Atazanavir as Initial Therapy for HIV-1 Infection (ET Study) [NCT00544128] | Phase 4 | 109 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| An Evaluation of the Bioequivalence of a Combined Formulated Tablet (50mg/600mg/300mg Dolutegravir/Abacavir/Lamivudine) Compared to One Dolutegravir 50mg Tablet and One EPZICOM† (600mg/300mg Abacavir/Lamivudine) Tablet Administered Concurrently and the Ef [NCT01622790] | Phase 1 | 66 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Phase IV Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients [NCT00084253] | Phase 4 | 200 participants (Anticipated) | Interventional | 2004-06-30 | Completed | ||
| An International, Double Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical AIDS Progression Events or Death When Used in Combination With Lamivudine (3TC) and Stable (>= [NCT00002368] | Phase 3 | 2,000 participants | Interventional | Completed | |||
| A Phase I Study of Methotrexate for HIV Infection [NCT00000834] | Phase 1 | 30 participants | Interventional | Completed | |||
| Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals [NCT00001080] | 0 participants (Actual) | Interventional | Withdrawn(stopped due to as of 4/23/97) | ||||
| A Pilot Study of Once-Daily Therapy With Amprenavir, Ritonavir, Lamivudine and Abacavir in HIV-Infected, Antiretroviral-Naive Patients [NCT00001968] | Phase 1 | 25 participants | Interventional | 2000-01-31 | Completed | ||
| A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3 [NCT00002124] | Phase 3 | 1,250 participants | Interventional | Completed | |||
| A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients [NCT00002190] | Phase 2 | 30 participants | Interventional | Completed | |||
| A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC [NCT00002208] | Phase 3 | 400 participants | Interventional | Completed | |||
| A Randomized Controlled Clinical Study to Determine If the Addition of HIV RNA Viral Load Is an Effective Tool in Determining Treatment Regimens for HIV-Infected Patients [NCT00002376] | Phase 4 | 540 participants | Interventional | Completed | |||
| A Multicenter, Double-Blind, Randomized Pilot Study to Compare the Safety and Activity of L-756423/Indinavir, 1600/800 Mg Qd or 800/400 Mg Bid Versus Indinavir, 800 Mg q8h, All in Combination With Stavudine and Lamivudine [NCT00002424] | Phase 2 | 186 participants | Interventional | Suspended | |||
| A Randomized Lamivudine (3TC)/Dideoxycytidine (ddC) Double-Blind Multicenter Trial (With Open-Label AZT) to Evaluate the Safety and Efficacy of Low Dose 3TC Administered Concurrently With AZT Versus High Dose 3TC Administered Concurrently With AZT Versus [NCT00002436] | Phase 3 | 325 participants | Interventional | Completed | |||
| Phase I/II Study of ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naive HIV-Infected Patients [NCT00004578] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 1997-11-30 | Completed | ||
| A 96-Week, Randomized, Open-Label, Multicenter Trial to Evaluate the Safety and Tolerability of the Antiretroviral Activity of Stavudine (40mg BID) Plus Lamivudine (150mg BID) Plus Nelfinavir (1250mg BID) Versus Abacavir (300mg BID) Plus Combivir (3TC 150 [NCT00005106] | Phase 4 | 230 participants | Interventional | 1999-09-30 | Completed | ||
| Tipranavir (PNU-140690): A Fourteen Day Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients. Report on the Post-study Option, a 46-week Treatment Period of Triple Thera [NCT02249130] | Phase 2 | 18 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects [NCT02403674] | Phase 3 | 734 participants (Actual) | Interventional | 2015-06-05 | Completed | ||
| An Open Label, Randomized Study to Compare Antiretroviral Therapy (ART) Initiation When CD4 is Between 15% to 24% to ART Initiation When CD4 Falls Below 15% in Children With HIV Infection and Moderate Immune Suppression [NCT00234091] | Phase 3 | 300 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin [NCT00100581] | 2 participants (Actual) | Interventional | Completed | ||||
| A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (G [NCT00256828] | Phase 4 | 360 participants | Interventional | 2004-06-30 | Completed | ||
| A Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of Zidovudine (ZDV)/Lamivudine (3TC) in HIV-1 Therapy-Experienced Pediatric Patients. [NCT00002391] | Phase 3 | 0 participants | Interventional | Completed | |||
| Safeguard the Household: A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country [NCT00080522] | 813 participants | Interventional | 2005-02-28 | Completed | |||
| A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Activity of Indinavir Sulfate 1200 Mg q.d. and Ritonavir 200 Mg q.d. in Combination With Stavudine and Lamivudine in Treatment Naive HIV-1 Infected Patients [NCT00002451] | Phase 2 | 8 participants | Interventional | Active, not recruiting | |||
| Long-Term Lamivudine Therapy for Chronic Hepatitis B [NCT00120354] | Phase 4 | 50 participants | Interventional | 2005-07-11 | Completed | ||
| A Randomized Clinical Trial to Determine the Efficacy of Early Versus Standard Antiretroviral Therapy in HIV Infected Adults With CD4+ T Cell Counts Between 200 and 350 Cells/mm3 [NCT00120510] | 816 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| Abacavir Pharmacokinetics During Chronic Therapy in HIV-1 Infected Adolescents and Young Adults [NCT00087945] | 30 participants | Interventional | 2004-07-31 | Completed | |||
| Efficacy and Tolerability of an Antiretroviral bi-Therapy in HIV-1 Infected Patients With Multidrug Resistant HIV ANRS 109 Vista Trial. [NCT00120783] | Phase 2 | 40 participants | Interventional | 2002-02-28 | Terminated | ||
| MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) [NCT00122226] | Phase 4 | 50 participants | Interventional | 2003-01-31 | Active, not recruiting | ||
| HAART Regimen Comprising 3TC + ddI + EFV in Once-daily Administration in HIV-1 Infected Children in Burkina Faso [NCT00122538] | Phase 2 | 52 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| See Detailed Description [NCT00085943] | Phase 3 | 866 participants | Interventional | 2004-05-31 | Completed | ||
| AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (Presumed Pre-core Mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN. [NCT00354653] | Phase 4 | 100 participants | Interventional | 2002-02-09 | Completed | ||
| Difference in Efficacy Between Umbilical Cord Mesenchyma Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients [NCT01718587] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2012-11-30 | Not yet recruiting | ||
| Clinical Trial: Backup With Combivir (AZT/3TC) or Single Dose (sd) Truvada (FTC/TDF) in Order to Avoid NNRTI Resistance After sd Nevirapine for the Prevention of Mother-to-child Transmission (MTCT) [NCT00346567] | 566 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| See Detailed Description [NCT00094367] | Phase 3 | 900 participants | Interventional | 2004-07-31 | Completed | ||
| A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B [NCT00131742] | Phase 3 | 0 participants | Interventional | 2004-07-31 | Completed | ||
| A Pilot Study of Safety, Effectiveness, and Adherence of Lamivudine/Zidovudine and Efavirenz (3TC/ZDV + EFV) to Treat HIV-1 Infection in Senegal [NCT00100568] | 44 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 2 [NCT01714414] | Phase 2 | 120 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Randomized Clinical Trial Assessing Continuous HAART Versus Interrupted HAART in a Resource Poor Clinic [NCT00100646] | 30 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| Combivir, 1592U89, 141W94 Triple Antiretroviral, Experienced Patient Trial [NCT00002217] | 0 participants | Interventional | Completed | ||||
| A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Two Antiretroviral Therapeutic Strategies: A Dual PI-Based HAART Regimen Versus a Multi-NRTI ART Regimen, in ART-Experienced Children and Youth Who Have Experienced Virol [NCT00102206] | Phase 2 | 6 participants (Actual) | Interventional | Completed | |||
| A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy [NCT00489151] | 70 participants (Anticipated) | Interventional | 2005-06-30 | Recruiting | |||
| A Randomized, Double-Blind Multicenter Trial to Compare the Safety and Efficacy of Lamivudine (3TC; GR109714X) Monotherapy Versus Zidovudine (AZT) Monotherapy Versus 3TC Administered With AZT in the Treatment of HIV-1 Infected Patients Who Are AZT Naive ( [NCT00002320] | Phase 3 | 320 participants | Interventional | Completed | |||
| A Phase 3b, Multi-center, Randomized, Parallel-group, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen Compared to Oral Bictegravir/Emtricitabine/Tenofov [NCT05979311] | Phase 3 | 412 participants (Anticipated) | Interventional | 2023-12-29 | Not yet recruiting | ||
| A Phase II Trial of Lamivudine in Combination With Chemoimmunotherapy in Patients With Extensive Stage SCLC [NCT04696575] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | ||
| A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs [NCT00002162] | Phase 2 | 140 participants | Interventional | Completed | |||
| A Phase I Safety and Pharmacokinetic Study of 1592U89 Alone and In Combination With Other Antiretroviral Agents in Infants and Children With HIV Infection [NCT00000865] | Phase 1 | 32 participants | Interventional | Completed | |||
| Viral and Immune Dynamics in HIV-Infected Patients With Tuberculosis [NCT00004736] | Phase 1 | 44 participants | Interventional | Completed | |||
| Treatment Rollover for Subjects Formerly on ACTG 328 With Subcutaneous Interleukin-2 (IL-2) in Combination With Highly Active Antiretroviral Therapy (HAART) [NCT00000923] | 110 participants | Interventional | Completed | ||||
| Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV [NCT04340388] | Phase 4 | 10 participants (Actual) | Interventional | 2020-09-17 | Completed | ||
| A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV- Infected Children; PRAM-1: ZDV+3TC vs. d4T+Ritonavir vs. ZDV+3TC+Ritonavir; PRAM-1, Step 2: d4T+Nevirapine+Ritonavir; PRAM-1, Step 3: d4T+Indinavir vs [NCT00001083] | Phase 2 | 240 participants | Interventional | Completed | |||
| A Study of the Effects of Combination Antiretroviral Therapy in Acute HIV-1 Infection With an Emphasis on Immunological Responses [NCT00001119] | 288 participants | Interventional | 1999-10-31 | Completed | |||
| A Randomized, Open-Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination With Abacavir and Lamivudine for 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Subjects [NCT00009061] | Phase 3 | 624 participants | Interventional | 2000-11-30 | Active, not recruiting | ||
| Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy [NCT00017719] | Phase 3 | 440 participants | Interventional | 2002-05-31 | Completed | ||
| Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma [NCT00555334] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| A Phase IIb Extension Study of LdT (Telbivudine), Lamivudine or LdT Plus Lamivudine in Patients With Chronic Hepatitis B Who Have Completed Study NV-02B-003 [NCT00124241] | Phase 2 | 0 participants | Interventional | Completed | |||
| Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis [NCT00332306] | Phase 3 | 180 participants (Anticipated) | Interventional | 2006-06-30 | Active, not recruiting | ||
| A Randomized Controlled Study Comparing the Impact of Prophylactic Versus Deferred Lamivudine on the Delivery of Cytotoxic Chemotherapy in Hepatitis B Surface-antigen Positive Patients With Malignant Solid Tumor [NCT00516945] | 110 participants (Anticipated) | Interventional | 2004-09-30 | Completed | |||
| A Randomized Controlled Trial to Compare the Efficacy of a Four Drug Antiretroviral Regimen Alone or in Combination With GM-CSF or IL-12 Administered to HIV-1 Infected Subjects as Measured by the Characteristics of Viral Decay [NCT00000896] | 24 participants | Interventional | Completed | ||||
| A Phase I/II Study of Safety and Efficacy of Lamivudine (EPIVIR®) and Tenofovir Disoproxil Fumarate (VIREAD®) Used to Lower the Plasma Level of Viral RNA of HERV-K(HML2) in Patients With Lymphoma [NCT01528865] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn(stopped due to Funding was removed.) | ||
| ART Pharmacokinetics, Mitochondrial Integrity, and Antioxidant Capacity in Severely Malnourished HIV-infected Malawian Children [NCT01529125] | 42 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| Efficacy of Adefovir and Lamivudine Combination Therapy in Patients With Entecavir Resistance [NCT01546116] | Phase 4 | 20 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Feasibility Study of Lamivudine/Zidovudine (3TC/ZDV) Plus Efavirenz (EFV) as Initial Therapy of HIV-1 Infected Patients in a Rural Area of China [NCT00100594] | 100 participants (Anticipated) | Interventional | 2005-05-31 | Completed | |||
| Evaluation of the Relationship Between Immunologic Recovery After Highly Active Antiretroviral Therapy and the Ability to Mobilize CD34+ Stem Cells Following G-CSF Administration [NCT00006578] | 0 participants (Actual) | Interventional | Withdrawn | ||||
| An Open-Label, Single Center Trial to Evaluate the Efficacy and Safety of Quadruple Chemotherapy (Zidovudine, EPIVIR, 1592U89, and 141W94) in Subjects Infected With HIV-1 (GW QUAD) [NCT00006617] | 25 participants | Interventional | Completed | ||||
| Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection [NCT00120796] | Phase 3 | 8 participants (Actual) | Interventional | 2005-08-31 | Terminated(stopped due to poor patient recrutment) | ||
| Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities [NCT00021463] | Phase 2 | 342 participants | Interventional | Completed | |||
| A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Mainte [NCT00011895] | Phase 4 | 400 participants | Interventional | 2001-02-28 | Active, not recruiting | ||
| Randomized Study to Evaluate Immediate Potent Antiretroviral Therapy for HIV-Infected Subjects With CD4 Cell Counts Less Than 350 Cells/mm3 Admitted to Intensive Care Areas With an AIDS-Defining Illness, Pneumonia, or Sepsis [NCT00028327] | Phase 3 | 250 participants | Interventional | Completed | |||
| A Randomized, Controlled Trial of Two Potent, Simplified Regimens Utilizing A Protease Inhibitor-Sparing Regimen Versus A Nucleoside-Sparing Regimen for HIV-Infected Subjects Who Participated in ACTG 388 or Who Responded to A First Potent Combination Regi [NCT00014937] | 240 participants | Interventional | Completed | ||||
| A Randomized, Double-Blind, Phase II Study of 141W94 (VX-478) Monotherapy vs. 141W94 (VX-478) Plus ZDV Plus 3TC in HIV Infected Individuals [NCT00001085] | Phase 2 | 94 participants | Interventional | Completed | |||
| A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensifi [NCT00038506] | Phase 4 | 100 participants | Interventional | 2002-03-31 | Completed | ||
| Lamivudine for Chronic Hepatitis B [NCT00001457] | Phase 2 | 60 participants | Interventional | 1995-09-30 | Completed | ||
| A Phase III, Randomized, Open-label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-dose Combination Tablet as a Once-daily Regimen in Antiretroviral-naive HIV [NCT00053638] | Phase 3 | 345 participants | Interventional | 2003-02-28 | Completed | ||
| A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B [NCT00057265] | Phase 3 | 0 participants | Interventional | 2003-02-28 | Completed | ||
| Delaying HIV Disease Progression With Punctuated Antiretroviral Therapy in HIV-Associated Tuberculosis [NCT00078247] | Phase 3 | 350 participants (Anticipated) | Interventional | 2004-10-31 | Completed | ||
| A Randomised Trial of Lamivudine Plus Interferon Versus Lamivudine for the Treatment of HBeAg Positive Chronic Hepatitis B Virus (HBV) [NCT00140725] | Phase 3 | 160 participants | Interventional | 2000-04-30 | Completed | ||
| A Pilot Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor Sparing Regimen in Antiretroviral-Naïve, HIV-infected Patients [NCT00143689] | Phase 4 | 13 participants (Actual) | Interventional | 2002-04-30 | Completed | ||
| A Randomized Study to Evaluate Virologic Response Following Discontinuation vs. no Discontinuation of 3TC in Patients Who Are Infected With HIV With Previously Documented Reduced Susceptibility to 3TC and Who Have Adequate Virologic Suppression on Combina [NCT00143728] | Phase 4 | 152 participants (Anticipated) | Interventional | 2004-01-31 | Suspended(stopped due to Enrollment.) | ||
| Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection [NCT00013520] | Phase 3 | 1,125 participants | Interventional | Completed | |||
| A Randomized, Double-Blind Trial of Telbivudine (LdT) Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis. [NCT00275652] | Phase 3 | 6 participants | Interventional | 2004-06-30 | Completed | ||
| Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375 [NCT00034086] | 22 participants | Interventional | Completed | ||||
| A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults [NCT00034359] | Phase 2 | 79 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to Completely Suppress Viral Replication in Subjects Infected With HIV-1 [NCT00038220] | Phase 2 | 40 participants | Interventional | 2000-07-31 | Completed | ||
| A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection [NCT00050895] | Phase 3 | 775 participants | Interventional | Completed | |||
| Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV [NCT00051090] | 0 participants (Actual) | Interventional | Withdrawn | ||||
| Augmenting the Magnitude of HAART-Induced Immune Restoration With the Use of Cyclosporine [NCT00031070] | Phase 2 | 40 participants | Interventional | Completed | |||
| Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL) [NCT00005764] | Phase 4 | 100 participants | Interventional | 2000-05-31 | Completed | ||
| Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma [NCT00041327] | Phase 2 | 19 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Phase II, Randomised, Double-blind, Dose-ranging Study of AVX754 Versus Lamivudine in Treatment-experienced HIV-1 Infected Patients With the M184V Mutation in Reverse Transcriptase [NCT00126880] | Phase 2 | 52 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients [NCT00127972] | Phase 4 | 763 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Randomized, Open-Label Study Exploring a Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects [NCT00075231] | Phase 2 | 150 participants | Interventional | 2003-12-31 | Completed | ||
| A Randomized Trial of Switching Antiviral Therapy From Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults With Chronic Hepatitis B [NCT00132652] | Phase 3 | 240 participants | Interventional | 2005-02-28 | Completed | ||
| A Phase II Open Label Clinical Trial of Maternal Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Maximal Reduction of Mother-to-child HIV Transmission in Resource-limited Settings Among Breastfeeding Populations [NCT00146380] | Phase 2 | 520 participants (Anticipated) | Interventional | 2003-07-31 | Active, not recruiting | ||
| Free Study: a Randomised, Open Label, Multicentre Strategic Study to Evaluate the Efficacy and Toxicity of an Early Switch From a PI-containing Regimen to Trizivir ® on Guidance of Viral Load in HIV-1 Infected , Antiretroviral naïve Adults [NCT00405925] | Phase 3 | 207 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Phase II Study of Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects [NCT00043953] | Phase 2 | 30 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Feasibility Study of a Once Daily Antiretroviral Regimen for HIV-Infected Patients With CD4 Below 200/mm3, in Hô Chi Minh City, Vietnam [NCT00158470] | Phase 3 | 100 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavir [NCT00158821] | Phase 3 | 180 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| See Detailed Description [NCT00044577] | Phase 3 | 166 participants | Interventional | 2002-07-16 | Completed | ||
| Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease [NCT00162643] | Phase 4 | 300 participants | Interventional | 2004-12-31 | Recruiting | ||
| A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine [NCT00013897] | Phase 3 | 0 participants | Interventional | 2001-02-28 | Completed | ||
| A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination With a PI or NNRTI in Antiretr [NCT00046176] | Phase 3 | 240 participants | Interventional | 2002-08-26 | Completed | ||
| Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral naïve Patients With HIV/HBV Co-infection [NCT00192595] | Phase 4 | 36 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study. [NCT00192634] | Phase 4 | 357 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL [NCT00342355] | Phase 4 | 1,771 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study of AG1549 in Combination With Viracept (Nelfinavir Mesylate) and Combivir (Zidovudine + Lamivudine) in Treatment-Naive HIV-Infected Patients [NCT00004999] | Phase 2 | 350 participants | Interventional | 1999-08-31 | Suspended | ||
| Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (6-12 Month RCT) [NCT00427297] | Phase 3 | 34 participants (Actual) | Interventional | 2007-09-30 | Terminated(stopped due to There is no longer equipoise. DSMB recommended termination.) | ||
| Open Label Randomized Controlled Trial to Assess the Impact of Prophylactic Exposure to Tenofovir Gel on the Efficacy of Subsequent Tenofovir-containing Antiretroviral Therapy on Viral Suppression [NCT01387022] | 59 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection [NCT00662545] | Phase 4 | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years [NCT00915655] | Phase 2 | 12 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen Versus Lopinavir/Ritonavir in Combination With Lamivudine/Zidovudine in Antiretroviral Naïve Patients [NCT00234923] | Phase 3 | 138 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Randomised Open Label Multi-centre Trial to Evaluate the Pharmacokinetic, Efficacy and Safety Parameters of Nevirapine 150mg/m2 and Nevirapine 4 or 7 mg/kg When Administered in Combination With AZT and 3TC for 48 Weeks in Antiretroviral naïve Paediatric [NCT00273975] | Phase 2 | 123 participants | Interventional | 2002-01-31 | Completed | ||
| Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. A Multicenter Randomised Phase II/III Open Label Study With a Group of 100 Pregnant Women Receiving Lopinavir/Ritonavir a [NCT00424814] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Molecular, Biochemical and Clinical Differences Between Stavudine and Tenofovir, Each Combined With Lamivudine and Efavirenz in South African HIV-infected Patients [NCT01601899] | Phase 4 | 60 participants (Actual) | Interventional | 2008-10-31 | Terminated(stopped due to DSMB decision to begin closeout process in view of April 2010 SA HAART guideline) | ||
| Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial [NCT00272480] | Phase 2/Phase 3 | 16 participants (Actual) | Interventional | 1999-11-08 | Completed | ||
| A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women [NCT01910402] | Phase 3 | 499 participants (Actual) | Interventional | 2013-08-22 | Completed | ||
| A Phase 3, Open Label, Randomised, Parallel Group Study to Compare the Effect on Prevention and Resolution of Treatment Related Adverse Events of a Simplified, Once Daily Regimen of a Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus [NCT00323544] | Phase 3 | 220 participants | Interventional | 2004-10-31 | Completed | ||
| Efficacy of Adefovir Dipivoxil Versus Adefovir Dipivoxil Plus Lamivudine for the Treatment of Chronic Hepatitis B in Patients With Normal Baseline ALT [NCT00230477] | Phase 4 | 19 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Viral Decay Kinetics During Induction Therapy With or Without the Use of Enfuvirtide in HAART-naÃ-ve Patients With Advanced HIV [NCT00344760] | Phase 4 | 2 participants (Anticipated) | Interventional | 2005-01-31 | Completed | ||
| PHPT-5 Second Phase: Perinatal Antiretroviral Intensification for the Prevention of Mother-to-child Transmission of HIV in Thai Women Having Received Less Than 8 Weeks of HAART During Pregnancy [NCT01511237] | Phase 3 | 379 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naïve Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC [NCT01620944] | Phase 3 | 3 participants (Actual) | Interventional | 2012-07-31 | Terminated(stopped due to Business objectives have changed) | ||
| Comparison Between Lamivudine and Entecavir Treatment in Patients With Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B. [NCT01627223] | Phase 4 | 17 participants (Actual) | Interventional | 2012-07-31 | Terminated(stopped due to Slow progress in recruiting study patients) | ||
| Maraviroc Switch Central Nervous System (CNS) Substudy: a Substudy of MARCH, a Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N [NCT01637233] | 28 participants (Actual) | Observational | 2012-06-30 | Completed | |||
| Maraviroc Switch Collaborative Study Renal Substudy [NCT01637259] | Phase 4 | 76 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [NCT01693679] | Phase 4 | 120 participants (Anticipated) | Interventional | 2012-09-30 | Active, not recruiting | ||
| Single-Dose Fasting and Fed Pilot BE Study in Healthy Males and Females Not of Childbearing Potential [NCT05030025] | Early Phase 1 | 43 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| Open-Label Study With Rilpivirine in Treatment-naïve Indian Subjects With HIV-1 Infection to Determine Safety and Efficacy [NCT03563742] | Phase 3 | 58 participants (Actual) | Interventional | 2018-09-24 | Terminated(stopped due to High SF rate (less treatment-naïve subjects & subjects with viral load <100000). Reevaluation in scientific position in India after internal discussion.) | ||
| Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA. [NCT01732367] | Phase 4 | 171 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| The Efficacy and Safety of Telbivudine and Lamivudine Use in Highly Viremic Mothers to Prevent Hepatitis B Transmission [NCT01743079] | Phase 4 | 700 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study [NCT01772940] | Phase 4 | 425 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Nucleoside Analogue in Late Preganancy to Prevent Vertical Transmission of Hepatitis B Virus [NCT01788371] | Phase 4 | 700 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study [NCT01804387] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-05-31 | Recruiting | ||
| The Incidence of Lactic Acidosis During Entecavir Treatment in Chronic Hepatitis B Patients With Severe Cirrhosis or Hepatic Failure [NCT01354652] | Phase 4 | 5 participants (Actual) | Interventional | 2011-05-31 | Terminated(stopped due to Tenofovir has become available in Korea.) | ||
| A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) [NCT02397096] | Phase 3 | 673 participants (Actual) | Interventional | 2015-06-09 | Completed | ||
| A Phase II Study of the Prolongation of Virologic Success (ACTG 372A) and Options for Virologic Failure (ACTG B/C/D) in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320 [NCT00000885] | Phase 2 | 440 participants | Interventional | Completed | |||
| A Phase II Study of 1) Amprenavir (141W94/VX478) Plus 3TC Plus ZDV (or d4T) or 2) IDV Plus NVP Plus 3TC Plus d4T in Subjects Previously Treated With Amprenavir and 3) Other Treatment Regimens (Observational ARM) in Subjects Previously Treated With Amprena [NCT00001095] | Phase 2 | 94 participants | Interventional | Completed | |||
| An Open-Label, Non-Comparative Study of Saquinavir-SGC in Combination With Zidovudine (AZT) and Lamivudine (3TC) in the Treatment of HIV-1 Infected Patients With No Previous Anti-Retroviral Drug Therapy [NCT00002367] | Phase 3 | 40 participants | Interventional | Completed | |||
| A Phase II, Stratified, Randomized, Open-Label, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil and Indinavir in Combination With Zidovudine, Lamivudine, or Stavudine for the Treatment of Therapy Naive HIV-Infected Patients With CD4 Ce [NCT00002379] | Phase 2 | 100 participants | Interventional | Completed | |||
| A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects. [NCT00002199] | Phase 3 | 550 participants | Interventional | Completed | |||
| An Exploratory Study of Fortovase (Saquinavir) Soft Gelatin Capsules (SGC) Plus d4T and 3TC or Fortovase (Saquinavir) SGC Plus Nelfinavir and d4T in Patients With HIV-1 Associated Nephropathy [NCT00002397] | Phase 3 | 24 participants | Interventional | Completed | |||
| A Phase IIIB, Open-Label, Randomized Study of the Effect of an Education Intervention on Virological Outcomes, Adherence, Immunological Outcome, and Health Outcomes in HIV-Infected Subjects From Under-Represented Populations Treated With Triple Nucleoside [NCT00002409] | Phase 3 | 200 participants | Interventional | Completed | |||
| A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Efficacy of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 100 Mg/d4T/3TC b.i.d. in HIV-Infected Individuals [NCT00002241] | Phase 2 | 80 participants | Interventional | Active, not recruiting | |||
| Randomised Double-Blind Placebo-Controlled Phase 3 Trial of Triumeq in Amyotrophic Lateral Sclerosis [NCT05193994] | Phase 3 | 390 participants (Anticipated) | Interventional | 2022-02-24 | Recruiting | ||
| Long Term Follow-up of Patients Experiencing Structured Treatment Interruption (STI) With or Without Low Doses of Interleukin-2 During Primary HIV Infection (PHI) [NCT02300623] | Phase 4 | 12 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| A Phase II, Randomized Study of the Antiviral Activity and Resistance Interactions of Lamivudine (3TC) in Combination With Zidovudine (AZT), Stavudine (d4T), or Didanosine (ddI) Versus Monotherapy With ddI or d4T in HIV-Infected Individuals With 200 - 600 [NCT00000838] | Phase 2 | 256 participants | Interventional | Completed | |||
| A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma [NCT00000916] | Phase 2 | 399 participants | Interventional | Completed | |||
| Multi-Drug Antiretroviral Therapy for Heavily Pretreated Pediatric AIDS Patients: A Phase I Proof of Concept Trial [NCT00001108] | Phase 1 | 6 participants | Interventional | Completed | |||
| [NCT00380614] | Phase 4 | 0 participants | Interventional | 2002-01-31 | Completed | ||
| A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) [NCT00380770] | Phase 4 | 112 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Multiclinic, Open Pilot Study to Investigate the Effect of Combination Antiretroviral Therapy Including Indinavir Sulfate on Coagulation Factors, on Platelet Aggregation, and on Factor VIII/IX Half-Life in HIV-1 Seropositive Patients With Hemophilia A o [NCT00002386] | Phase 4 | 55 participants | Interventional | Completed | |||
| A Phase III, Multicenter, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Different Combination Regimens (DMP 266 + Indinavir, DMP 266 + Zidovudine + Lamivudine, Indinavir + Zidovudine + Lamivudine) in HIV-Infecte [NCT00002410] | Phase 3 | 0 participants | Interventional | Completed | |||
| A Randomized, Open-Label Equivalence Study of FTC Versus Lamivudine in Patients on a Stable Triple Antiretroviral Therapy Regimen Containing Lamivudine, Stavudine or Zidovudine, and a Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor [NCT00002416] | Phase 3 | 390 participants | Interventional | Completed | |||
| A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg Once Daily Vs. Lamivudine 150mg BID in Combination With Zidovudine 300mg BID and Efavirenz 600mg Once Daily in Antiretr [NCT00004852] | Phase 2 | 0 participants | Interventional | 1999-09-30 | Completed | ||
| Evaluation of HIV RNA Suppression Produced by a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine (ddI EC) Administered Once Daily Compared to a Reference Combination Regimen [NCT00002429] | Phase 3 | 500 participants | Interventional | 1999-07-31 | Completed | ||
| Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1 [NCT04904406] | Phase 4 | 95 participants (Anticipated) | Interventional | 2020-10-22 | Recruiting | ||
| Phase 3b, Single Arm, Single Site Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) [NCT03311945] | Phase 3 | 49 participants (Anticipated) | Interventional | 2018-05-03 | Recruiting | ||
| Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B [NCT00023309] | Phase 2 | 41 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Randomized Phase II Study of the Safety, Immunologic, and Virologic Effects of Cyclosporine A in Conjunction With Trizivir(R) and Kaletra(R) Versus Trizivir(R) and Kaletra(R) Alone During Primary HIV-1 Infection [NCT00084149] | Phase 2 | 54 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Preliminary Assessment of Safety and Antiviral Activity of Open-label Entecavir in Subjects With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials [NCT01438424] | Phase 2 | 1,053 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| A Comparison of a Four-Drug Regimen Comprised of 141W94, 1592U89, and Combivir With a Three-Drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naive HIV-Infected Patients. [NCT00002216] | 0 participants | Interventional | Completed | ||||
| A Phase 2b Study to Evaluate the Efficacy, Safety and PK of a Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate for Treatment of HIV-1 Infection in Patients With Drug-susceptible Tuberculosis on a Rifampicin-based Regimen [NCT04734652] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-02-18 | Recruiting | ||
| A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects [NCT05526911] | Phase 1 | 28 participants (Actual) | Interventional | 2022-07-20 | Completed | ||
| An Open Label Study to Investigate the Safety and Efficacy of Abacavir/Lamivudine/Dolutegravir and the Pharmacokinetic Profile of Dolutegravir in HIV-infected Patients of 60 Years of Age and Older [NCT02509195] | Phase 4 | 40 participants (Anticipated) | Interventional | 2015-08-04 | Completed | ||
| A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation [NCT01597934] | Phase 4 | 104 participants (Anticipated) | Interventional | 2012-08-31 | Active, not recruiting | ||
| Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression [NCT01599364] | Phase 4 | 266 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Pharmacokinetic, Safety and Acceptability Study of the Abacavir/Lamivudine/Lopinavir/Ritonavir/-30/15/ 40/10mg vs. Lopinavir/Ritonavir 40/10mg Pellets Plus Dual Abacavir/Lamivudine-60/30mg Tablets in HIV Infected Children [NCT03836833] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2019-06-04 | Recruiting | ||
| Early Intensive Antiretroviral Combination Therapy in HIV-1 Infected Infants and Children [NCT00000872] | Phase 2 | 55 participants (Anticipated) | Interventional | Completed | |||
| A Phase I/II, Open-Label Study to Evaluate the Safety, Tolerance and Pharmacokinetics of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Infected Pregnant Women and Their Infants [NCT00000878] | Phase 1 | 26 participants | Interventional | Completed | |||
| RAD-1: A Phase I/II Antiretroviral Management Algorithm for Pediatric Subjects of Four-Drug Combination Therapies Based on Prior Antiretroviral Experience [NCT00000902] | Phase 1 | 217 participants | Interventional | Completed | |||
| A Phase I Trial of the Safety and Pharmacokinetics of Fortovase (Saquinavir-SGC) Co-Administered With Low Dose (Ritonavir) RTV, ZDV and 3TC in HIV Seropositive Pregnant Women During Gestation and Postpartum, and in Their Infant's Post-Maternal Dosing [NCT00000920] | Phase 1 | 24 participants | Interventional | Completed | |||
| A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Indinavir Co-Administered With Lamivudine (3TC) and Zidovudine (ZDV) in HIV-1-Infected Pregnant Women During Gestation and Post Partum, and in Their Infants Post Maternal Dosing [NCT00000944] | Phase 1 | 24 participants | Interventional | Completed | |||
| 3TC (Lamivudine; GR109714X) Open-Label Program [NCT00002108] | 0 participants | Interventional | Completed | ||||
| An Open Label, Randomized, Comparative Study of Zerit (d4T) + Videx (ddI) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700/mm3 and HIV RNA Baseline Copy Number of > [NCT00002168] | 200 participants | Interventional | Completed | ||||
| A Phase II, 48 Week, Open-Label Study Designed to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Simplified Dosing Regimen of Preveon (Adefovir Dipivoxil; bis-POM PMEA), Videx (Didanosine; ddI), Sustiva (Efavirenz; DMP-266), and Ep [NCT00002234] | Phase 2 | 25 participants | Interventional | Completed | |||
| A Randomized Phase IIIB Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) TID Regimen in Combination With Two NRTIs Versus Saquinavir Soft Gel Capsule (SGC) BID Regimen in Combination With Two NRTIs Versus Saquinavir Soft Gel Capsule (SGC) B [NCT00002378] | Phase 3 | 825 participants | Interventional | Completed | |||
| A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine (AZT) and Lamivudine (3TC) in Subjects With HIV Infection With CD4 Cell Counts <= 200 Cells/mm3 and >= 6 Months of Prior AZT Experience [NCT00000841] | Phase 3 | 1,750 participants | Interventional | Completed | |||
| A Multicenter, Open-Labeled, 96-Week Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Indinavir in Combination With Stavudine and Lamivudine in Pediatric Patients With HIV-1 Infection [NCT00000901] | Phase 1 | 24 participants | Interventional | Completed | |||
| A Randomized, Double-Blind, Parallel-Group, Multicenter Trial to Evaluate the Safety and Efficacy of 1592U89 in Combination With Lamivudine (3TC) and Zidovudine (ZDV) Versus 3TC/ZDV in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects With CD4+ Counts [NCT00002389] | Phase 3 | 210 participants | Interventional | Completed | |||
| A Randomized Open-Label Strategic Study to Evaluate the Safety and Efficacy of 3 Different Convergent and Divergent Drug Combination Therapies in Anti-Retroviral Naive HIV-1 Infected Patients With CD4+ Counts Above 200/mm3 [NCT00002407] | 0 participants | Interventional | Completed | ||||
| A Randomized, Multicenter Study of Epivir 150 Mg Bid, Retrovir 200 Mg Tid and a Protease Inhibitor Vs 3TC 150 Mg/ZDV 300 Mg Fixed Dose Tablet Given Bid With a Protease Inhibitor in HIV-Infected Patients [NCT00002203] | 0 participants | Interventional | Completed | ||||
| A Phase II, 48-Week, Uncontrolled, Open-Label Study Designed to Evaluate the Safety and Efficacy of Quadruple Antiretroviral Therapy (EPIVIR, Abacavir, Amprenavir, and Indinavir) in Subjects Acutely Infected With HIV-1 [NCT00002233] | Phase 2 | 30 participants | Interventional | Completed | |||
| Effect of Amprenavir on Carbohydrate and Lipid Metabolism in Patients With HIV Infection [NCT00002245] | Phase 3 | 0 participants | Interventional | 1999-04-30 | Completed | ||
| A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients [NCT00005000] | Phase 4 | 200 participants | Interventional | 1999-12-31 | Active, not recruiting | ||
| Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study [NCT02211482] | Phase 4 | 20 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| A Randomized, Open-Label, Pilot Treatment Trial Evaluating Cellular Dynamics and Immune Restoration in Treatment-Naive HIV-Infected Subjects Receiving Either the Protease Inhibitor LPV/r or the Nucleoside Analogue Reverse Transcriptase Inhibitors d4T/3TC/ [NCT00004855] | 55 participants | Interventional | Completed | ||||
| A Phase IIIB Randomized, Multicenter Study of the Efficacy and Safety of Combivir 1 Tablet Po Bid Plus Ziagen 300mg Po Bid Versus an Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet Po Bid, Administered for 24 Weeks in Subjects With HIV [NCT00004981] | Phase 3 | 230 participants | Interventional | Active, not recruiting | |||
| A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infe [NCT00005017] | Phase 4 | 300 participants | Interventional | Active, not recruiting | |||
| A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy With Combivir (Lamivudine 150mg/Zidovudine 300mg) BID, Ziagen (Abacavir) 300mg BID, and Sustiva (Efavirenz) 600mg QD for 24 Weeks, Followe [NCT00004585] | Phase 4 | 40 participants | Interventional | 1999-10-31 | Completed | ||
| Comparison of 2 Alternative Antiretroviral Combinations in HIV Post-exposure Prophylaxis: AZT-3TC (Combivir®) + Lopinavir-ritonavir (Kaletra®) Versus AZT-3TC (Combivir®)+ Atazanavir (Reyataz®). Multicentre, Prospective, Randomized, Open Study [NCT00385645] | Phase 4 | 255 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Comparison of Antiretroviral Activity and Immunological Effect of Two Triple Treatments With and Without Protease Inhibitors in naïve HIV-1-infected Patients With CD4 < 100/mm3 [NCT00385957] | Phase 4 | 70 participants | Interventional | Completed | |||
| Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection [NCT00000875] | 16 participants | Interventional | Terminated | ||||
| A Phase II Randomized Study of the Virologic and Immunologic Effects of Zidovudine Plus Lamivudine (3TC) Versus d4T Versus Zidovudine Plus d4T in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and No Previous Nucleoside Experience [NCT00001067] | Phase 2 | 105 participants | Interventional | Completed | |||
| A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV-Infected Children. PRAM-2: A Phase I/II Randomized, Multicenter Protocol Comparing Four Antiretroviral Regimens Containing Combinations of Protease Inh [NCT00001091] | Phase 1 | 200 participants | Interventional | Completed | |||
| An Open Label, Randomized, Comparative Study of Zerit (d4T) + Epivir (3TC) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700 Cells/mm3 and HIV RNA Baseline Copy Numb [NCT00002369] | 200 participants | Interventional | Completed | ||||
| A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection [NCT00002183] | Phase 1 | 60 participants | Interventional | Completed | |||
| A Phase III Trial to Evaluate the Safety and Antiviral Efficacy of 141W94 in Combination With Retrovir and Epivir Compared to Retrovir and Epivir Alone in Patients With HIV Infection. [NCT00002195] | Phase 3 | 290 participants | Interventional | Completed | |||
| SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL) [NCT01928511] | Phase 4 | 254 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Observational Retrospective Multicenter Study Aimed at Evaluating the Incidence of Hepatitis B Reactivation in Patients Affected by Chronic Lymphocytic Leukemia Treated With Ibrutinib [NCT03528941] | 109 participants (Actual) | Observational | 2018-11-28 | Completed | |||
| A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppres [NCT01641809] | Phase 2 | 244 participants (Actual) | Interventional | 2012-08-06 | Completed | ||
| An Open-Label, 48-Week Extension Study of Elvucitabine Administered In Combination With Background Antiretroviral Agents in Participants Who Have Completed 14 Days of Treatment in Protocol ACH443-014A. [NCT00380159] | Phase 2 | 4 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study [NCT02263326] | Phase 3 | 89 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer [NCT03144804] | Phase 2 | 36 participants (Actual) | Interventional | 2017-10-31 | Completed | ||
| An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects [NCT02634073] | Phase 4 | 16 participants (Actual) | Interventional | 2016-01-01 | Completed | ||
| Phase 3b, Single Arm, Simplification Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk [NCT03333083] | Phase 3 | 50 participants (Anticipated) | Interventional | 2018-05-03 | Recruiting | ||
| Investigating Influence of Pregnancy-induced Changes in Antiretroviral Pharmacokinetics, Together With Polymorphisms in Drug Disposition Genes, on Viral Decay Dynamics in HIV Positive Women Starting Therapy Late in Pregnancy and Postpartum [NCT03284645] | 194 participants (Actual) | Observational | 2017-12-22 | Completed | |||
| A Phase 3b, Randomized, Open-Label Study to Evaluate Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppress [NCT02616783] | Phase 3 | 167 participants (Actual) | Interventional | 2015-12-22 | Completed | ||
| Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK- [NCT02116660] | Phase 2 | 11 participants (Actual) | Interventional | 2014-09-03 | Terminated(stopped due to This study was terminated early due to poor recruitment.) | ||
| A Multiclinic, Open Study to Evaluate the Ability of the Combination of Indinavir, Zidovudine and Lamivudine to Result in Sustained Suppression of HIV-1 in Asymptomatic HIV-1 Seropositive Patients [NCT00002179] | Phase 4 | 200 participants | Interventional | Completed | |||
| A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Lamivudine in Antiretroviral Therapy-Naive HIV-Infected Patients [NCT00002227] | Phase 2 | 60 participants | Interventional | Completed | |||
| A Phase II, Randomized, Controlled, Open-Label Trial of Combination Therapy With Nelfinavir (NFV) and Saquinavir (SQV)Sgc With Delavirdine (DLV) or 3TC/ZDV Versus Nelfinavir (NFV) and 3TC/ZDV in Subjects With HIV Infection and > 5,000 HIV RNA Copies/ML [NCT00001094] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) in Triple and Quadruple Combinations With Zidovudine (ZDV), Indinavir (IDV), and Lamivudine (3TC) in HIV-1 Infected Individuals [NCT00002401] | 160 participants | Interventional | Completed | ||||
| A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC [NCT00002155] | 600 participants | Interventional | Completed | ||||
| A Study Evaluating the Efficacy and Tolerability of Dolutegravir Plus Lamivudine in HIV Infected Adults Who Are Virologically Suppressed and With Evidence of TDF Toxicity [NCT05493969] | Phase 4 | 100 participants (Anticipated) | Interventional | 2022-08-31 | Not yet recruiting | ||
| Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial [NCT02431975] | Phase 4 | 73 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Efficacy and Safety of Albuvirtide for Injection Combined With LPV/r for Treatment of HIV-1-Infected Patients Failed First-line Antiretroviral Therapy [NCT02369965] | Phase 3 | 418 participants (Actual) | Interventional | 2014-02-19 | Completed | ||
| A Phase II, Open-Label Trial for Treatment of HIV Infection in Subjects Who Have Failed Initial Combination Therapy With Regimens Containing Indinavir or Nelfinavir: Combination Therapy With 3TC (150 Mg BID), Abacavir (300 Mg BID) and Amprenavir (1200 Mg [NCT00002423] | Phase 2 | 100 participants | Interventional | 1999-03-31 | Completed | ||
| A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents [NCT02337127] | Phase 4 | 500 participants (Anticipated) | Interventional | 2011-06-30 | Recruiting | ||
| Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology [NCT04731103] | Phase 2 | 24 participants (Anticipated) | Interventional | 2022-08-24 | Recruiting | ||
| Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana [NCT00270296] | Phase 2 | 730 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects [NCT00244712] | Phase 4 | 688 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis [NCT01720238] | 621 participants (Actual) | Observational | 2012-03-31 | Active, not recruiting | |||
| A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC [NCT02469246] | Phase 3 | 567 participants (Actual) | Interventional | 2015-06-29 | Completed | ||
| Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study [NCT02245022] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2017-03-14 | Completed | ||
| IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect [NCT02384395] | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected Treatment-naive Participants. There is a 36 Week, Open-label, Extension Phase for Eligible Participants. [NCT00350272] | Phase 2 | 76 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Effect of Substituting Truvada for Combivir or Trizivir vs Continuing Combivir or Trizivir on Physiologic Correlates of Mitochondrial Function in Subjects Infected With Human Immunodeficiency Virus on Highly Active Antiretroviral Therapy [NCT00960622] | Phase 4 | 17 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults [NCT01025830] | Phase 4 | 20 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana [NCT02369406] | Phase 2/Phase 3 | 67 participants (Actual) | Interventional | 2015-05-04 | Active, not recruiting | ||
| Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2 [NCT04903847] | Phase 4 | 126 participants (Anticipated) | Interventional | 2021-02-02 | Recruiting | ||
| A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa [NCT02028676] | Phase 4 | 1,206 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: an Open-label Randomized Clinical Trial [NCT04884139] | Phase 4 | 555 participants (Anticipated) | Interventional | 2021-07-14 | Active, not recruiting | ||
| A Randomized, Double-Blind, Phase III Study of ABT-378/Ritonavir Plus Stavudine and Lamivudine vs Nelfinavir Plus Stavudine and Lamivudine in Antiretroviral Naive HIV-Infected Subjects [NCT00004583] | Phase 3 | 660 participants | Interventional | 1999-03-31 | Completed | ||
| A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Versus Adefovir Added to Continuing Lamivudine in Adults With Lamivudine- Resistant Chronic Hepatitis B Virus Infection [NCT00605384] | Phase 3 | 4 participants (Actual) | Interventional | 2008-08-31 | Terminated(stopped due to Business Objectives Have Changed) | ||
| Sex and Disease Dependent Nucleoside Analog Toxicity [NCT01386970] | Phase 4 | 43 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks [NCT02470650] | Phase 4 | 150 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Antiretroviral Regime for Viral Eradication in Newborns After Intervention Failure of Mother-to-child Transmission of HIV [NCT02712801] | Phase 4 | 600 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| IMPAACT 1092: Phase IV Evaluation Of The Steady State Pharmacokinetics Of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in Severely Malnourished HIV-1-Infected Children [NCT01818258] | Phase 4 | 52 participants (Actual) | Interventional | 2015-10-26 | Completed | ||
| A Randomized Study of the Long-Term Suppression of Plasma HIV RNA Levels by Triple Combination Regimens in Treatment Naive Subjects [NCT00002411] | 0 participants | Interventional | 1998-03-31 | Completed | |||
| A 14 Day Randomized, Double-blind, Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation [NCT00312039] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| A Phase IV Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Two Different Potent Regimens in HIV Infected Women Initiating Triple Antiretroviral Regimens Between 20 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child [NCT01618305] | Phase 4 | 408 participants (Actual) | Interventional | 2013-09-05 | Completed | ||
| Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents [NCT03332095] | Phase 1/Phase 2 | 55 participants (Actual) | Interventional | 2018-07-02 | Completed | ||
| Booster-free Antiretroviral Therapy for Persons Living With HIV and Multidrug Resistance: A Multicentre Multi-stage Randomized Trial [NCT06037564] | Phase 4 | 210 participants (Anticipated) | Interventional | 2023-11-13 | Enrolling by invitation | ||
| A Pilot Study on the Efficacy of DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women Who Have Detectable Viral Load After 14 Weeks of Gestation [NCT04808973] | Phase 3 | 20 participants (Actual) | Interventional | 2021-07-01 | Completed | ||
| A Phase IIIb, Randomized, Open-Label Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Patients in Children With HBeAg Positive Chronic Hepatitis B in the Immune-Tolerant Phase [NCT02263079] | Phase 3 | 62 participants (Actual) | Interventional | 2014-06-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||